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n INTRODUCTION
Aspiration pneumonia is a distinct form of bacterial pneumonia resulting from mac-
roaspiration of oropharyngeal or gastric content 
in patients with specific predisposing factors. Its 
incidence in hospitalized patients with commu-
nity-acquired pneumonia ranges from 8.7% to as 
high as 60.1% in recent research, depending on the 
definition each study used [1-5]. In-hospital mor-
tality rate also varies between studies, reaching up 
to 23% in patients treated at pulmonary or inter-
nal medicine departments and to 40% in patients 
admitted to intensive care units (ICU) [1, 3-9]. The 
microbiological etiology of aspiration pneumonia 
Microbiology and prognosis 
assessment of hospitalized patients 
with aspiration pneumonia: a single-
center prospective cohort study
Dimitrios Papadopoulos, Iosif Bader, Efthalia Gkioxari, Vasiliki Petta,  
Theodoros Tsaras, Nikoletta Galanopoulou, Maria-Anna Archontouli,  
Filia Diamantea, Emmanouil Kastanakis, Napoleon Karagianidis, Vasiliki Filaditaki
2nd Pulmonology Department, “Sismanoglio” General Hospital of Attica, Marousi, Greece
Aspiration pneumonia has a high incidence in hospi-
talized patients with community-acquired pneumo-
nia and results in high mortality rates. We aimed to 
evaluate microbiology and assess prognostic factors 
of aspiration pneumonia in the setting of a tertiary 
hospital pulmonology department. Community-ac-
quired (CAAP) and healthcare-associated aspiration 
pneumonia (HCAAP) cases hospitalized over a period 
of a year were prospectively followed. Demographic, 
clinical, biological and radiological data were record-
ed at admission, while sputum, tracheal aspirates or 
bronchial washing samples were collected within 48 
hours of admission. During hospital stay, therapeutic 
and supportive measures and resulting complications 
were recorded. Regression analysis was applied to find 
statistically significant prognostic factors. The sample 
consisted of 70 patients (67.1% men); 55.7% of them 
presented as HCAAP. 94.3% had positive culture of 
lower respiratory tract specimens with isolation of 115 
pathogens, 47 of which were multidrug- or extensive-
ly drug-resistant. The most common pathogens were 
Pseudomonas aeruginosa (37.1%), Klebsiella pneumoniae 
SUMMARY
(27.1%), Staphylococcus aureus (25.7%) and Acinetobacter 
baumannii (20%). Empiric antimicrobial therapy was 
combination therapy in 70% and included antipseu-
domonal and MRSA-targeted antibiotics in 61.4% and 
11.4%, respectively. Patients in the HCAAP group had 
a higher rate of antibiotics usage in the previous trimes-
ter, more frequent isolation of resistant strains and were 
more likely to receive inadequate empiric treatment 
than those in the CAAP group. In-hospital mortality 
was 52.2%; no difference between groups was noted. 
Independent factors of increased mortality were old-
er age (p=0.004), low serum albumin levels (p=0.039), 
increased radiological involvement (p=0.050) and in-
effective initial therapy (p=0.001). We concluded that 
patients hospitalized for aspiration pneumonia have 
frequent contact with healthcare services and acquire 
multidrug-resistant Gram-negative bacteria. Empiric 
therapy should target these specific microorganisms as 
its success determines the prognosis.
Keywords: aspiration pneumonia, microbiology, empir-
ic therapy, mortality.
104 D. Papadopoulos, I. Bader, E. Gkioxari, et al.
is reported to have significantly changed over the 
last 50 years, shifting from anaerobic-only isolates 
to mixed flora, with Gram-negative bacilli, often 
multi-drug resistant, dominating the picture [10]. 
The effectiveness of initial empiric antimicrobi-
al therapy is considered a significant prognostic 
factor and the choice of drug or combination of 
drugs should be made according to knowledge of 
local epidemiological data [7, 9].
Previous research has examined microbiologi-
cal data of hospitalized patients with aspiration 
pneumonia mostly in the context of ICU admis-
sion [7-9]. Since they do not represent the entire 
spectrum of aspiration pneumonia cases, it is pos-
sible that results cannot be generalized to guide 
treatment and determine prognosis in patients 
hospitalized in general wards. This study aimed 
to identify the bacteriological flora and resist-
ance patterns of patients admitted for aspiration 
pneumonia in a pulmonology department over a 
year’s period and assess prognostic factors relat-
ed to mortality and length of hospital stay.
n PATIENTS AND METHODS
Setting
We conducted a prospective study of patients that 
were admitted with aspiration pneumonia within 
a year in a public tertiary hospital’s pulmonolo-
gy department in Greece. “Sismanoglio” Gen-
eral Hospital of Attica is a reference hospital for 
pulmonary diseases, serving the regional unit of 
North Athens, with a population of 591680 inhab-
itants, and the broader north-eastern part of Atti-
ca. All patients admitted in the 2nd Pulmonology 
department with a diagnosis of aspiration pneu-
monia between 1 December 2015 and 30 Novem-
ber 2016 were screened for enrolment and those 
included were followed during their hospitaliza-
tion and up to three months from admission. 
The study was conducted in accordance with the 
ethical standards of the institutional review board 
and the Helsinki Declaration of the World Medical 
Association and informed consent was obtained 
from participants or their health care proxy.
Participants
The presence of aspiration pneumonia required 
the following criteria assessed at initial presenta-
tion or within 48 hours of hospitalization:
a) acute onset of at least two symptoms or signs 
suggestive of lower respiratory tract infection 
(fever >38oC, cough or sputum production, 
dyspnoea or respiratory rate >20 breaths per 
minute, altered mental status, pleuritic chest 
pain, crackles or consolidation on physical ex-
amination);
b) evidence of a new gravity-dependent pulmo-
nary infiltrate on thoracic imaging;
c) presence of aspiration risk factors (reduced lev-
el of consciousness, impaired swallowing reflex 
or abnormalities of the upper aerodigestive 
tract) or witnessed large aspiration [11]. A sim-
ple water-swallowing test was used to evaluate 
the adequacy of the swallowing reflex.
Patients were divided in two groups:
a) a healthcare-associated aspiration pneumo-
nia (HCAAP) group, consisting of residents 
of nursing or long-term care facilities and pa-
tients receiving haemodialysis, intravenous 
chemotherapy, radiation therapy or special-
ized healthcare at home (intravenous therapy, 
wound care, urinary catheterization, etc.) in 
the last month before admission or being hos-
pitalized for over two days in the previous tri-
mester;
b) a community-acquired aspiration pneumonia 
(CAAP) group, including the rest [12]. 
Participants were evaluated continuously during 
their hospital stay until death or discharge and 
the latter also received a telephone call after three 
months to assess their clinical condition.
Data sources
Data collected upon admission included demo-
graphic information, type of residence, function-
al (ambulatory or bedridden) and nutritional 
(based on estimated body mass index with cut-
off value 18.5 kg/m2) assessment, comorbidities 
and calculation of Charlson index, history of hos-
pitalizations, long-term oxygen therapy and pro-
tein pump inhibitors (PPIs), histamine-2 receptor 
antagonists (H2 antagonists) and antibiotic usage 
in the previous trimester [13]. Within 48 hours 
after admission the following clinical, biologi-
cal and radiological data were recorded: initial 
vital signs; presenting symptoms; mechanism of 
aspiration; arterial blood gases; biochemical and 
hematological tests (white blood cell count and 
type, platelet count, hematocrit, serum albumin, 
glucose, urea, creatinine, sodium and C-reactive 
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protein); and findings in chest radiograph (num-
ber of lung fields involved, bilateral involvement, 
presence of pleural effusion). Disease severity 
and prognosis assessment was made by calcula-
tion of the Pneumonia Severity Index (PSI) [14]. 
Septic shock was defined according to recently 
published criteria [15].
In all cases, a sputum, tracheal aspirate or bron-
choscopy-directed bronchial washing sample 
was obtained within 48 hours following admis-
sion, while blood cultures were performed only 
in patients with fever. Standard suitability criteria 
of >25 leukocytes and <10 squamous epithelial 
cells per low-power field for bacterial cultures of 
lower respiratory tract specimens were applied, 
followed by qualitative analysis and antimicro-
bial susceptibility testing, according to EUCAST 
guidelines, in suitable samples, while cases with 
unacceptable specimens were excluded [16]. Uri-
nary antigens for Streptococcus pneumoniae and 
Legionella pneumophila were not routinely ordered 
because of limited availability in our hospital 
throughout the study period. Therapeutic and 
supportive measures, such as initial antimicro-
bial therapy, use of systemic corticosteroids or 
inotropic drugs, blood transfusion, parenteral 
nutrition, placement of central venous catheters, 
nasogastric feeding tube or gastrostomy, inva-
sive or noninvasive mechanical ventilation and 
therapeutic bronchoscopy were recorded in all 
patients. Endotracheal intubation was not per-
formed in cases where a “do not resuscitate” 
order was applied. The choice of antibiotics was 
made by the treating physicians based on existing 
guidelines and local epidemiological factors. Pat-
terns of antibiotic resistance were identified using 
expert proposed definitions [17]. Initial antimicro-
bial therapy was considered adequate if the iso-
lated pathogens were susceptible to at least one 
of the used antibiotics and effective when a clin-
ical response (decline of fever, leukocytosis and 
C-reactive protein, improvement of hypoxemia 
and shock) was observed in the first 72 hours of 
treatment. During the patients’ hospitalization, 
the occurrence of pneumonia complications in 
the form of total lung atelectasis, hypoventilation 
and respiratory acidosis, bronchopulmonary hos-
pital-acquired superinfections, secondary septic 
shock or multiple organ failure was also recorded.
In-hospital mortality and mortality at the end of 
follow-up were the primary study endpoints. For 
patients discharged from hospital, length of stay 
(LOS) was also considered an outcome variable.
Statistical analysis
In descriptive statistical analysis, continuous 
variables were expressed as mean±standard de-
viation and categorical variables in the form of 
frequencies. Frequency differences between cate-
gorical variables were analysed by the chi-square 
test or Fisher’s exact test, while the differences in 
means between continuous variables with Stu-
dent’s t test or Mann-Whitney test, depending 
on the normality of data. To examine prognostic 
factors of mortality and LOS we used multiple 
logistic and linear regression models with the 
backward stepwise method. In linear regression, 
high influential points were excluded when their 
Cook’s distance value exceeded three times the 
sample mean value. All significance tests were 
two-sided, with p-value <0.05 being considered 
statistically significant. Analysis was conducted 
with the statistical software package IBM® SPSS® 
Statistics Version 20.
n RESULTS
Sample demographics
During the study period, 94 patients were ad-
mitted with diagnosis of aspiration pneumonia 
and were eligible for enrolment. Three patients 
did not consent and 21 were excluded for having 
unacceptable lower respiratory tract specimens, 
limiting the final sample to 70 patients. Forty-sev-
en were males (67.1%) and 23 females (32.9%), 
while the mean age of the sample was 79.84±14.53 
years. Reasons for aspiration were impaired swal-
lowing reflex due to neurological conditions in 
36, abnormalities of the upper aerodigestive tract 
in 13 (presence of feeding tubes=11, anatomical 
or functional disorders=2), reduced level of con-
sciousness in 9 (cerebral infarct or tumour=3, en-
cephalopathy=5, drug use=1) and witnessed large 
aspiration in 12 (vomiting=8, food aspiration=4) 
cases. Thirty-nine (55.7%) of the participants were 
assigned to the HCAAP group; of them 56.4% were 
nursing home residents, 5.1% received home care 
and 2.6% intravenous chemotherapy over the last 
month, 59% and 15.4% had one and two hospital-
izations in the previous trimester respectively and 
28.2% had been hospitalized for aspiration pneu-
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Table 1 - Demographic and clinical characteristics of study sample at admission.
Variable CAAP HCAAP p
Sex
Male
Female
21 (67.7)
10 (32.3)
26 (66.7)
13 (33.3)
0.924
Age (years) 81.45±16.82 78.56±12.50 0.413
Function
Ambulatory
Bedridden
4 (12.9)
27 (87.1)
6 (15.4)
33 (84.6)
1.000
Nutrition
Adequate
Undernutrition
19 (61.3)
12 (38.7)
25 (64.1)
14 (35.9)
0.809
Comorbidities
Cardiovascular disease
Cerebrovascular disease
Dementia
Parkinson disease
Psychiatric disease
Chronic pulmonary disease
Diabetes mellitus
Malignancy
Charlson index
Median (IQR)
18 (58.1)
9 (29.0)
26 (83.9)
6 (19.4)
2 (6.5)
2 (6.5)
7 (22.6)
3 (9.7)
2.48±1.90
2 (1, 3)
19 (48.7)
13 (33.3)
33 (84.6)
4 (10.3)
12 (30.8)
6 (15.4)
7 (17.9)
4 (10.3)
2.67±1.90
2 (1, 4)
0.436
0.700
1.000
0.320
0.012
0.287
0.630
1.000
0.740
Drug usage
PPIs-H2 antagonists
Antibiotics
Oxygen therapy
7 (22.6)
7 (22.6)
2 (6.5)
13 (33.3)
31 (79.5)
9 (23.1)
0.323
0.000
0.096
Aspiration risk factors
Witnessed large aspiration
Reduced level of consciousness
Impaired swallowing reflex
Abnormalities of the upper aerodigestive tract
7 (22.6)
3 (9.7)
18 (58.1)
3 (9.7)
5 (12.8)
6 (15.4)
18 (46.2)
10 (25.6)
0.236
Presenting symptoms
Fever
Tachypnea
Altered mental status
10 (32.3)
13 (41.9)
16 (51.6)
12 (30.8)
15 (38.5)
13 (33.3)
0.894
0.768
0.123
Biological data
Systolic blood pressure
Heart rate
PaO2/FIO2
PaCO2 (mmHg)
Median (IQR)
pH
Lactate (mmol/L)
Median (IQR)
White blood cell count (x103/μL)
% neutrophils (%)
Hematocrit (%)
Platelet count (x103/μL)
Glucose (mg/dL)
Median (IQR)
Urea (mg/dL)
Median (IQR)
Creatinine (mg/dL)
116.77±28.99
92.03±19.28
182.32±66.03
45.39±19.53
39 (33, 52)
7.38±0.13
1.59±1.08
1.3 (0.9, 2.3)
12.70±7.14
84.21±8.32
35.80±5.95
265.03±114.59
145.94±66.72
128 (104, 177)
76.29±41.50
67 (43, 109)
1.17±0.59
118.49±29.21
98.62±24.75
191.13±81.51
41.56±17.16
38 (30, 45)
7.41±0.11
1.71±1.15
1.5 (1.1, 2.1)
12.80±5.68
83.24±9.60
35.76±6.21
243.38±93.57
142.26±63.79
129 (113, 155)
66.54±53.10
40 (34, 88)
1.06±0.64
0.808
0.228
0.628
0.378
0.254
0.558
0.947
0.658
0.978
0.387
0.929
0.099
0.190
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monia in the same period. The demographic and 
clinical characteristics of the study population at 
admission are presented in Table 1. The HCAAP 
group was more likely to present with a psychiat-
ric comorbidity (p=0.012) and to have used antibi-
otics in the previous trimester (p<0.001) than the 
CAAP group.
Microbiological data
Blood cultures were obtained from 27 (38.6%) 
patients at admission and were positive only in 
one patient, consisting of Staphylococcus homin-
is. Thoracentesis was performed in six cases, re-
vealing one transudate, four exudates and one 
empyema, with only the last having positive 
pleural fluid culture, consisting of Streptococcus 
constellatus. Positive cultures of lower respirato-
ry tract specimens were found in 66 (94.3%) pa-
tients. Overall, 115 pathogens (47 in CAAP group 
and 68 in HCAAP group) were identified (Table 
2); 40%, 40%, 12.9% and 1.4% of participants had 
one, two, three and four pathogens respectively. 
Pseudomonas aeruginosa was the most common 
pathogen isolated (37.1%), followed by Klebsiella 
pneumoniae (27.1%), Staphylococcus aureus (25.7%) 
and Acinetobacter baumannii (20%). Corynebacteri-
um species were significantly more prevalent in 
the HCAAP group (p=0.015). Regarding antibiot-
ic resistance, 24 multidrug-resistant (MDR) and 
23 extensively drug-resistant (XDR) pathogens, 
including Staphylococcus aureus, Enterobacteriace-
ae, Pseudomonas aeruginosa and Acinetobacter bau-
mannii, were isolated from 34 cases (7 cases in 
CAAP group and 27 in HCAAP group, p<0.001). 
HCAAP group was found to have significant-
ly more Klebsiella pneumoniae (p=0.045) and Es-
cherichia coli (p=0.036) MDR isolates than CAAP 
group. Mycobacterial cultures of lower respirato-
ry tract specimens were performed in 17 patients 
and they were all negative. Urinary antigens for 
Streptococcus pneumoniae and Legionella pneumoph-
ila were tested in six patients and were negative 
in all of them.
Follow-up data collection
Therapeutic choices, complications and outcome 
data of the study population are reported in Ta-
ble 3. Initial antimicrobial therapy was mono-
therapy in 30% and combination therapy in 70% 
of patients. The predominant single agent drug 
used was piperacillin-tazobactam (90.5%), while 
the most common combinations were ampicil-
lin-sulbactam plus clindamycin or metronidazole 
(36.7%), piperacillin-tazobactam plus clindamycin 
(20.4%) and ceftriaxone plus clindamycin (8.2%). 
Meropenem-based regimens were initiated in 
8 cases and amikacin was added in the empiric 
therapy in 4 cases. Only 5.7% of participants re-
Variable CAAP HCAAP p
Median (IQR)
Albumin (g/dL)
Sodium
C-reactive protein (mg/L)
1.1 (0.8, 1.3)
3.05±0.61
136.68±11.77
151.51±122.21
0.8 (0.6, 1.5)
2.95±0.63
135.69±11.22
167.52±139.24
0.543
0.722
0.616
Radiological data
Number of lung fields involved
Median (IQR)
Bilateral involvement
Pleural effusion
2.55±1.18
2 (2, 4)
24 (77.4)
9 (29.0)
2.67±1.20
3 (2, 3)
28 (71.8)
5 (12.8)
0.755
0.593
0.092
Initial septic shock 2 (6.5) 5 (12.8) 0.452
PSI
Risk class I-III
Risk class IV
Risk class V
142.74±38.30
1 (3.2)
12 (38.7)
18 (58.1)
135.74±31.46
2 (5.1)
13 (33.3)
24 (61.5)
0.404
0.919
CAAP: community-acquired aspiration pneumonia; HCAAP: healthcare-associated aspiration pneumonia; IQR: interquartile range; PPIs: proton 
pump inhibitors; PaO2: partial pressure of arterial oxygen; FIO2: fraction of inspired oxygen; PaCO2: partial pressure of arterial carbon dioxide; PSI: 
Pneumonia Severity Index.
Categorical data are presented as frequency count (%) and analyzed with chi-square or Fisher’s exact test.
Continuous data are presented as mean±standard deviation and analyzed with Student’s t test, except from non-normal data presented also as 
median (IQR) and analyzed with Mann-Whitney test.
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ceived adequate coverage for atypical pathogens. 
Patients in the HCAAP group were more likely to 
receive methicillin-resistant Staphylococcus aureus 
(MRSA)-targeted antibiotics as empiric therapy 
(p=0.007) and less likely to receive adequate initial 
therapy (p=0.013) than those in the CAAP group. 
Isolation of Acinetobacter baumannii and Stenotro-
phomonas maltophilia was related with significant-
ly higher risk of being untreated during empiric 
therapy compared to other isolates (p=0.001 and 
p=0.014 respectively). Sixty-three patients were 
available for reevaluation after 72 hours; six cas-
es died and one withdrew from the study before 
that time. Empiric therapy was judged ineffective 
in 25 (39.7%) patients, with 4 of them having ad-
equate empiric antibiotic coverage. On the other 
hand, only 20 of the 38 effectively treated patients 
had adequate initial antimicrobial therapy. Pa-
tients with polymicrobial flora and drug-resistant 
pathogens were less likely to improve after 72 
hours (p=0.020 and p=0.027 respectively), while 
those that received antipseudomonal or adequate 
Table 2 - Microbiological data of study sample.
Pathogens CAAP HCAAP p
Pseudomonas aeruginosa
MDR
XDR
13 (41.9)
0 (0.0)
2 (15.4)
13 (33.3)
1 (7.7)
5 (38.5)
0.459
1.000
0.378
Klebsiella pneumoniae
MDR
XDR
8 (25.8)
0 (0.0)
2 (25.0)
11 (28.2)
5 (45.5)
1 (9.1)
0.823
0.045
0.546
Staphylococcus aureus
MDR
XDR
8 (25.8)
2 (25.0)
0 (0.0)
10 (25.6)
8 (80.0)
0 (0.0)
0.987
0.054
*
Acinetobacter baumannii
MDR
XDR
5 (16.1)
0 (0.0)
4 (80.0)
9 (23.1)
0 (0.0)
9 (100.0)
0.470
*
0.357
Escherichia coli
MDR
XDR
2 (6.5)
0 (0.0)
0 (0.0)
6 (15.4)
6 (100.0)
0 (0.0)
0.287
0.036
*
Corynebacterium spp 0 (0.0) 7 (17.9) 0.015
Stenotrophomonas maltophilia 2 (6.5) 5 (12.8) 0.452
Enterobacter spp 3 (9.7) 1 (2.6) 0.315
Serratia marcescens 1 (3.2) 3 (7.7) 0.624
Haemophilus influenzae 3 (9.7) 0 (0.0) 0.082
Alcaligenes xylosoxidans 0 (0.0) 1 (2.6) 1.000
Moraxella catarrhalis 0 (0.0) 1 (2.6) 1.000
Proteus mirabilis 1 (3.2) 0 (0.0) 0.443
Streptococcus pneumoniae 1 (3.2) 0 (0.0) 0.443
Polymicrobial
Number per patient
Median (IQR)
15 (48.4)
1.52±0.89
1 (1, 2)
23 (59.0)
1.74±0.79
2 (1, 2)
0.377
0.231
MDR-XDR
Number per patient
Median (IQR)
7 (22.6)
0.32±0.65
0 (0, 0)
27 (69.2)
0.95±0.79
1 (0, 1)
0.000
0.000
CAAP: community-acquired aspiration pneumonia; HCAAP: healthcare-associated aspiration pneumonia; MDR: multidrug-resistant; XDR: exten-
sively drug-resistant; IQR: interquartile range.
Categorical data are presented as frequency count (%) and analyzed with chi-square or Fisher’s exact test.
Continuous data are presented as mean±standard deviation, median (IQR) and analyzed with Mann-Whitney test.
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initial therapy were more likely to show clinical 
response at 72 hours (p=0.008 and p=0.003 respec-
tively) (Table 4). In 39 cases, the initial antibiotic 
scheme was changed over the course of treatment, 
mainly consisting of replacement of a penicillin 
or a cephalosporin with a carbapenem in 20 cases 
and addition of colistin or a MRSA-targeted agent 
in 16 and 14 cases respectively.
Ten patients required therapeutic bronchoscopy 
for various degrees of atelectasis, four patients 
were intubated and transferred to the intensive 
care unit with mean LOS 22.5±17.41 days, three 
patients were treated with non-invasive venti-
lation for hypoventilation and emergency tra-
cheostomy was performed in one patient after 
laryngeal edema. There was a significant dif-
ference in the number of patients that required 
bronchoscopy between the CAAP and HCAAP 
groups (p=0.035). Nasogastric tube and gastrosto-
my placement were performed in 49.3% and 4.3% 
of participants respectively, while central venous 
catheterization was performed in 18.8%. 34.8% 
Table 3 - Therapeutic choices, complications and outcome data of study sample.
Variable CAAP HCAAP p
Empiric antimicrobial therapy
Combination
Anaerobic-specific
Antipseudomonal
MRSA-targeted
Atypical-targeted
Adequate
20 (64.5)
19 (61.3)
16 (51.6)
0 (0.0)
1 (3.2)
17 (54.8)
29 (74.4)
21 (53.8)
27 (69.2)
8 (20.5)
3 (7.7)
10 (25.6)
0.372
0.532
0.133
0.007
0.624
0.013
Reevaluation after 72 hours
Effective
Antibiotic change
Change in PaO2/FIO2
Change in WBC (x103/μL)
Change in CRP (mg/L)
18 (69.2)
9 (34.6)
59.50±73.49
-1.96±4.43
-59.24±122.42
20 (54.1)
19 (51.4)
31.86±99.49
-2.01±4.74
-55.24±123.30
0.225
0.188
0.234
0.968
0.899
Bronchoscopy 1 (3.3) 9 (23.1) 0.035
Mechanical ventilation 1 (3.3) 5 (12.8) 0.223
Feeding tube placement
Nasogastric tube
Gastrostomy
16 (53.3)
1 (3.3)
18 (46.2)
2 (5.1)
0.554
1.000
Central venous catheter placement 3 (10.0) 10 (25.6) 0.100
Parenteral nutrition 6 (20.0) 18 (46.2) 0.024
Inotropic support 5 (16.7) 12 (30.8) 0.178
Corticosteroids 6 (20.0) 9 (23.1) 0.759
Blood transfusion 7 (23.3) 9 (23.1) 0.980
Complications
Total lung atelectasis
Hypoventilation-respiratory acidosis
Hospital-acquired superinfections
Septic shock-multiple organ failure
1 (3.3)
2 (6.7)
3 (10.0)
7 (23.3)
9 (23.1)
4 (10.3)
8 (20.5)
11 (28.2)
0.035
0.690
0.327
0.648
Outcome
LOS (days)
In-hospital mortality
90-day mortality
13.33±8.82
18 (60.0)
23 (76.7)
18.67±17.51
18 (46.2)
27 (69.2)
0.334
0.254
0.493
CAAP: community-acquired aspiration pneumonia; HCAAP: healthcare-associated aspiration pneumonia; MRSA: methicillin-resistant Staphylococcus 
aureus; PaO2: partial pressure of arterial oxygen; FIO2: fraction of inspired oxygen; WBC: white blood cell; CRP: C-reactive protein; LOS: length of stay.
Categorical data are presented as frequency count (%) and analyzed with chi-square or Fisher’s exact test.
Continuous data are presented as mean±standard deviation and analyzed with Student’s t test.
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of patients received parenteral nutrition; signifi-
cantly more in the HCAAP group (p=0.024). Ino-
tropic support and corticosteroids were initiated 
in 24.6% and 21.7% of patients respectively and 
23.2% were transfused during their hospital stay. 
There was no difference between groups in terms 
of observed complications, except from the fact 
that patients in the HCAAP group developed a 
total lung atelectasis more frequently than the 
CAAP group (p=0.035). During their hospitali-
zation, 11 patients developed nosocomial pneu-
monia with alteration of their initial bronchial 
pathogens (Klebsiella pneumoniae=5, Acinetobacter 
baumannii=5, Pseudomonas aeruginosa=4, MRSA=2, 
Stenotrophomonas maltophilia=2), while three of 
them had positive blood cultures (Klebsiella pneu-
moniae, Acinetobacter baumannii and Candida par-
apsilosis).
Table 4 - Association between effectiveness of empiric 
therapy and microbiology or antibiotic therapy used.
Variable Effective Non-
effective
p
Microbiology
Pseudomonas aeruginosa 14 (36.8) 7 (28.0) 0.466
Klebsiella pneumoniae 7 (18.4) 9 (36.0) 0.117
Staphylococcus aureus 9 (23.7) 7 (28.0) 0.700
Acinetobacter baumannii 7 (18.4) 7 (28.0) 0.371
Escherichia coli 5 (13.2) 3 (12.0) 1.000
Corynebacterium spp 2 (5.3) 5 (20.0) 0.103
Stenotrophomonas maltophilia 5 (13.2) 1 (4.0) 0.389
Enterobacter spp 2 (5.3) 2 (8.0) 1.000
Serratia marcescens 2 (5.3) 1 (4.0) 1.000
Haemophilus influenzae 2 (5.3) 1 (4.0) 1.000
Polymicrobial 16 (42.1) 18 (72.0) 0.020
MDR-XDR 15 (39.5) 17 (68.0) 0.027
Antibiotic therapy
Combination 26 (68.4) 20 (80.0) 0.311
Anaerobic-specific 20 (52.6) 18 (72.0) 0.124
Antipseudomonal 28 (73.7) 10 (40.0) 0.008
MRSA-targeted 5 (13.2) 2 (8.0) 0.693
Atypical-targeted 3 (7.9) 1 (4.0) 1.000
Adequate 20 (52.6) 4 (16.0) 0.003
MDR: multidrug-resistant; XDR: extensively drug-resistant; MRSA: 
methicillin-resistant Staphylococcus aureus.
Data are presented as frequency count (%) and analyzed with chi-
square or Fisher’s exact test.
Figure 1 - Kaplan-Meier graph of cumulative survival 
over time for CAAP and HCAAP groups (log-rank chi-
square test: 0.834, p=0.361) during the three-month 
follow-up.
Figure 2 - Receiver operator characteristic curve of PSI 
against in-hospital mortality (AUC: 0.752, 95%CI: 0.636, 
0.867, p<0.001).
Prognosis assessment
In-hospital and 90-day mortality was 52.2% and 
72.5% respectively; no difference between CAAP 
and HCAAP groups was found, neither in LOS 
among survivors. Median survival time at the end 
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of follow-up for the whole sample was 3 weeks; 
no significant difference between CAAP (median: 
1.5 weeks) and HCAAP (median: 4 weeks) groups 
was noted (p=0.322) (Figure 1). In-hospital mor-
tality across PSI risk classes was 0%, 36% and 
65.9% for classes I-III, IV and V respectively; pa-
tients in classes IV and V had significantly higher 
in-hospital mortality (p<0.001) compared to the 
original derivation cohort [14]. PSI significantly 
predicted overall in-hospital mortality, with an 
area under the receiver operator characteristic 
curve (AUROC) of 0.752 (95% CI: 0.636, 0.867, 
p<0.001) (Figure 2). PSI performed similarly for 
both groups (AUROC CAAP: 0.743, p=0.026, AU-
ROC HCAAP: 0.771, p=0.004, AUROC difference: 
-0.028, p=0.818).
Regression analysis was performed to identify 
statistically significant predictors of in-hospital 
mortality and LOS among survivors, using dif-
ferent models for demographic, clinical, microbi-
ological and therapeutic factors. For in-hospital 
mortality, increased age (p=0.002), use of oxygen 
therapy during the previous trimester (p=0.008) 
and impaired swallowing reflex as an aspiration 
risk factor compared to witnessed large aspi-
ration (p=0.026) were significant demographic 
correlates; low serum albumin (p=0.032) and in-
creased radiological involvement (p=0.027) were 
significant clinical correlates; ineffective initial 
therapy (p=0.015) was a significant therapeu-
tic correlate, while none of the microbiological 
factors was found to be significant. Applying a 
unique model including all of the above signifi-
cant predictors, four variables were found to be 
independently associated with in-hospital mor-
tality: age (p=0.004), albumin (p=0.039), radiolog-
ical involvement (p=0.050) and ineffective thera-
py (p=0.001). The model was statistically signif-
icant (p<0.001), explained 56.5% of the variance 
in aspiration pneumonia prognosis and correctly 
classified 81% of cases (AUROC: 0.892, 95% CI: 
0.812, 0.973, p<0.001).
For LOS in patients discharged from hospital, 
lower age (p<0.001), being ambulatory (p=0.010), 
higher comorbidity burden (p=0.005), not using 
oxygen therapy (p=0.006), hospitalization in the 
previous trimester (p=0.015) and reduced lev-
el of consciousness as an aspiration risk factor 
compared to witnessed large aspiration (p=0.001) 
were significant demographic factors; high white 
blood cell (WBC) count (p=0.002), low serum 
creatinine (p=0.002) and albumin (p=0.005) and 
high serum sodium (p=0.001) were significant 
clinical factors; isolation of Klebsiella pneumoniae 
(p=0.029), Corynebacterium (p=0.050) or Enterobac-
ter species (p=0.010) were significant microbio-
logical factors; need for bronchoscopy (p<0.001) 
or change in antibiotic regimen (p<0.001) were 
significant therapeutic factors. Applying a unique 
model including all of the above significant pre-
dictors, the following variables were identified 
as independent correlates of increased LOS: age 
(p<0.001), comorbidities (p=0.018), oxygen ther-
apy (p=0.005), WBC (p=0.002), serum creatinine 
(p=0.048), Enterobacter species isolation (p=0.005), 
bronchoscopy (p<0.001) and antibiotic change 
(p=0.001). The model was statistically significant 
(p<0.001) and explained 84.5% of the variance in 
LOS among patients discharged from hospital.
n DISCUSSION
The majority of patients that were hospitalized 
with diagnosis of aspiration pneumonia in our 
department over a year’s period had increased 
contact with healthcare services. These cases 
(HCAAP) were more likely to have history of 
psychiatric disease, increased antibiotic usage 
and lower respiratory tract isolation of MDR-XDR 
pathogens. Although they were initially treat-
ed more frequently with MRSA-targeted agents, 
they were less likely to receive adequate empiric 
therapy than CAAP cases. They also developed 
more often total lung atelectasis requiring ther-
apeutic bronchoscopy and were more likely to 
receive parenteral nutrition. Half the patients 
died during their hospital stay, but no difference 
in mortality rate was observed between the two 
groups. Effectiveness of empiric therapy was the 
most important prognostic factor, followed by 
older age, low serum albumin and increased radi-
ological involvement.
Our study has several limitations. Even with the 
current definition of aspiration pneumonia, it 
could be difficult to distinguish aspiration pneu-
monia from aspiration pneumonitis and a degree 
of contamination may exist. The variety in the 
acquisition of lower respiratory tract specimens 
and the lack of anaerobic microbiological inves-
tigation was dictated by the daily routine of a 
large pulmonology department, since it was not 
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possible for all patients to undergo bronchoscopy 
or to maintain adequate sampling, transport and 
culture conditions respectively. The use of qual-
itative instead of quantitative cultures makes it 
less possible to clearly identify microbial etiology; 
however, a recent meta-analysis has shown that 
there is no clinical advantage in terms of mortal-
ity, length of mechanical ventilation or ICU stay 
and antibiotic change in patients with ventila-
tor-associated pneumonia (VAP) [18].
Our microbiological data are in accordance with 
most recent research and confirm the predomi-
nance of Gram-negative bacilli in lower respirato-
ry tract flora of patients with aspiration pneumo-
nia and the growing challenge posed by antibiot-
ic-resistant strains, especially in, but not limited 
to, healthcare-associated cases [8, 9]. Similar to 
Wei et al., we identified Pseudomonas aeruginosa as 
the leading pathogen and showed that isolation 
of Streptococcus pneumoniae, Haemophilus influen-
zae and Escherichia coli has decreased since last 
decade’s studies and that the emergence of XDR 
Acinetobacter baumannii is already becoming a ma-
jor issue [6-9]. Our data also correspond to pre-
vious epidemiologic studies of hospital-acquired 
pneumonia (HAP), VAP and respiratory tract col-
onization in the ICU in Greece, where Pseudomonas 
aeruginosa - and especially resistant strains - is the 
most frequent isolate [19-21]. A novel finding of 
our study is the isolation of Corynebacterium spe-
cies from nearly one fifth of the HCAAP cases. 
Recent reports have highlighted the pathogen-
ic role of non-diphtheriae Corynebacterium spe-
cies in lower respiratory tract infections, such as 
HAP or VAP and acute exacerbation of chronic 
obstructive pulmonary disease or bronchiectasis, 
occurring in immunocompromised or debilitat-
ed patients with pre-existing chronic pulmonary 
diseases, presence of medical devices, prolonged 
hospitalizations and use of broad-spectrum anti-
biotics [22, 23].
Our cohort exhibited higher in-hospital mortal-
ity than previous studies, while 90-day mortali-
ty exceeded 2/3 of the sample [1, 3-9]. The high 
proportion of old-aged, bedridden and demented 
patients may partially explain the observed worse 
prognosis. PSI modestly predicted in-hospital 
mortality, with an AUROC much lower than the 
summary of 0.81 from a recent meta-analysis of 
hospitalized patients with community-acquired 
pneumonia (CAP) [24]. Lanspa et al. also found 
that another prediction tool, CURB-65, performed 
significantly poorer in their retrospective cohort 
compared to a cohort of CAP patients from the 
same hospital [3]. Most of the prognostic factors 
for in-hospital mortality identified in this study 
were also evident in previous research, such as 
older age, chronic respiratory insufficiency, poor 
nutritional status, increased radiological involve-
ment and ineffective initial therapy [7-9]. The 
finding that patients with impaired swallowing 
reflex had significantly higher mortality rate than 
patients with a witnessed large aspiration event 
can be possibly attributed to repeated silent as-
piration episodes, accumulating a large bacterial 
load over time, in those with swallowing difficul-
ties or misclassification of aspiration pneumonitis 
cases as aspiration pneumonia in those with mac-
roaspiration.
We further tested statistically significant cor-
relates of prolonged hospital stay in patients 
discharged from hospital, although, due to the 
small sample size, results must be interpreted 
with caution. Younger ambulatory patients had 
high LOS mostly because they were more likely 
to receive mechanical ventilation than older de-
bilitated patients, who had more often a “do not 
resuscitate” order applied, while it is possible that 
patients not on long-term oxygen therapy had to 
stay longer in hospital to fully recover from hy-
poxemia. More comorbidities, previous hospitali-
zation, malnutrition, high inflammatory markers 
and electrolyte disorders seem to complicate and 
prolong hospital stay, findings consistent with 
previous research in CAP [25, 26]. Patients that re-
quired bronchoscopic intervention for atelectasis 
and change in their antibiotic therapy because of 
clinical deterioration or hospital-acquired super-
infections had also late discharge. In a study ex-
amining clinical impact of bronchoscopy in aspi-
ration pneumonia patients admitted to ICU, those 
that underwent bronchoscopy within 24 hours 
after intubation had lower mortality and shorter 
duration of mechanical ventilation and ICU LOS 
than patients that had bronchoscopy later during 
their stay [27]. Finally, identified microbiological 
predictors of LOS are based on limited number of 
isolates to reach a safe conclusion.
Despite the unavailability of anaerobic cultures 
and the inability to distinguish between etiolog-
ical pathogens and simple colonization in our 
study, we strongly believe that the microbiologi-
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cal landscape of aspiration pneumonia has indeed 
changed over the last decades. Our findings cor-
respond with those of recent research which has 
found that effective empiric antimicrobial thera-
py is the cornerstone of management of these pa-
tients. In light of the above, selection of antibiotics 
for empiric treatment should be guided by the 
need to cover for Gram-negative bacilli, especial-
ly Pseudomonas aeruginosa. Moreover, aspiration 
pneumonia patients who have increased contact 
with healthcare services or facilities are at risk of 
colonization with resistant strains of Gram posi-
tive bacteria, such as MRSA and Corynebacterium 
species, and should be evaluated for the necessity 
to receive glycopeptides or linezolid in the initial 
regimen. More studies are required to examine 
the impact of Acinetobacter baumannii isolation in 
HCAAP cases in order to determine the need for 
empiric coverage.
In conclusion, we have shown that Gram-nega-
tive bacilli are the main isolates from aspiration 
pneumonia cases and that they demonstrate mul-
ti-drug resistance patterns in healthcare-associat-
ed infections. Proper assessment of severity re-
garding demographic, clinical and radiobiological 
factors, along with administration of appropriate 
initial antibiotic therapy may lead to more favora-
ble outcomes in clinical practice.
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n INTRODUCTION
A considerably high fraction of the world pop-ulation is infected chronically by Helicobacter 
pylori (HP). This bacterium has been known to be 
a cause of several diseases from a simple infec-
tion to stomach cancer. Thus, it warrants an im-
mediate treatment but depending on the discrep-
ancies at resistance rates in different countries, as 
well as due to incomplete implementations of the 
corresponding protocols, the success rates of the 
treatment protocols differ considerably among 
different countries. In the countries where bis-
muth procurement is possible and considering 
resistance rates in the country, bismuth plus two 
antibiotics and proton pump inhibitors (PPI), i.e., 
a quadruple treatment protocol, is offered. On the 
other hand, in the developing countries where 
bismuth is not available, a combination of PPI 
plus three antibiotics is used as a varied foursome 
treatment protocol. In these treatment protocols, 
the antibiotics such as metronidazole and tetracy-
cline are commonly used [1]. In our country, HP is 
as widespread as other countries in our region [2].
The primary use of antibiotics is the protection 
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Microbiota is a dynamic system showing individual 
differences in both the number and species of micro-
organisms. Dietary habits, lifestyle, age, genetic pre-
disposition of the host and use of antibiotics are ef-
fective on microbiota. The aim of our research was to 
carry out a quantitative comparison of Bifidobacterium 
spp, Bacteroides fragilis, Lactobacillus spp, Akkermansia 
mucinophilia and Faecalibacterium prausnitzii, impor-
tant bacterial microbiota species, before and after an-
tibiotic therapy treated with tetracycline and metroni-
dazole in patients who are diagnosed as positive for 
Helicobacter pylori (HP), and to determine the effects 
of antibiotic use on the microbiota. Eighteen HP-pos-
itive patients were enrolled in this study. A special 
extraction kit (QIAmp DNA Stool Mini Kit, QIAgen, 
Germany) was used for the DNA isolation procedure. 
Primers specific to the 16S rRNA region of the bacte-
SUMMARY
ria included in the study were used for the amplifi-
cation of the target region. All the bacteria were sub-
jected to real-time quantification procedure with PCR 
method on RotorGene® 20 device (Qiagen, Germany). 
According to quantification before and after antibiot-
ic use in patients receiving HP treatment, statistically 
significant decreases were observed in Bifidobacterium 
spp (p=0.001), B. fragilis (p=0.001), Lactobacillus spp 
(p=0.001), A. mucinophilia (p=0.001) and F. prausnitzii 
(p=0.001). We were unable to identify B. fragilis in the 
microbiota of five patients after treatment. Based on 
the data obtained, it can be concluded that antibiotics 
used to treat HP can prepare the ground that could 
result in dysbiosis in microbiota.
Keywords: Helicobacter pylori, antibiotic treatment, 
bismuth, microbiota.
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from a pathogenic agent and to ensure a therapy 
[3]. Antibiotics, besides their expected changes 
on target microorganisms, may also lead to un-
desirable changes in microbiota. Although found 
to be extremely safe medications so far, they have 
recently gained interest as their effects on micro-
biota and host. Antibiotics may deteriorate the 
stability of microbiota, which has been quite sta-
ble in a host. Regarding the antibiotic utilization, 
variations in terms of quantity used and the types 
have been observed. These conditions usually 
lead to dysbiosis which, in a long term, results 
in the changes in the functional properties of mi-
crobiota. The impact of antibiotics on microbiota 
has been studied since 1940s. However, at that 
time, only short-term effects on variations could 
be investigated by culture-based techniques [4]. 
The data obtained by these methods are not ad-
equate to find out completely the whole range of 
antibiotic effects on the microbiota. At present, it 
is possible not only to put forward the short-term 
effects of antibiotics but also the long-term effects 
in terms of molecular techniques [5, 6]. The stud-
ies on antibiotic treatments have shown that the 
microbiota decreases by one-fourth to one-third 
of its initial quantity and more, resulting in con-
siderable changes in the composition of micro-
biota [5]. In this context, the modern molecular 
methods have boosted both the sensitivity and 
specificity of the analysis done on microbiota [7].
In this study, we aimed to screen, by real-time pol-
ymerase chain reaction (qPCR), the changes in the 
gut microbiota of HP patients, on whom a treat-
ment protocol involving PPI, tetracycline, metro-
nidazole, and bismuth was applied.
n PATIENTS AND METHODS 
Ethics committee approval and informed consent 
An approval was obtained at the beginning of 
the study from the local ethics committee of the 
Zekai Tahir Burak Women’s Health Training and 
Research Hospital. Written informed consent was 
obtained from all patients who participated in 
this study.
Patients’selection
For this study, 26 HP-positive patients admitted 
to Department of Gastroenterology, Gazi Univer-
sity, were enrolled after screening their baseline 
stool samples. Exclusion criteria were the history 
of antibiotic therapy right before up to one month 
of starting the study; the patients who were treat-
ed by corticosteroids, prebiotics or/and probiot-
ics in last six months; and a medical history of 
kidney disorder, gut surgery, diabetes, obesity, 
inflammatory bowel disease, irritable bowel syn-
drome, mental disorder, neurological disorders or 
cardiopulmonary disease. The patients who were 
not able to complete the HP eradication treatment 
were not included.
Only 18 out 26 patients completed the study. The 
others were excluded due to medication side-ef-
fects (n=2), failure to comply with the treatment 
protocol (n=2), and protocol violation due to ex-
clusion criteria [6].
The compliance to the treatment was checked by 
empty medication boxes returned after the treat-
ment.
The HP eradication protocol was a quadruple 
bismuth-containing regimen (PPI bid, tetracy-
cline 500 mg qid, metronidazole 500 mg tid, and 
bismuth subsalicylate 262 mg qid for 10 days). 
Among 18 patients, 15/18 (83%) were responders 
(HP eradication) and 3 were still positive for HP. 
These 18 patients had the full dosage of the treat-
ment regimen and for this reason, the results were 
presented as per protocol analysis. These patients 
(completing the full protocol) were enrolled in the 
microbiome study.
Pre-treatment HP diagnosis was made by patho-
logical evaluation of endoscopic biopsies (2 an-
trum, 2 corpus and 1 incisura angularis). Any 
positive result from these biopsies confirmed HP 
diagnosis. Post-treatment HP eradication was 
confirmed by C13 urea breath test after 6 weeks.
Thirty-six stool samples were collected before 
and after six weeks of HP eradication therapy. All 
samples collected both before and after antibiotic 
medication were kept at -80 °C until the day of 
study.
n REAL TIME PCR CONDITIONS
Preparation of Standards
In this study, Bifidobacterium breve ATCC 15700, 
Bacteroides fragilis ATCC 25285, Lactobacillus acido-
philus ATCC 4356, Akkermansia muciniphila ATCC 
BAA-835 and Faecalibacterium prausnitzii ATCC 
27766 from the American type standard culture 
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collections (ATCC) were used (Table 1) [6-10]. The 
primary sequences specific to 16S rRNA of the 
bacteria were used and at least three standards 
were implemented to obtain the standard curve. 
The numbers of copies of the bacterium in the 
clinical samples were determined from the drawn 
standard curves.
DNA extraction
The DNA was isolated from the stool samples 
using an extraction kit designed for special stool 
samples (QIAamp DNA Stool Mini Kit, Qiagen, 
Hilden, Germany) following the extraction pro-
tocol prescribed for the kit (Protocol: Using Stool 
Tubes for Isolation of DNA from Stool for Human 
DNA Analysis).
qPCR
Amplification reaction for the quantitation was 
realized using the SYBR green (RT2 SYBR Green 
qPCR, Qiagen, Germany) Rotor-Gene 6000 instru-
ment. For each sample, an amplification mixture 
in a final volume of 25 μL was prepared. Melting 
curve analysis using the fluorescence by qPCR 
was drawn.
Statistical analysis 
The data were fed into a Microsoft Excel sheet and 
the amount of bacterium in logarithmic scale was 
calculated. The evaluation of the data was real-
ized by using Statistics package for Social Scienc-
es (SPSS) 22 package program (Inc. USA). Average 
and percentile values were calculated and neces-
sary comparisons were made. The average values 
of the data related to both pre- and post-antibiot-
ic utilization were assessed by Mann-Whitney U 
test and p<0.05 was accepted as significant (SPSS 
version 22, Inc USA).
n RESULTS
The study population consisted of 7 males (39%) 
and 11 females (61%). The mean age value was 
42±13 years. The quantitation of all bacterial spe-
cies in the baseline stool samples revealed that the 
bacterial composition was similar at the baseline, 
regardless of the gender and the age of the pa-
tients. Seven patients were overweight according 
to their body mass index (BMI) (between 25 and 
9.9 kg/m2). However, we did not detect any signif-
icant difference in the gut microbiota composition 
of these patients (Bifidobacterium spp. p=0.508, B. 
fragilis p=0.456, Lactobacillus spp. p=0.204, A. mu-
cinophilia p=0.714, F. prausnitzii p=0.714).
The quantification of bacteria in stool was rep-
resented under log10/g logarithmic scale. In ad-
dition, the average values of the bacterium at 
log10/g stool are also shown in Table 2.
Bifidobacterium spp. qPCR results
Bifidobacterium breve ATCC 15700 was used to 
determine the copy number in both pre and 
post-treatment samples. Bifidobacterium spp. were 
Table 1 - Primers belonging to standard strains, target region volume and PCR temperature.
Microorganism Primer name Primer (5’=>3’)
Target Region 
Volume (bp*)
Annealing 
temperature (ºC)
Reference
Bifidobacterium spp.
g-Bifid-F CTCCTGGAAACGGGTGG
550 55 [8]
g-Bifid-R GGTGTTCTTCCCGATATCTACA
Bacteroides fragilis 
group
g-Bfra-F ATAGCCTTTCGAAAGRAAGAT
495 50 [8]
g-Bfra-R CCAGTATCAACTGCAATTTTA
Lactobacillus spp.
Lact-F AGCAGTAGGGAATCTTCCA
341 50 [9]
Lact-R CACCGCTACACATGGAG
Akkermancia 
mucinophilia
AM-1 CAGCACGTGAAGGTGGGGAC
327 60 [10]
AM-2 CCTTGCGGTTGGCTTCAGAT
Faecalibacterium 
prausnitzii
Fprau223F GATGGCCTCGCGTCCGATTAG
199 58 [11]
Fprau420R CCGAAGACCTTCTTCCTCC
*bp: base pair.
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significantly decreased (p=0.001) and were de-
tected in four patients.
B. fragilis qPCR results
Bacteroides fragilis ATCC 252855 isolate was used 
to determine the copy number of B. fragilis before 
and after antibiotic medication. By comparing the 
samples taken before and after antibiotic medica-
tion, it was observed that B. fragilis was signifi-
cantly decreased (p=0.001). This bacterium was 
not detected in five patients and all of them were 
of an age over 60 years.
Lactobacillus spp. qPCR results
Lactobacillus acidophilus ATCC 4356 was taken as a 
standard strain to determine the copy number of 
Lactobacillus spp. before and after antibiotic use. 
From the samples taken before and after the anti-
biotic medication, it was concluded that Lactoba-
cillus spp. were significantly decreased (p=0.001).
A. mucinophilia qPCR results
Using the standard Akkermansia muciniphila ATCC 
BAA-835 isolate, indicated a decrease in the copy 
number of A. mucinophilia after antibiotic use at a 
statistically significant level (p= 0.001).
F. prausnitzii qPCR results
Faecalibacterium prausnitzii ATCC 27766 was used 
as a standard isolate, and copy numbers of F. 
prausnitzii were determined before and after the 
antibiotic use. We found that F. prausnitzii was 
significantly decreased after antibiotic treatment 
(p=0.001).
Antibiotic effect on microbiota
All bacterial groups were significantly decreased 
following HP eradication regimen. Mann-Whit-
ney U test was carried out for each bacterial 
species and indicated that the differences were 
statistically significant (p=0.001). The degree 
of decrease in bacterial groups in patients who 
had eradicated or failed eradication was similar 
(p>0.05).
n DISCUSSION
In this study, we aimed to investigate the effects 
of antibiotics on microbiota, which are used for 
the treatment of HP patients in Turkey and oth-
er countries. For this purpose, volunteer patients, 
who were diagnosed with HP at the gastroenter-
ology department, faculty of medicine at Gazi 
University, were enrolled in the study. A gastro-
enterology specialist implemented the standard 
treatment protocol to the volunteers. Regarding 
the protocol, a quadruple treatment protocol, 
involving PPI, tetracycline, metronidazole, and 
bismuth subsalicylate, was administered for ten 
days. Two stool samples were taken from the pa-
tients: before antibiotic medication and six weeks 
after the medication. We believe that 6 weeks is a 
short time for recovery of the gut microbiota. In 
the study, two different classes of antibiotics were 
used: tetracycline and metronidazole. The simul-
taneous medication of both tetracycline and met-
ronidazole significantly affected Bifidobacterium 
spp., B. fragilis, Lactobacillus spp., A. mucinophil-
ia, and F. prausnitzii, whose concentrations were 
found to be significantly lowered after antibiotic 
use as compared to the pre-medication condition.
It has been reported that a couple of weeks after 
the treatment, the microbiota returns back to its 
pre-treatment state. However, in some other cas-
es, this effect lasted for a long-term and even three 
months after the medication, the microbiota was 
not able to come back to its pre-medication state 
Table 2 - Bacteria qPCR results average and standard deviation.
Microorganism Before antibiotic usage average±SD* (log10/g) After antibiotic usage average±SD* (log10/g)
Bifidobacterium spp 7.81±1.12 6.11±2.74
B. fragilis 8.24±1.19 5.69±2.89
Lactobacillus spp 7.39±0.61 6.32±1.74
A. mucinophilia 8.08±0.60 6.10±0.86
F. prausnitzii 9.21±2.09 6.32±1.59
*SD: standard deviation.
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completely [12-14]. Earlier analysis of gut micro-
biota in our study might yield a false result due to 
slow recovery in some patients. 
In an experimental animal model, an antibiotic 
cocktail of ampicillin, gentamicin, metronidazole, 
neomycin, and vancomycin was implemented to 
animals for ten days. In the presence of a bacterial 
loading, anatomical, histological, and immuno-
logical variations were detected. After studying 
the microbiome by 16S rDNA and qPCR, it was 
noticed that the number of bacteria has decreased 
by ten times compared to that of the control group 
and this reduction was more prominent on Firmi-
cutes spp. However, in the case of Bacteroides and 
Akkermansia spp, an increase was observed [15]. 
Similarly, in our study, the reduction of Firmicutes 
was more than ten-times but in contrast to the 
previous reports, we found a ten-fold decrease in 
Bacteroides and Akkermansia spp. Moreover, no B. 
fragilis were found in five patients. 
The antibacterial activity of bismuth, involved 
in the treatment protocol, has been well estab-
lished [16]. It can be speculated that the use of 
bismuth could have contributed to the decrease 
in the number of these bacteria. It was observed 
that in the HP patients on whom clarithromycin 
and metronidazole treatment protocol had been 
implemented, in culture-based studies, as a short-
term effect of antibiotics, an absolute change at 
microbiota was noted [17-19].
A sharp and considerable decrease was noted 
soon after the treatment for the bacteria, Bifidobac-
terium, Clostridium, and Bacteroides spp, which can 
be cultured, and Bifidobacterium spp. and Bacte-
roides spp. bacteria showed a sustainable decrease 
lasting up to four weeks after the treatment [17]. 
A research group, considering the importance of 
individual evaluation of the effects of antibiotics, 
investigated both short and long term effects of 
antibiotics on intestine microbiota at three HP pa-
tients taking clarithromycin and metronidazole. 
The stool samples were evaluated at zero day, 
8-13 day, first year, and fourth year. However, a 
decrease in bacteroides was observed in all pa-
tients. The discrepancies in the bacteria type were 
followed for all patients [20]. As a similarity to 
our study, a decrease in all groups of bacteria was 
noticed among the individuals along with their 
different decrease rates.
Regarding our data, it can be speculated that the 
statistically significant decline of all the bacteria 
may be brought by the high sensitivity of the an-
aerobic bacteria to metronidazole. In fact, in our 
country, the rate of metronidazole resistance of B. 
fragilis is under 1% [21].
A continuous and long-term medication using 
antibiotics leads to the occurrence of dysbiosis in 
the intestine, which actually triggers the factors 
leading to several diseases. In a study carried on 
718 volunteers with a four-year follow-up, a pos-
itive correlation between antibiotic use of the pa-
tients and the evolution of intestine inflammatory 
disease was observed. Moreover, it was expressed 
that the intensity of the disease had increased 
with the increasing rate of antibiotic use [22].
There are studies investigating the role of antibi-
otic-induced dysbiosis and carcinogenesis [23]. In 
a similar study involving 4029 patients, antibiot-
ic-induced dysbiosis was related with colon can-
cer risk. Moreover, an antibiotic prescription for 
five or more times in a year significantly increased 
cancer risk [24].
There are many weak points in our study. We had 
chosen only 5 bacterial species which represents 
the major species that might change after antibi-
otic therapy. Another reason is that these bacteria 
were associated with many conditions in previ-
ous reports. This approach (may be not complete) 
might facilitate the translation of this complex 
and expensive microbiome analysis procedure 
into clinical practice.
Probiotics have been studied for their protec-
tive role in antibiotic-induced dysbiosis. Some 
researchers claimed that probiotics are effective 
in reducing side effects of HP eradication and 
no probiotic is superior to the other [25]. On this 
aim, in a study, a group of patients took anti-HP 
treatment and another group had HP treatment 
plus a probiotic. Consequently, in both groups, 
Firmicutes filum was decreased statistically but 
the change was mild in the group treated with 
the probiotic. It has been proved that probiotics 
are effective in both protecting microbiota bal-
ance connected to antibiotic use and keeping the 
changes caused by antibiotics at minimum levels 
[26]. Probiotics also increase patient adherence to 
HP eradication regimens by attenuating antibiot-
ic-related side effects [27, 28]. Recent Maastricht 
Guideline recommended probiotic supplementa-
tion in HP eradication [29].
Our study is the first attempt in the literature in-
vestigating the effect of bismuth-based quadru-
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ple therapy on gut microbiota. Bismuth is widely 
used in areas where clarithromycin resistance has 
increased. However, bismuth salt is a strong topi-
cal antibiotic with widespread effects on local gut 
community. This study, which assesses the short-
term effect of HP treatment on microbiota, is a 
preliminary study. We need of long term studies 
to assess whether dysbiosis in HP-treated patients 
is a risk factor for disease.
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n INTRODUCTION
Surgical site infections (SSIs) are among the most common health care associated infec-
tions in children, with rates ranging from 2.5% 
to 5.4%. They are connected to significant post-
operative morbidity (such as delayed wound 
healing, increased antibiotics administration with 
their related adverse effects and possible systemic 
spread) and mortality [1-6].
Oncological patients could be considered at par-
ticular risk of SSIs because of the neoplastic pro-
cess itself and the immunosuppression induced 
by the chemotherapy [7].
Antibiotic prophylaxis is a well-known strategy 
for preventing SSIs also in the field of surgical on-
cology [8]. Unfortunately, there are no data on its 
effectiveness of in children.
The aim of this study is to investigate the inci-
dence of SSIs in children undergoing surgery for 
abdominopelvic neoplastic diseases receiving a 
24 hours prophylaxis with cefazolin.
n PATIENTS AND METHODS
The Istituto Giannina Gaslini (IGG) in Genoa-Ita-
ly is a tertiary care center for children.
Clinical data of children undergoing abdomin-
opelvic surgery for neoplastic diseases from Jan-
uary 2008 to December 2016 were retrospective-
ly analyzed. The incidence of SSIs in the 30 days 
following the surgical procedure was investigat-
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Little is known about the effectiveness of antibiotic 
prophylaxis for prevention of surgical site infections 
(SSIs) in paediatric abdominopelvic surgical oncology. 
A retrospective analysis was performed upon the inci-
dence of SSIs in children receiving a 24-hour antibiotic 
prophylaxis with cefazolin for abdominopelvic onco-
logical surgery. 
In all, 145 patients (57% females) with a median age 
of 4 years underwent surgical procedures for abdomi-
nopelvic tumours. No SSIs were detected, despite the 
SUMMARY
various risk factors known to be associated with their 
occurrence (such as pre- and post- surgical chemother-
apy, long hospitalization, intensive care unit admission 
and drain placement). Cefazolin prophylaxis seems to 
be safe and effective in preventing SSIs in children 
undergoing abdominopelvic surgery for oncological 
diseases.
Keywords: surgical site infections, antibiotic prophylax-
is, paediatric surgical oncology.
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ed. All patients received antibiotic prophylaxis 
with cefazolin 25 mg/kg (maximum 2000 mg) 30 
minutes before skin incision and two more times 
within the first 24 hours after surgery (total: 3 dos-
es). Adherence to prophylactic protocol was mon-
itored through a checklist routinely completed 
before skin incision. Povidone-iodine was used as 
skin preparation agent in all cases.
For each patient the following data were collected: 
demographics, type of malignancy, the American 
Society of Anesthesiologists status (ASA), type 
of surgical procedure, wound classification [12], 
insertion of a central venous catheters (CVC), re-
quirement of blood transfusion, placement of uri-
nary catheter, suction or open drain placement, 
postoperative intensive care unit admission, pre- 
and post- operative length of hospital stay, previ-
ous hospitalization within 30 days, pre- and post- 
surgical chemotherapy.
SSIs were diagnosed when the infectious process 
affected either the incision or the deep tissue at 
the operation site [9]. Wound cultures and medi-
cal imaging were performed in case of sign of SSIs 
as erythema, tenderness, induration or purulence 
at the site of incision, associated or not with sys-
temic signs. Blood cultures were performed in 
case of clinical signs of systemic infections (i.e., 
fever, chills, and/or hypotension). Central ve-
nous catheter related infections were diagnosed 
according to our previous definitions [10]. Urine 
cultures were performed in case of fever in ab-
sence of signs of SSIs or in case of suspected uri-
nary tract infections.
In consideration of the descriptive nature of the 
study and in the absence of any prospective ran-
domization or historical control comparison, no 
statistical analysis was performed.
n RESULTS
During the study period a total of 146 patients 
underwent surgery for abdominopelvic tumors. 
Table 1 reports tumor diagnosis in prevalence or-
der, while Table 2 summarizes demographic data. 
Particularly, median age at surgery was 4 years 
(1 month -28 years), with 4 patients (3%) young-
er than 30 days of life. Median weight was 15 kg 
(4 kg - 76 kg). In 38% of cases chemotherapy was 
administered before surgery. The majority of pa-
tients (96%) was hospitalized more than 24 hours 
before surgery with 56% of them at least 30 days 
before it. The ASA score was I-II in ¾ of patients, 
with only 1 patient that was ASA score IV. The 
median duration of the surgical procedure was 
180 minutes (25 minutes - 845 minutes), but in ¼ 
of cases the procedure was longer than 5 hours. 
Laparoscopic surgery was performed in near 1/5 
of cases. After surgery a drain was placed in 57% 
of patients. Admission in intensive care unit was 
necessary in 23% of patients. Twenty-six percent 
of cases required blood transfusions. Finally, a 
CVC (80% tunneled) was inserted concomitant-
ly with the abdominal surgery in near a half of 
patients, while urinary catheter was positioned in 
66%. Median duration of hospitalization was 10 
days, in 8% of cases it was longer than 30 days. 
Surgical wound was classified as clean (class I) 
in 135 (92%) cases, as clean/contaminated (class 
II) in 7 (5%) and as class III (dirty) in 4 (3%) be-
Table 1 - Histological types categorized in relation to 
tumor primary site.
Diagnosis n (%)
Adrenal tumor
Peripheral neuroblastic tumor
Mesothelial cyst
Adrenaline producing tumor
82 (56%)
78
1
3
Ovarian tumor
Teratoma
Cistoadenoma
Leydig Sertoli cell tumor
Fibrothecoma
Embrional carcinoma
Dysgerminoma
26 (18%)
14
8
1
1
1
1
Renal tumor
Wilms tumor
Sarcomatoid cancer
Rhabdoid tumor
Carcinoma
Cystic nephroma
25 (17%)
21
1
1
1
1
Pelvic tumor
Sacrococcygeal teratoma
Pelvic rhabdomyosarcoma
Pelvic york sac tumor
Pelvic schwannoma
8 (6%)
3
3
1
1
Gastrointestinal tumor
Gastric teratoma
Hepatoblastoma
Anaplastic tumor of the colon
3 (2%)
1
1
1
Abdominal wall tumor
Sarcoma
2 (1%)
2
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cause of gross contamination or spillage of the 
operative field. After surgery, fever occurred in 18 
(12%) patients. No case of SSIs was detected. In 
5 cases (28% of febrile episodes) an infection of 
the CVC-insertion site that required its removal 
occurred. In 3 cases (3% of patients with urinary 
catheter) urinary tract infections were diagnosed, 
in 2 cases due to Escherichia coli, in a single case 
due to Candida albicans.
Chemotherapy was administered to 43% of pa-
tients within 1 month after surgery, but no case 
of SSIs was observed, even in presence of granu-
locytopenia.
No adverse event related with cefazolin adminis-
tration was observed.
n DISCUSSION
In the present study we evaluated the incidence of 
SSIs in children undergoing surgery for abdomin-
opelvic neoplastic diseases who received 24 hours 
antibiotic prophylaxis with cefazolin that still rep-
resents the recommended prophylaxis in many sur-
gical procedures [11-16]. Although oncological sur-
gery is usually clean (as in the 92% of our patients), 
considering the lack of specific recommendations, 
we decided to administer an antibiotic prophylaxis 
because of the immunocompromission induced by 
the neoplastic disease itself and by the chemother-
apy administered. Even if chemotherapy-induced 
granulocytopenia is a well-known risk factor for 
infections in oncological patients, data from adults 
indicate that surgical and ICU-related factors are 
more critical [7].
Our patients presented many risk factors gener-
ally associated with SSIs [2, 8, 17-20]. As a matter 
of fact, 3% percent were neonates, 25% of the sur-
gical procedures lasted more than 5 hours, 57% 
required drains, 49% CVCs and 66% urinary cath-
eters, while surgical wound contamination was 
infrequent (3% only). Moreover, 96% were inpa-
tient for more than 24 hours at time of surgery, 
23% required ICU admission and postoperative 
length of hospital stay was longer than 30 days in 
12%. In spite of all these risk factors, no SSIs was 
observed.
Few studies have been published in the last 10 
years on the rate of infectious complications in 
children undergoing surgery for abdominal solid 
tumors [2, 21-24]. Qureshi et al. reported a 4% of in-
Table 2 - Patient demographics, surgery-related data 
and admission-status features.
n (%)
Patient demographics
Sex
- Male
- Female
63 (43%)
83 (57%)
Age, median, range 4 years (1 month 
-28 years)
Weight (kg), median, range 15 (4-76) 
ASA physical status
- I - II
- III - IV
107 (73%)
39 (27%)
Surgery-related data
Wound class
- I
- II
- III
135 (92%)
7 (5%)
4 (3%)
Surgical time (minutes), median, range 180 (25-845)
Type of procedure
- Open
- Laparoscopic
115 (79%)
31 (21%)
Procedures requiring blood transfusion 38 (26%)
Central venous catheter placement 
concomitantly with surgery
- Partially implanted central  
venous catheters (Broviac) 
- Totally implanted central  
venous catheters (port) 
- Non-tunneled central  
venous catheters 
- Peripherally inserted central  
catheters
71 (49%)
57
10
3
1
Urinary catheter placement 97 (66%)
Drain placement
- Suction
- Open
- Both
82 (57%)
76 
6
1
Admission-related data
Preoperative chemotherapy 56 (38%)
Previous hospitalization within 30 days  82 (56%)
Being inpatients 140 (96%)
Postoperative admission 
- Intensive care unit
- Surgery ward
34 (23%)
112 (77%)
Postoperative chemotherapy 63 (43%)
Length of hospital stay (days),  
median, range
10 (2-384)
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cidence of SSIs in 106 neuroblastoma patients treat-
ed from 2006 to 2011, while Ritchey et al. rated a 2% 
of SSIs in 534 children required surgery for Wilms’ 
tumor from 1986 to 1994 [23, 24]. However no data 
on antibiotic prophylaxis were documented.
In conclusion, in the absence of a randomized 
clinical trial, our results demonstrate that antibi-
otic prophylaxis with cefazolin is safe and effec-
tive in preventing SSIs in children undergoing 
abdominopelvic surgery for tumors.
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n INTRODUCTION
Antiretroviral therapy (ART) has dramati-cally improved the quality of life of people 
living with HIV; despite its remarkable effective-
ness and tolerability, ART is currently a lifelong 
treatment that can be associated with long-term 
side effects on liver, kidney, bone and lipid me-
tabolism, according to type of drug regimen used 
[1]. Pill burden and fatigue are also common is-
sues of lifelong treatments and both are major 
causes of poor adherence and treatment failure 
[2]. Furthermore, the cost of a lifelong ART is a 
major concern for healthcare systems world-
wide [3]. To date, several strategies have been at-
tempted to reduce pill burden and/or long-term 
side effects. Single-tablet regimens (STR) are the 
Day-On, Day-Off emtricitabine, 
tenofovir disoproxil fumarate  
and efavirenz single tablet regimen 
(DODO) as maintenance therapy  
in HIV-infected patients
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Reduced dose schedules may be feasible options to 
simplify antiretroviral therapy (ART) in selected HIV-
1-infected individuals. Efficacy and safety of a Day-on, 
Day-off (DODO) schedule of tenofovir disoproxil fu-
marate, emtricitabine and efavirenz (FTC/TDF/EFV) 
single tablet regimen (STR) was assessed. Twenty-
seven patients were prescribed the DODO schedule 
and were monitored for 48 weeks. Switching crite-
ria were: no previous ART failure, no AIDS-defining 
illnesses, T CD4 cell nadir >200/mm3, and HIV-RNA 
below detection limit (40 copies/mL) for at least six 
months. Clinical and laboratory data, including plasma 
HIV-RNA levels, T CD4 and CD8 counts, liver and kid-
ney function, lipid levels and ultrasensitive C-reactive 
protein (us-CRP) were assessed at baseline, week 4, 12, 
24, and 48. Statistical analysis was performed by paired 
Student’s T-test for comparison between baseline and 
each time point, and Chi square test for CD4/CD8 ratio 
comparison. In all, 26 out of 27 patients maintained plas-
SUMMARY
ma HIV-RNA levels below the detection limit through 
the entire follow-up. One patient experienced low level 
plasma HIV-RNA rebound at week 36 (47 copies/ml) 
and immediately reverted to the conventional dose 
schedule of FTC/TDF/EFV; plasma HIV-RNA was un-
detectable after four weeks. No major changes on liver 
and kidney function tests, lipid levels and us-CRP were 
observed. Although no profound modifications of T 
CD4 count were observed during follow-up, the CD4/
CD8 ratio increased significantly at week 48 compared 
to the baseline (p<0.05). In conclusion, 48-week DODO 
administration of the fixed dose FTC/TDF/EFV STR 
combination was safe and effective in maintaining HIV 
viral replication below the detection limit in a selected 
group of HIV-1-infected individuals.
Keywords: HIV-1, antiretroviral therapy, simplification/
dose reduction, emtricitabine/tenofovir DF/efavirenz, 
single tablet regimen.
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therapeutic options with the lowest pill burden, 
intended for use in both naïve and experienced 
patients. Available combinations include two nu-
cleoside reverse transcriptase inhibitors (NRTIs) 
plus a third drug (either non-nucleoside reverse 
transcriptase inhibitors, NNRTI or integrase in-
hibitors, INSTI) in a single tablet, administered 
once daily. However, STR long-term side effects 
are comparable with non-STR regimens, given 
that the number of drugs used is unchanged. 
The so-called “less drug regimens” (LDR) repre-
sent an alternative therapeutic approach, widely 
evaluated in recent years, either constituted by a 
single antiretroviral drug (mono therapy, usual-
ly boosted protease inhibitors) or a combination 
of two drugs (dual therapy) [4, 5]. Mono/dual 
therapy are feasible options in selected groups of 
patients as maintenance regimens, allowing to re-
duce the number of drugs for long-term treatment 
and sometimes to reduce the overall pill burden 
[6, 7]. Such treatment is, however, not recom-
mended for patients naïve to ART, with history of 
AIDS-defining illnesses or ART-experienced with 
multiple drug resistance [8]. Besides, data on the 
long-term benefit of such reduction on overall liv-
er, kidney, bone and lipid metabolism are current-
ly unavailable. A third ART simplification strate-
gy, namely reduced schedule of administrations, 
has been recently proposed and this option may 
potentially reduce the burden of long-term side 
effects and poor adherence due to pill fatigue. The 
FOTO and BREATHER trials have shown that re-
ducing the number of administrations (e.g. five 
days on/two days off) is a potentially safe and 
effective option, as long as drugs with prolonged 
half-lives (i.e. efavirenz, EFV) are included in the 
regimen [9, 10]. To date, there is little evidence on 
EFV-based STR regimens with alternative admin-
istration schedule in clinical practice. We report 
on effectiveness and safety of an alternate-day 
administration schedule of emtricitabine (FTC)/
tenofovir disoproxil fumarate (TDF)/efavirenz 
(EFV)-based STR performed in a real-life setting.
n PATIENTS AND METHODS
Between July 2014 and August 2015, twenty-sev-
en HIV-1-infected patients undergoing once dai-
ly FTC/TDF/EFV STR were switched to a Day-
On Day-Off (DODO) schedule, as simplification 
strategy in the context of routine clinical practice. 
The switch was proposed to patients meeting the 
following criteria: no previous failure to ART; no 
previous AIDS-defining illnesses; T CD4 cells na-
dir >200/mm3; HIV RNA below detection limit 
(undetectable or <40 copies/mL) for at least 6 
months prior study entry. Extensive information 
was provided to the patients and a written in-
formed consent was obtained before switching 
to DODO schedule. To reduce the risk of missed 
doses due to forgetfulness, patients were in-
structed to take their medication every odd day 
of the month. Clinical and laboratory data were 
collected at baseline, week 4, 12, 24, 36, and 48 of 
treatment; an additional time point (week 52) was 
settled to further confirm end of follow-up plas-
ma HIV viral load levels. In case of viral rebound 
(defined as a single detection of plasma HIV-
RNA equal to or above 40 cp/ml) patients were 
instructed to switch to the conventional admin-
istration schedule and viral load was reassessed 
after 4 weeks. The main endpoint was to assess 
the proportion of subjects who maintained plas-
ma HIV RNA below the detection limit (<40 cop-
ies/mL or undetectable); secondary endpoint was 
to define the impact of DODO regimen on renal 
and liver function tests, lipid profile, mean T CD4 
and T CD8 cell count, CD4/CD8 ratio and ultra-
sensitive C-reactive protein (us-CRP). T cell sub-
sets were assessed by flow cytometry (FacsCanto, 
Becton Dickinson, NJ); HIV plasma viral load was 
assessed by Real-Time HIV-1 assay (Abbott, IL). 
Statistical analysis was performed by coupled 
paired Student’s T-test to compare baseline data 
to those obtained at the subsequent time-points, 
and Chi square test for CD4/CD8 ratio compari-
son; differences were considered statistically sig-
nificant if p<0.05.
n RESULTS
Twenty-seven patients were included in the anal-
ysis; no patient was lost to follow-up during the 
48-week monitoring. Four subjects (14.8%) were 
females; mean age at enrollment was 48.5±9.5 
years. Mean nadir of T CD4 cell count was 346/
mm3 (range 204-736) and mean T CD4 cell count at 
enrollment was 735/mm3 ±350. Mean number of 
previous ART regimens was 2.26 (range 1-8) and 
mean number of years from initial HIV diagnosis 
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was 13.9 (range 5-30). Duration of suppression of 
HIV replication before the initiation of the DODO 
schedule was 65 months on average (range 6-204). 
Twenty-six out of 27 subjects (96%) maintained 
plasma HIV viral load below the detection limit 
throughout the 48-week follow-up. One patient 
experienced low-level viral rebound at week 36 
(plasma HIV-RNA: 47 cp/ml) and was instruct-
ed to revert immediately to the conventional once 
daily FTC/TDF/EFV schedule; HIV viral load 
was again undetectable 4 weeks after interrup-
tion of the DODO schedule and in subsequent as-
sessments. No increased prevalence of HIV-RNA 
values “<40 copies/ml” over “undetectable” was 
observed among the other 26 patients during the 
follow-up: 22 of them were “undetectable” and 
4 were “<40 copies/ml” both at baseline and at 
week 48. In addition, only 1 patient out of the 26 
had plasma HIV-RNA <40 copies/ml at the addi-
tional time point of week 52, while in the others 
Table 1 - Laboratory test results during the day-on, day-off FTC/TDF/EFZ dose reduction schedule.
Test NR Baseline Wk 4 Wk 12 Wk 24 Wk 36 Wk 48
Creatinine (mg/dl) 0.60-1.40
0.89
(±0.16)
0.86
(±0.13)
0.85
(±0.16)
0.82
(±0.15)
0.85
(±0.14)
0.91
(±0.15)
eGFR (ml/min) >90
112.8
(±32.35)
117.9
(±31.65)
117.9
(±36.25)
120.8
(±33.01)
115.8
(±29. 06)
108.2
(±31.42)
AST (U/l) 0-40
20.3
(±5.98)
18.3
(±5.97)
18.28
(±5.07)
18.68
(±6.92)
20.4
(±7.63)
20.5
(±9.53)
ALT (U/l) 0-40
33.6
(±12.95)
33.2
(±14.47)
29.8
(±11.9)
32.0
(±19.4)
34.0
(±14.4)
33.9
(±16.3)
Cholesterol (mg/dl) <200
201.8
(±40.05)
183.8
(±56.7)
186.4
(±55.95)
197.5
(±53.55)
190.1
(±54.8)
191.5
(±44.5)
Triglycerides (mg/dl) <170
149.6
(±96.6)
168.9
(±56.7)
160.7
(±103.61)
163.8
(±121.0)
187.7
(±162.6)
150.3
(±78.0)
us-CRP (mg/l) <3
1.06
(±0.94)
1.10
(±1.18)
2.20
(±3.86)
2.40
(±4.77)
1.23
(±1.23)
1.59
(±1.26)
Mean and standard deviation (in brackets) are showed for each test at different time points. Abbreviations: NR, normal range; Wk, week; eGFR, 
estimated glomerular filtration rate (Cockroft-Gault formula); AST, aspartate aminotransferase: ALT, alanine aminotrasferase; us-CRP, ultrasensitive 
C-reactive protein.
Figure 1 - HIV-RNA plas-
ma viral load trend dur-
ing the day-on, day-off 
FTC/TDF/EFZ dose re-
duction schedule fol-
low-up.
Note: Each row represents a 
single patient. Data from the 
patient who experienced a vi-
ral load rebound (patient 20) 
are showed during the day-on 
day-off schedule and after the 
once daily administration was 
resumed (week 36).
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it was undetectable (Figure 1). Self-reported com-
pliance to the Day-On, Day-Off schedule was ex-
cellent. No major changes of liver function tests, 
total cholesterol, triglycerides and us-CRP were 
observed during follow-up (Table 1); a slight in-
crease in estimated glomerular filtration rate was 
observed at week 24 (p<0.05), but reverted to base-
line values by week 36. A small but significant in-
crease in T CD4 cell count (p<0.05) was observed 
at week 48 compared to baseline (Figure 2 panel 
A), while circulating T CD8 cell counts decreased 
significantly by week 24 (p<0.05); CD4/CD8 ratio 
increased by week 48 compared to baseline values 
(p<0.05, Figure 2 panel B).
n DISCUSSION
The present study was conducted with the aim 
to report our clinical experience obtained by pre-
scribing an FTC/TDF/EFZ dose reduction sched-
ule in the context of our clinical routine. Forty-
eight weeks Day-On, Day-Off administration of 
the fixed dose combination FTC/TDF/EFV STR 
was safe and effective in maintaining HIV viral 
replication below the detection limit in a select-
ed group of HIV-1-infected individuals. To our 
knowledge, this is the first report suggesting this 
peculiar reduced dose administration schedule 
as a potential simplification strategy for patients 
with sustained undetectable HIV replication, sta-
ble immunological profile and no previous ART 
failures. 
Robust evidence of the feasibility of an EFZ dose 
reduction schedule comes from the double-blind, 
placebo-controlled ENCORE1 study. Week 48 
and week 96 analysis demonstrated durable vi-
rological non-inferiority of EFZ 400 mg to the 
standard 600 mg dose when given in combina-
tion with TDF and FTC to a large population of 
HIV-infected antiretroviral-naïve patients, re-
gardless of baseline HIV viral load levels [11, 12]. 
Figure 2 - Immunolog-
ical trend during the 
day-on, day-off FTC/
TDF/EFZ dose reduction 
schedule.
Note: Timepoint percentages of 
T CD4 and T CD8-positive cells 
(Panel A), and CD4/CD8 ratio 
(Panel B) are represented. Mean 
values and standard deviations 
are shown; **p value <0.05 com-
pared to baseline.
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The week 96 intention-to-treat analysis showed 
that 90% of patients in the reduced 400 mg EFZ 
group versus 90.6% in the standard dose 600 mg 
group had plasma HIV viral load of less than 
200 copies/mL (primary endpoint). In addition, 
non-inferiority was also demonstrated for viral 
load threshold of 50 copies/mL. Compared to the 
standard 600 mg, lower 400 mg dose was associ-
ated with fewer EFZ-related adverse events and 
reduced number of drug discontinuations over 
the 96 weeks follow-up period [12]. Of note, study 
population was heterogeneous in terms of ethnic 
origin, geographical areas, baseline T CD4 count 
and plasma HIV-RNA levels, making the results 
of the study broadly applicable. Based on these 
results, the authors advocated the redefinition of 
the efavirenz dose for first line treatment among 
HIV-infected adults. In the FOTO study, 48-week 
Five days-On, Two days-Off Lamivudine (3TC), 
TDF and EFV regimen was effective in maintain-
ing HIV-1 replication suppressed in a small group 
of adult patients [9]. More recently, encouraging 
results were obtained by the open-label non-infe-
riority trial BREATHER, that compared continu-
ous FTC/TDF/EFV with short cycle treatment, 
consisting in two days off therapy per week, in 
199 HIV-infected patients aged 8-24 years who 
had been virologically suppressed for at least 12 
months before enrollment [10]. Efavirenz, tenofo-
vir DF and emtricitabine are drugs characterized 
by long half-lives whose pharmacokinetics and 
wash-out timing have been elucidated; the po-
tency of this combination, in the absence of HIV 
resistance mutations, has also been demonstrat-
ed [13-15]. Finally, a study presented at the 2016 
HIV Drug Therapy Conference held in Glasgow, 
reported that 96% of patients undergoing a four 
days-on three-days off schedule with different 
drug regimens maintained undetectable viral 
load throughout a 48-week period, despite low 
or undetectable plasma concentrations after three 
days of treatment interruption [16]. Economic 
savings are among the potential advantages of 
dose reduction schedules; indeed, the burden of 
cost of HIV treatment represents an important 
issue, both in the prospect of a progressive scal-
ing up of antiretroviral treatment worldwide and 
at single country level [3]. Recently, Costa and 
coll. conducted a local budget impact analysis of 
reducing EFZ dose from 600 mg to 400 mg dai-
ly, obtaining a cost saving of about 55,000 Euro 
over two-year period [17]. Of note, none of the 
39 HIV-infected patients undergoing reduced 400 
mg EFZ dose experienced viral rebound over the 
follow-up period. Although these results cannot 
be generalized, they underline the potential eco-
nomic benefits coming from reduction of antiret-
roviral drugs dosage. In our experience, 96% of 
the patients that switched to the DODO schedule 
maintained plasma HIV-RNA levels below the de-
tection limit throughout the 52-week monitoring. 
Collectively, these data suggest that a reduced 
administration schedule of an EFV-based antiret-
roviral drug regimen is a feasible option for se-
lected HIV-infected patients with uncomplicated 
disease; this strategy may also be evaluated with 
the most recent once daily antiretroviral drug 
combinations (either STR or not) such as those in-
cluding the INSTI elvitegravir/cobicistat and do-
lutegravir, although no supporting data are avail-
able at the moment. Of note, the only patient who 
experienced an HIV viral rebound had a previous 
history of small vessel cutaneous vasculitis and 
showed increased us-CRP levels throughout the 
entire observation period (range: 5.5 - 22.9 mg/L, 
upper laboratory limit 3 mg/L). Transient low 
level viral replication in the context of a well func-
tioning antiretroviral therapy has been associated 
with increased risk of viral rebound and treat-
ment failure over time [18-20]. Therefore, to min-
imize the risk of drug failure and development of 
resistance, the patient resumed immediately the 
once daily FTC/TDF/EFV administration; plas-
ma HIV-RNA level decreased below the detection 
limit 4 weeks later and in further assessments. 
The immune reconstitution process was not im-
paired during the follow-up; although no robust 
changes of T CD4 cell number were recorded, 
week 48 mean CD4/CD8 ratio increased signifi-
cantly compared to baseline. Data from literature 
point out that interruption of TDF administration 
is associated with an increase of total cholesterol 
levels, due to a possible statin-like effect of TDF; 
in our study, no significant modification of total 
cholesterol levels, LDL, HDL, triglycerides, and 
liver and renal function tests (with the exception 
of transient increase in mean glomerular filtration 
rates) was observed compared to baseline [21-
23]. Of note, us-CRP values also remained stable, 
suggesting the absence of a consistent increase in 
inflammation due to potential - although not de-
tectable by clinical routine methods - outbreak of 
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low level viral replication following FTC/TDF/
EFV dose reduction, that could potentially lead to 
loss of viral replication control in the future. No 
missed doses or lack of adherence to the alternate 
administration schedule were recorded; self-re-
ported-adherence to the alternate day regimen 
was excellent, throughout the follow-up, further 
supporting the feasibility of the DODO schedule. 
Additional follow-up may be helpful to better 
establish the long-term effectiveness of this regi-
men. Limitations of the study were the single-arm 
design, the small number of patients enrolled and 
the short duration of the follow-up. However, the 
persistence of high rates of HIV viral suppression 
during the observation period suggests that the 
Day-On, Day-Off FTC/TDF/EFV dose reduc-
tion schedule is an effective, safe and cost-sav-
ing choice as a potential maintenance regimen 
in selected HIV-infected patients. Moreover, our 
findings suggest that dose reduction schedules 
may also be conceived with other once daily an-
tiretroviral drug combinations, including those 
containing the INSTI elvitegravir/cobicistat and 
dolutegravir, given that the prolonged half-lives 
of these drugs may allow a reduced schedule of 
administrations. Further studies are needed to 
confirm these findings.
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In this study, we aimed to determine the late relapse rate 
in hepatitis C patients with sustained virological response 
after interferon-based regimens, and evaluated the predic-
tors of late relapse while comparing the real-life data of 
our country with that of others. A multicenter retrospec-
tive study was performed to investigate the data of pa-
tients infected with HCV who obtained sustained virolog-
ical response after classical or pegylated interferon alpha 
(PegIFNα) and ribavirin (RBV) for 48 weeks. Sustained vi-
rological response was based on negative HCV RNA level 
by PCR at the end of six months after the therapy. The in-
formation of patients enrolled in the study was retrieved 
from the hospital computer operating system and outpa-
tient follow-up archives. We evaluated the age, gender, 
HCV RNA levels, HCV genotype, six-month and further 
follow-up of patients with sustained virologic response, 
presence of cirrhosis, steatosis and relapse. In all, 606 out 
of 629 chronic hepatitis C patients (mean age was 53±12 
SUMMARY
years; 57.6 % of them were female) with sustained viro-
logical response were evaluated. We excluded 23 patients 
who relapsed within six months after the end of treatment 
(EOT). The mean follow-up period of the patients was 71 
months (range: 6-136) after therapy. Late relapse rate was 
1.8% (n=11) in all patients. Univariate Cox proportional 
hazard regression models identified that cirrhosis and 
steatosis were associated with the late relapse [(p=0.027; 
Hazard Ratio (HR) 2.328; 95% confidence interval (CI): 
1.309-80.418), (p=0.021; HR 1.446; 95% CI: 1.243-14.510, re-
spectively]. In multivariable Cox regression analysis, stea-
tosis was the only independent risk factor for late relapse 
(p=0.03; HR 3.953; 95% CI: 1.146-13.635). Although the late 
relapse rate was approximately 2% in our study, clinicians 
should consider that pretreatment steatosis may be an im-
portant risk factor for late relapse.
Keywords: hepatitis C, HCV, relapse, steatosis.
134 F. Arslan, B. Ceylan, A. Riza Sahin, et al.
n INTRODUCTION
A great deal of progress and success have been achieved in treatment of chronic hepatitis 
C (CHC) infection with newly introduced di-
rect-acting antiviral agents [1]. Besides, on a glob-
al perspective, all these favorable achievements 
still remain as a distant hope for patients living 
in countries with limited resources [2]. The rate 
of long-term relapse (developing after 24 weeks) 
in patients with CHC infection has been reported 
to be 0-17% [3, 7]. We could not find any study 
including quite a number of cases genotype 1 pa-
tients and focused their late relapse in medical 
literature. In another aspect, we are of the opin-
ion that this late relapse rates may reflect the new 
therapies long term results.
In this study, we aimed to determine the late re-
lapse rate in a total of 629 patients with sustained 
virological response and the risk factors of late 
relapse.
n PATIENTS AND METHODS
Study patients and design
In this study, the records of adult CHC patients 
who were admitted to 15 center of chronic hepa-
titis outpatient clinics of university and training 
and research hospitals after presenting sustained 
virological response (SVR) following therapy 
with recombinant or pegylated interferon alpha 
(PegIFNα) + ribavirin (RIB) and were followed up 
between 2000-2015 were evaluated retrospective-
ly. SVR was based on negative HCV RNA level 
by PCR at the end of six months after EOT. Late 
relapse was defined HCV RNA detectability after 
have achieving an SVR.
Patients who were not treated adequately in terms 
of therapy duration (12 months for genotype 1 or 4 
patients, and 6 months for genotype 2 or 3 patients) 
or due to drug-related side effects and those who 
were lost to follow-up were excluded. The patients 
with HBV/HCV, HIV/HCV co-infection, drug 
abuse, malignant disease, or autoimmune hepatitis 
and those who were pregnant were also excluded. 
Patients who relapsed within six months after EOT 
were not included in the study.
The data of the patients in terms of age, gender, 
serum HCV RNA level by PCR, HCV genotype, 
treatment regimens, presence of cirrhosis and 
Child Pugh scores, presence of steatosis were ob-
tained from patients’ data files.
Treatment regimens
Patients who received interferon-alpha 2a or 2b or 
pegylated INF alpha 2b 1.5 mg/kg/w or 2a 180 
mg/kg/w; subcutaneously + RIB (1200 mg/day 
or 1000 mg/day for those with body weight of 
>75 kg and <75 kg, respectively; per oral) combi-
nation were included. The treatment regimen was 
continued for 12 months in patients with HCV 
genotype 1 or 4 and 6 months in those with gen-
otype 2 or 3.
HCV RNA and HCV genotype assays
HCV RNA was assessed using bDNA (branched 
DNA) signal amplifier (Versant HCV RNA 3.0 
Assay, Bayer Corporation Diagnostics, USA [de-
tection range 615-7690000 U/ml]) or RT-PCR (real 
time polymerase chain reaction, Cobas TaqMan 
HCV test v 2.0 [detection range 25-391000000 U/
ml]) in 70% of patients. The patients were grouped 
according to their pre-treatment HCV RNA lev-
els. That is, one group comprised the patients 
with pre-treatment HCV RNA levels of ≥600000 
IU/L and the other group included patients with 
pre-treatment RNA levels of <600000 IU/mL.
HCV genotype was assessed by using Innolipa 
HCV II commercial kit (Bayer Diagnostics, USA). 
The patients were grouped according to their 
HCV genotypes. That is, the patients having gen-
otype 1 and those with genotype 2, 3 or 4 were 
analyzed as separate groups.
Evaluation of cirrhosis and liver steatosis
Liver biopsy findings were evaluated using the 
modified Knodell (Ishak) scores. A fibrosis score 
of 5/6 was accepted as cirrhosis. Child Pugh score 
was calculated if a patient had been diagnosed as 
cirrhosis. Cirrhosis was also accepted according 
to radiological (ultrasonography, magnetic reso-
nance imaging) appearances (liver contour lob-
ulation, caudate/left lobe hypertrophy spleno-
megaly and thrombocytopenia). All patients were 
evaluated with ultrasonography for the diagnosis 
of hepatic steatosis.
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Statistical analysis
The data were expressed as mean ± SD or %. Late 
relapsed and non-relapsed HCV patients were 
presented by age, genders, quantitative HCV 
RNA, follow up time and the proportion of cir-
rhosis and steatosis in Table 1.
The Chi-square test or Fisher’s exact test (when 
Chi-square test assumptions do not hold due to 
low expected cell counts), where appropriate, 
was used to compare proportions in late relapsed 
and non-relapsed patient groups. A p-value lower 
than 0.05 was considered as statistically signifi-
cant.
Associations between possible risk factors and 
late relapse were evaluated using the Multivari-
able Cox proportional hazard regression models 
based on variables with a p-value of ≤0.05. The 
following variables were considered in the uni-
variate analysis for late relapse: age (<60 years, 
≥60 years), gender, HCV RNA level (<6x105 IU/
mL, ≥6x105 IU/mL), HCV genotype, treatment 
regimens (standard IFN or pegylated IFN), pres-
ence of cirrhosis and steatosis. Variables that were 
found significant in univariate analysis were 
evaluated with multivariable analysis. All p-val-
ues were based on two-sided hypothesis tests, 
and α were set at 0.05. Analysis was performed 
with SPSS Statistics version 16.0 (IBM, Chicago, 
IL, USA).
n RESULTS
Investigation of the hospital records of a total of 
606 patients with sustained virological response 
after treatment with pegylated INF α2b + RIB 
(n=298), pegylated INF α2a + RIB (n=285), INF 
α2b + RIB (n=32), or INF α2a + RIB (n=14) com-
binations revealed that they completed the thera-
py period and showed virological response at the 
end of therapy. The mean follow-up period of the 
patients was 71 months (range, 6-136) after the 
therapy.
The mean age of the patients was 53±12 and 58% 
of them were female. Genotype 1 was detected in 
98% of the patients. Late relapse was recorded in 
Table 1 - Clinical and laboratory features of study patients.
Non-relapsed patients (n = 595) Late relapsed patients (n =11) P value
Variables
Age 53±12 years 58±8.5 years 0.133
Gender (Female) 349/595 (58.6) 5/11 (45.5 ) 1
HCV RNA 850000 (IQR, 284946- 2835000 IU/ml) 2107950 (IQR, 594500- 3130000 IU/ml) 0.699
Cirrhosis 9/585 (1.5%) 1/11 (9.1 %) 0.169
Steatosis 164/589 ( 27%) 7/11 (63.6 ) 0.016
Follow up duration 43±27 months 42±30 months 0.0001
Relapse duration - 17±5.6 months -
Table 2 - Results of univariate and multivariate Cox regressions model analysis for the development of late relapse.
Variable N (%) Hazard Ratio (%95 Confidence Interval) P value (univariate) P value (multivariate)
Gender (Female) 349 (58.6) 1.134 0.346-3.716 0.835
Age >60 years 379 (62.7) 2.342 0.276
Liver steatosis
171 (28.2)
1.446
3.953
1.243-14.510
1.146-13.635
0.021 0.03
Cirrhosis 10 (1.7) 2.328 1.309-80.418 0.027 0.063
Pre-treatment HCV 
RNA level
(>2x106IU/mL)
361 (59.7) 1.945 0.516-7.73 0.326
Standard INF+RIB 48 (8.1) 0.966 0.124-7.553 0.974
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11 patients (1.8%). The mean late relapse time was 
16.9±5.3 months. Ten patients were diagnosed as 
cirrhosis before the treatment. All cirrhotic pa-
tients had a Child Pugh classification of A. The 
clinical and laboratory features of late relapsed vs. 
non-relapsed patients are summarized in Table 1.
Gender, age, genotypes, HCV RNA load at the be-
ginning of therapy, classical IFN- based treatment 
were not found as predictive factors to predict 
late relapse rate. Univariable Cox proportional 
hazard regression models identified that cirrhosis 
and steatosis were independently associated with 
the late relapse [p=0.027; Odds Ratio (OR) 2.328; 
95% confidence interval (CI): 1.309-80.418, and 
p=0.021; OR 1.446; 95% CI: 1.243-14.510, respec-
tively]. Multivariable Cox proportional hazard 
regression models identified that steatosis is only 
independent factor for late relapse (p=0.03; HR 
3.953; 95% CI: 1.146-13.635) (Table 2).
n DISCUSSION
Chronic hepatitis C virus (HCV) infection, which 
is a global health problem, affects approximately 
170 million people all over the world [2]. Addi-
tionally, long-term carriage may lead to the de-
velopment of cirrhosis, liver decompensation, 
hepatocellular carcinoma and even death [6]. 
Although the treatment regimens for hepatitis C 
virus (HCV) infection has moved beyond inter-
ferons and toward direct-acting antiviral agents 
(DAAs) such as protease inhibitors and NS5A 
and NS4B inhibitors, payers and the governments 
even in high income countries have been limiting 
the coverage of these therapies because of their 
high costs. This situation makes it difficult to ac-
cess DAAs in some regions of the world. For this 
reason, in some countries, interferon based regi-
mens are still in use.
It is well-known that SVR is a good marker of re-
sponse to CHC treatment [8-10]. Moreover, late 
HCV recurrence (relapse or re-infection) still re-
mains as a problem. In high-risk group patients 
(such as HIV-positive subjects, patients on he-
modialysis, intravenous drug users), increased 
recurrence rates support the higher possibility 
of re-infection [11]. In this study, particularly pa-
tients who have low risk of re-infection were in-
vestigated and compared with medical literature 
in Medline (Table 3). 
The phenomenon of late relapse and re-infection 
Table 3 - Chronic HCV infection studies with late relapse rates in patiens with low risk for reinfection.
Study/publicationyear
Total number of 
patients with SVR
Follow Up Time
Late Relapse, 
n (%)
Risk factors for relapse
Veldt et al, 2004 286 5 years 12 (4.7) None
E. Formann, 2006 187 29 months (0) NA
Desmond et al, 2006 147 Mean 2.3 years (range 0.3-10.3) (0) NA
daCostaFerreira et al, 
2010
174 Median duration 47 months 
(12-156)
(0) NA
Swain et al, 2010 1077 Annually (for 5 years) (0) NA
Sood et al, 2010 100 6 months to 8 years 8 (8) Cirrhosis
Giannini et al, 2010 231 Median duration 41 months 
weeks
2 (1) NA
Li et al, 2012 146 33.45 +/- 16.41 months  
(range: 12-85)
8 (8.9) Older Age
Rutter et al, 2013 103 21 months (range: 7-64) 2 (1) One patient was cirrhotic,
both carried the genotype 1b
Uyanikoglu et al, 2013 196 33.5 months (range, 6 to 112) 2 (0) NA
Papastergiou et al, 2013 145 68.8 ± 35 months 2 (1) NA
M. P. Manns 2013 1002 5 years (0) NA
Giordanino, Chiara, 
2014
115 9.2 years (0) NA
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in patients with CHC infection may be confused 
with each other. Even though the term “late re-
lapse” is used, it shouldn’t be overlooked that 
some of the patients with high relapse prevalence 
constitute those with high risk of re-infection [7, 
12]. In a meta-analysis, the rate of late relapse in 
low-risk patients for re-infection has been report-
ed as less than 2% [11]. In a study conducted with 
196 CHC patients in our country, relapse after 
SVR has been detected in 1.02% in a period of 33 
months in average and those cases had low levels 
of HCV viremia [13]. 
Most of the studies stated/emphasized the pre-
dictive factors for relapse developing after SVR as 
age, HCV genotype, IL-28B genotype/polymor-
phism, presence of steatosis, cirrhosis, viruses 
in peripheral blood mononuclear cells, ribavirin 
concentration at the end of treatment [5, 14, 20].
In addition to difficult achievement of SVR in 
cases with advanced liver injury (especially in pa-
tients infected with genotype 1 HCV), there are 
some studies which reveal that risk of develop-
ment of early relapse is higher in those patients 
[21, 23]. There are few studies investigating the 
relationship between late relapse and advanced 
liver injury (except for transplanted patients) oth-
er than this study [24, 25]. Late relapse was de-
tected in five out of 28 cirrhotic patients and this 
result was statistically significant compared to 
non-cirrhotic patients in the study conducted by 
Sood et al. [24, 25]. Rahman et al reported signifi-
cantly higher rates of late relapse in treatment ex-
perienced cirrhotic patients (three out of six) who 
achieved SVR compared to non-cirrhotic patients 
during a 5-year prospective study [26].
Hepatosteatosis develops as a result of deposition 
of fat droplets in hepatocytes [27]. HCV (especial-
ly genotype 3) is a risk factor for hepatosteatosis 
in addition to environmental factors triggering it 
[27]. It is known that presence of steatosis causes 
progressive fibrosis and decreases SVR rates [28]. 
Furthermore, it is under debate whether hepatos-
teatosis is an independent risk factor for recur-
rence in patients with SVR or not.
 In a study evaluating patients infected with Gen-
otype 2 and 3, it has been stated that presence of 
steatosis had positive correlation with early re-
lapse and the relapse rate was around 36.4% in 
patients with steatosis and high viral load [15]. 
This situation may be interpreted as being irrel-
evant to genotype 3. In studies focusing on gen-
otype 1 HCV patients similar to our study, it has 
been reported that hepatosteatosis had a negative 
effect on SVR [34]. In another study evaluating 
liver transplant patients, the sensitivity of pres-
ence of steatosis in forecasting of virologic relaps-
es in post-transplant liver biopsies was around 
89% [30]. To the best of our knowledge, we could 
not come across any studies focusing on relation 
between late relapse and steatosis in non-trans-
planted HCV patients in medical literature. We 
believe that our study is unique in this aspect.
Major limitations of our study are its retrospec-
tive design, inability to perform genetic studies in 
patients with relapse, and detection of steatosis 
only by ultrasound. However, inclusion of large 
number of patients and long-term follow-up are 
its strong aspects.
In conclusion, the rate of late relapse after SVR in 
patients with CHC infection in our study is con-
sistent with previous medical literature. Although 
SVR has been achieved in patients with cirrhosis 
and steatosis, the possibility of late relapse should 
be kept in mind. 
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Chlamydia trachomatis (Ct) and human papillomavi-
rus (HPV) are the most common sexually transmitted 
pathogens. Whereas it is well known that infection with 
oncogenic HPV genotypes increases the risk of cervical 
cancer (CC), the implication of Ct in the pathogenesis of 
CC is still controversial. Hence, to investigate the pos-
sible implication of Ct infection alone, or with concom-
itant HPV infection, in the severity of cervical lesions, 
we conducted a study in 164 Caucasian HIV-negative 
women with abnormal Pap. Genomic HPV and Ct DNA 
SUMMARY
were detected in 97 (59%) and 16 (10%) women respec-
tively, and 15 (9%) of women were infected by both. 
Of the HPV positive samples, 89 (79%) were HR-HPV 
types or probable HR types and HPV16 was the most 
represented genotype. Interestingly, it was observed 
that co-infection was more frequent than HPV infection 
alone in women with high grade lesions.
Keywords: Chlamydia trachomatis, HPV, genotyping, Pap 
test.
n INTRODUCTION
Chlamydia trachomatis (Ct) is the most common sexually transmitted bacterial pathogen, fre-
quently asymptomatic and consequently unrec-
ognized and untreated. The infection can become 
persistent and may promote a pathogenic process 
leading to chronic diseases such as pelvic inflam-
matory disease and infertility [1]. Serious Ct se-
quelae including cervical hypertrophy and induc-
tion of squamous metaplasia, suggest a possible 
relationship with human papillomavirus (HPV) 
infection [1-4]. In Italy, Ct infection is not subject to 
mandatory reporting, and a sentinel surveillance 
study recognized by a network of Italian clinical 
centers of sexually transmitted infections showed 
an overall prevalence of 3.2% [5]. High-risk on-
cogenic HPV genotypes (HR-HPVs) are the most 
important etiological agents of cervical cancer 
(CC). A systematic review of studies conducted in 
Italy revealed a HR-HPV infection prevalence of 
8% in the general population with no difference 
among the northern, central and southern regions 
of Italy. However, this percentage is higher in 
women aged 18-29 participating in CC screening 
programs [6, 7].
The involvement of Ct in the pathogenesis of 
CC is controversial and its specific role in this 
neoplasia has not yet been completely clarified. 
Chlamydial infection may damage the mucosal 
barrier thus increasing the susceptibility to HPV 
co-infection. Alternatively, the bacterium may 
interfere with the host immune response by de-
creasing the clearance of a concomitant HPV in-
fection, thereby increasing the persistence of the 
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virus and the possibility of progression to cancer 
[3-4]. The aim of the present study was to investi-
gate a possible implication of Ct infection alone or 
with a concomitant HPV infection, in the severity 
of cervical lesions.
n PATIENTS AND METHODS
The survey was carried out in DNA samples 
from 164 Caucasian HIV-negative women with 
abnormal Pap test, randomly selected among 
those participating in the Multi-center Cohort 
Study, known as the HPV Pathogen ISS study. 
This study was designed to determine risk factors 
for the progression of cervical lesions to cancer in 
HIV-positive and -negative women. All patients 
were enrolled from March 2002 to November 2003 
[8-10]. The women, who were referred for colpo-
scopic examination to the gynecological depart-
ments of five Italian hospitals in Milan, Bologna 
and Rome, were submitted to an epidemiological 
interview, and sampling for molecular and sero-
logical assays.
Table 1 - Patient’s characteristics, Pap test and histology data.
Frequency, no. (%)
Age group (years)
< 20 5 (3.05)
21-30 51 (31.10)
31-40 60 (36.59)
41-50 30 (18.29)
> 50 18 (10.98)
Smoking
No smoker 93 (56.71)
Current smoker 64 (39.02)
Ex - smoker 7 (4.27)
Age of earlier sexual activity (years)
< 15 16 (9.76)
15-20 128 (78.05)
21-25 20 (12.20)
Sexual partners during life
1-2 78 (47.56)
3-5 74 (45.12)
> 5 12 (7.32)
Pregnancies
None 142 (86.59)
1-2 21 (12.80)
3-4 1 (0.61)
Contraceptive method
None 60 (36.59)
Oral contraceptive 82 (50.00)
Intrauterine device 5 (3.05)
Condom 8 (4.88)
Natural method 9 (5.49)
Frequency, no. (%)
Previous genital infection reported
No 73 (44.51)
HSV 2 (1.22)
Candida 88 (53.66)
Chlamydia 1 (0.61)
Previous HPV infection reported
No 129 (78.66)
Yes 35 (21.34)
Frequency of Pap test
Regular (every 1-3 years) 59 (35.98)
Irregular 98 (59.76)
Never 7 (4.27)
Pap test
ASC-US 41 (25.00)
LSIL 97 (59.15)
HSIL 26 (15.85)
Histology
Normal 15 (9.15)
CIN1 36 (21.95)
CIN2 12 (7.32)
CIN3 35 (21.34)
HPV-NCIN 21 (12.80)
ND 45 (27.44)
ASC-US: atypical squamous cells of undermined significance; LSIL: 
low-grade squamous intraepithelial lesions; HSIL: high-grade squa-
mous intraepithelial lesions; CIN: cervical intraepithelial neoplasia; 
HPV-NCIN: HPV lesions without evidence of CIN; ND= not deter-
mined.
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Informed consent was obtained from all partici-
pants, and the study was approved by the insti-
tutional Ethical Committees of all the hospitals 
that contributed to the HPV Pathogen ISS study. 
Our work used the baseline data and cervical 
samples collected for the HPV Pathogen ISS 
study. For the molecular analyses, DNA was ex-
tracted from cells of cervical smears by QIAamp 
DNA mini kit (QIAGEN). The HPV genotyping 
was performed by sequencing of GP5/GP6 PCR 
amplicons, as previously described [9]. The Ct 
DNA was detected with primer set CTR 70/71 
targeting 16S-23S spacer rRNA, while Ct gen-
otyping was performed by MS-1F and MS-1R 
primers, spanning an approximately 936-bp re-
gion of the ompA gene [11, 12]. PCR amplicons 
were purified, sequenced and analyzed with 
BLAST program (http://www.ncbi.nlm.nih.
gov/BLAST).
Cytology and histology data were jointly mod-
eled by ordered logit regression in STATA13 (Stat-
aCorp. 2013) within a structural equation mode-
ling (SEM) framework.
n RESULTS
The characteristics of the patients are listed in 
Table 1. All women presented an abnormal Pap 
test diagnosed as: atypical squamous cells of un-
dermined significance (ASC-US) in 25% of cas-
es, high-grade squamous intraepithelial lesions 
(HSIL) in 59.15% and low-grade squamous in-
traepithelial lesions (LSIL) in 15.85%. A total of 
149 patients (90.85%) revealed moderate or se-
vere intra-epithelial lesions. 
After colposcopy examination and biopsy of le-
sional tissues, histological results highlighted 
Cervical Intraepithelial Neoplasia (CIN) 1, CIN 
2 and CIN 3 in 21.95%, 7.32%, and 21.34% of the 
women, respectively. Biopsies without evidence 
of CIN (HPV-NCIN) were detected in 12.8 % of 
patients (Table 1).
Genomic HPV DNA was detected in 97 (59%) and 
Ct DNA in 16 (10%) women, while 15 women 
(9%) had both infections. Out of the 112 HPV pos-
itive samples, 89 (79%) were considered HR-HPV 
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) or 
probable HR type (53, 66, 81). The most represent-
ed genotype was HPV16, found alone in 44% of 
the samples. Six different Ct serovars were identi-
fied: G (25%), H (25%), F (19%), D (12%), E (12%) 
and K (7%). In the HPV-Ct co-infected samples, 
the HPV 16 genotype was the most prevalent, 
being detected in 8 samples (53.33%), while the 
HPV 6, 31, 33, 45, 52,5 3, and 66 were detected in 
similar percentages (6.67%). Excluding HPV 6, all 
the genotypes found are considered at high risk 
or probable high risk for CC.
The association of patients’ demographic and 
clinical characteristics, including the presence of 
HPV infection, with cytological and histological 
diagnoses has been described for the whole co-
hort in a previous publication [8]. In our study 
the univariate ordinal logit models for Pap test 
results (categorized as ASCUS, LSIL, HSIL) 
showed that women infected with HPV, alone or 
concurrently with Ct had a twofold (2.71; 95%CI: 
1.38; 5.32) and fourfold (4.18; 95%CI: 1.31; 13.35) 
higher risk, respectively, of presenting a cervical 
intraepithelial neoplasia than their uninfected 
counterparts. Multivariate ordinal logit models 
for Pap test results, adjusted for factors signifi-
cantly associated with the outcome in the univar-
iate analysis (smoking and Pap test frequency), 
showed that women infected by HPV alone or in 
conjunction with Ct had proportional odds ratio 
(OR) of 2.17 (95%CI: 1.08; 4.39) and 3.87 (95%CI: 
1.19; 12.56) with respect to their uninfected coun-
terparts, for any cytological level (Table 2). Uni-
variate ordinal logit models for histological di-
agnosis (categorized as HPV-NCIN, CIN 1, CIN 
2 and CIN 3) found that the proportional OR 
of histological diagnosis was 2.83 (95%CI: 1.16; 
6.89) for women infected by HPV alone, and 2.89 
(95%CI: 0.82; 10.16) for those infected by HPV 
and Ct, compared to the not infected. The multi-
variate ordinal logit model for histological diag-
noses adjusted for age at first sexual intercourse, 
which was significantly associated with the out-
come at the univariate analysis, showed that 
women infected with HPV alone (3.08; 95%CI: 
1.26; 7.53) or with HPV and Ct (2.95; 95%CI: 0.83; 
10.46), had a threefold risk of presenting a cervi-
cal intraepithelial neoplasia with respect to their 
uninfected counterparts (Table 2).
n DISCUSSION
In agreement with previously published stud-
ies, our results showed that women with a high 
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Table 2 - Univariate and multivariate analyses of HPV and Ct infections in cytological and histological diagnoses.
Cytological diagnosis Histological diagnosis
Univariate analysis Multivariate analysis* Univariate analysis  Multivariate analysis**
OR (95%CI) p OR (95%CI) p OR (95%CI) p OR (95%CI) p
Age group 0.351 NI 0.795 NI
18-30 (n = 56) 1 1
> 30 (n = 108) 1.35 (0.72; 2.53) 0.92 (0.47; 1.78)
Smoking 0.058 0.624 NI
No (n = 93) 1 1 1
Yes (n = 71) 1.82 (0.98; 3.38) 1.58 (0.84; 2.98) 0.155 1.18 (0.61; 2.26)
Age of earlier sexual activity 0.646 0.132 1
13-20 (n = 144) 1 1 0.36 (012; 1.13) 0.079
>20 (n = 20) 0.80 (0.32; 2.03) 0.42 (0.14; 1.30)
Sexual partners during life 0.350 NI 0.265 NI
1-2 (n = 78) 1 1
>2 (n = 86) 1.33 (0.73; 2.45) 1.44 (0.76; 2.76)
Pregnancies 0.767 NI 0.542 NI
None (n = 142) 1 1
1-2 (n = 22) 1.15 (0.45; 2.93) 1.38 (0.49; 3.86)
Contraceptive method 0.662 NI 0.673 NI
None (n = 60) 1 1
Oral (n = 82) 1.31 (0.68; 2.53) 1.13 (0.56; 2.28)
Others (n = 22) 0.97 (0.37; 2.59) 1.14 (0.43; 3.07)
Previous genital infection 0.733 NI 0.441 NI
No (n = 73) 1 1
Yes (n = 91) 0.90 (0.49; 1.66) 0.77 (0.39; 1.51)
Frequency of Pap test 0.018 0.242 NI
Regular (n = 59) 1 1 1
Irregular/never (n 
= 105)
0.45 (0.24; 0.87) 0.56 (0.28; 1.10) 0.091 0.68 (0.35; 1.30)
Previous HPV infection 0.739 NI 0.888 NI
No (n = 129) 1 1
Yes (n = 35) 1.14 (0.54; 2.40) 1.05 (0.52; 2.15)
Microbial agent 0.005 0.003
Negative (n = 51) 1 1 1 1
HPV (n = 97) 2.71 (1.38; 5.32) 2.17 (1.08; 4.39) 0.031 2.83 (1.16; 6.89) 3.08 (1.26; 7.53) 0.014
HPV + Ct (n = 15) 4.18 (1.31; 13.35) 3.87 (1.19; 12.56) 0.025 2.89 (0.82; 10.16) 2.95 (0.83; 0.46) 0.095
OR: Odds Ratio; 95%CI: 95% confidence interval; NI: not included in the multivariate analyses. The association of demographic and clinical char-
acteristics of patients, including HPV infection, with cytological and histological diagnoses was already described in a previous publication not 
reported in the text [8-9]. *Adjusted for smoking and Pap test frequency. **Adjusted for age at first sexual intercourse.
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percentage (15/16; 94%) of Ct-HPV co-infections 
have more frequent high grade cervical lesions 
than those infected only with HPV [13-16]. Sev-
eral epidemiological studies corroborate our find-
ings evidencing that Ct may enhance the suscepti-
bility to HPV infection and promote the viral per-
sistence [4, 13, 14]. Ct infection is involved in cell 
proliferation, inhibits cell apoptosis and induces 
chronic inflammation. 
Specifically, Ct may increase the risk of HPV in-
fection through a plausible involvement in the ep-
ithelial disruption associated to the inflammatory 
response [15]. Furthermore, Ct may interfere with 
the immune response by decreasing the num-
ber of antigen presenting cells, and reduce the 
cell-mediated immunity thus allowing the persis-
tence of HPV [16]. 
The main limitations of our study are represent-
ed by the small group of patients examined, the 
low number of Ct infections found and the lack 
of follow-up data. Therefore, we were unable to 
verify whether previous Ct infection can promote 
the infection with HPV first and then, possibly, 
the formation of cytological lesions and the tumor 
progression of these.
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n INTRODUCTION
Toxoplasma gondii, a protozoan parasite with world-wide distribution, is the agent of toxo-
plasmosis in humans [1]. In vivo and in vitro pro-
duction of T. gondii tachyzoites is critical for Toxo-
plasma researches [2]. Due to ethical issues and in-
fra structural deficiencies in in vivo culture models 
such as animal models, these models  have been 
replaced by cell culture systems [3]. Toxoplasma 
gondii tachyzoites can be cultured and maintained 
in various culture systems and cell lines [4]. These 
tachyzoites are used in fundamental studies and 
diagnostic assays [5-9]. Furthermore, cell culture 
systems can be used in T. gondii cyst formation 
[10]. The aim of this study included compari-
son of the four cell lines of HeLa (human cervix 
carcinoma), Vero (African green monkey kidney 
carcinoma), RBK (Razi bovine kidney) and A549 
(human lung carcinoma) for culture of T. gondii 
tachyzoites in vitro. 
n MATERIALS AND METHODS
Preparation of T. gondii tachyzoite 
Tachyzoites of T. gondii (RH strain) were inoculat-
ed intraperitoneally into BALB/c mice. After 3-4 
days, tachyzoites were harvested using intraperi-
toneal wash with phosphate buffered saline (PBS; 
pH 7.3) and then were counted. Adherent cell 
lines of HeLa, Vero, RBK and A549 were grown 
in 10 mL of Dulbecco’s Modified Eagle culture 
media (DMEM; KB cell, Iran), supplemented with 
10% of inactivated fetal calf serum (FCS; Bovo-
gen, Australia), 10 mµ of hepes and 1% of peni-
cillin-streptomycin (Biowest, France) using 25 cm2 
flasks (Nunc, Denmark) and then were incubated 
in 5% CO2. 
After formation of confluent monolayers, the 
media was replaced by the maintenance media 
(DMEM/hepes with 5% FCS).
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Toxoplasma gondii is a protozoan parasite which can be 
grown in vivo and in vitro. Various cell lines are used 
for T. gondii culture in vitro. In this study, four cell 
lines of HeLa, Vero, RBK and A549 were compared 
with each other for T. gondii tachyzoites culture. The 
four cell lines were cultured and infected with 5 × 106 
tachyzoites, respectively. The number of tachyzoites 
and viable host cells and pH of the media were as-
sessed in each culture. The highest tachyzoite yield 
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was seen in HeLa cell culture. The lowest number of 
viable host cells and the lowest pH were seen in HeLa 
cell line culture. The lowest tachyzoite yield, the high-
est viable cell and the highest pH were observed in 
Vero cell line culture. HeLa and Vero cell lines are thus 
appropriate for rapid and long-term propagations of T. 
gondii tachyzoites, respectively.
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In vitro cell culture of T. gondii
Cell lines were infected 1:1 by tachyzoites of T. 
gondii, RH strain. Therefore, each flask was in-
fected with 50×106 tachyzoites. The culture media 
was replaced after 4 and 24 h by DMEM without 
FCS. Flasks were investigated on Days 3 and 5 
post infection. Number of tachyzoites, viability 
of cell lines and pH of media were calculated on 
Days 3 and 5 post infection.
n RESULTS
Number of tachyzoites of T. gondii, RH strain, in 
the four cell lines (HeLa, Vero, RBK and A549), 
number of the host cells and pH of each flask were 
shown in Table 1. On Days 3 and 5 post infection, 
number of derived tachyzoites from the four cell 
lines were in the following order of HeLa > RBK > 
A549 > Vero. The highest and the lowest numbers 
of tachyzotes of T. gondii, RH strain, on Days 3 and 
5 post infection were seen in HeLa and Vero cell 
lines, respectively. On Days 3 and 5 post infection, 
pH of the culture media for these four cell lines 
was as follows: A549 > RBK > Vero > HeLa. The 
pH of culture medium is an indicator of tachyzoite 
reproduction, so the lowest pH was seen in HeLa 
cell line in comparison with the others. The order 
of viable host cells in these four cell lines on Days 3 
and 5 post infection was as follows: Vero > A549 > 
RBK > HeLa. The lowest number of viable cells was 
seen in HeLa cell line, indicating multiplication 
of the tachyzoites and hence rupture of the host 
cells in this cell line. Comparison of the tachyzoite 
yields in these four cell lines with tachyzoites of T. 
gondii, RH strain, on Days 3 and 5 post infection is 
shown in Figure 1.
n DISCUSSION 
Propagation of Toxoplasma tachyzoites in cell cul-
ture systems includes multiple advantages com-
pared to that in animal models. These advantages 
include ethical value, low cost and easy manage-
ment [11]. Various cell lines have been used to 
produce T. gondii tachyzoites in vitro [12-14]. Un-
like passage in mice, passage of tachyzoites in cell 
cultures is not known to alter the virulence of the 
microorganism. Tachyzoites multiply in almost 
all mammalian cell lines. Yield of tachyzoites var-
ies based on the cell line and strain of T. gondii. 
Mean generation time of the tachyzoites of T. gon-
dii, RH strain, is reported nearly 5 h (15). In the 
present study, four cell lines were compared with 
each other for T. gondii, RH strain, cell culture. 
At the same condition, HeLa cell line was shown 
more appropriate than Vero, RBK and A549. Low 
levels of the host cell contamination and high lev-
els of tachyzoite yield were seen in HeLa cells on 
Days 3 and 5 post infection. In Vero cell line, the 
highest contamination and the lowest yield rates 
of tachyzoites were observed. Furthermore, pH of 
the culture media was more acidified in HeLa cell 
culture on Days 3 and 5 post infection than that 
of the other cell lines, indicating high reproduc-
Table 1 - Yield of tachyzoites, viable host cells and pH of each infected culture with 5×106 tachyzoites of T. gondii, 
RH strain, on Days 3 and 5 post infection.
HeLa Vero RBK A549
Cell line Day 3 Day 5 Day 3 Day 5 Day 3 Day 5 Day 3 Day 5
Yield of tachyzoites (×106/ml ) 60.2 107.7 53 90.1 59.5 95.6 54.3 93.1
Viable host cells (×106/ml) 2.1 1.05 2.4 1.91 1.9 1.1 2 1.75
pH of media 7.7 7.53 7.82 7.62 7.91 7.69 7.93 7.71
Figure 1 - Comparison of tachyzoite yields in HeLa, 
Vero, RBK and A549 cell lines on Days 3 and 5 post in-
fection with T. gondii, RH strain.
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tion rate of the parasite. Hughes et al. compared 
four cell lines of HEP2, Vero, MRC5 and AGMPK 
for in vitro T. gondii culture. They found that op-
timal growth conditions occurred in AGMRK 
cell line [16]. Evans et al. used three cell lines of 
HeLa, LLC and Vero for continuous production of 
T. gondii tachyzoites and investigated that HeLa 
cell line included a higher tachyzoite yield than 
that LLC and Vero cells did [17]. In the present 
study, RBK and A549 cell lines were ranked sec-
ond and third based on the tachyzoite yield, host 
cell contamination and pH of media. Therefore, 
RBK cell line can be substituted by HeLa cell line 
to have a large number of tachyzoites in cell cul-
ture. The Vero cell line seems to be appropriate for 
the long-time production of T. gondii tachyzoites 
in cell cultures.
n CONCLUSION
Of the assessed four cell lines of HeLa, Vero, RBK 
and A549 for T. gondii cell culture, HeLa is the best 
and Vero is the worst due to the number of de-
rived tachyzoites. However, the Vero cell line is 
appropriate for the long-time culture of the par-
asite.
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n INTRODUCTION
Foodborne diseases are considered a glob-al public health challenge. According to the 
World Health Organization (WHO) estimate, 600 
million cases of illness were induced by over 30 
foodborne pathogens in 2010. Over 200 diseases 
are caused by contamination of foods with harm-
ful bacteria, parasites, viruses and chemical ma-
terials [1]. Among bacteria, the genus Staphylococ-
cus is one of the most prominent food poisoning 
agents [2]. Staphylococcal food poisoning (SFP) 
often occurs following ingestion of at least 1.0 μg 
of staphylococcal enterotoxin in food [3]. Staphy-
lococcus spp. are considered as skin and mucosal 
normal flora of humans and several animal spe-
cies such as cows and sheep [4]. They can also 
be found in environmental sources and a wide 
range of foodstuffs [5]. Additionally, they are 
used as the starter in some fermented foods such 
as cheeses in order to produce favorite flavor and 
aroma [6]. Confectioneries often contain various 
amounts of different dairy products and can be 
produced by food handlers; thus they can act as 
sources of contamination and transmission of en-
terotoxigenic staphylococci. Currently, more than 
80 species and subspecies of the genus Staphy-
lococcus have been characterized [7]. They are 
commonly divided into 2 groups: coagulase-pos-
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Confectionery is one of the potential sources of contam-
ination and transmission of gastrointestinal infections 
to humans. Staphylococcus species, and particularly the 
coagulase-positive ones, have the remarkable capability 
to produce high amounts of enterotoxin in food. In the 
present study, the frequency and diversity of Staphylo-
coccus in confectioneries in Iran were assessed by using 
a combination of conventional and molecular methods. 
A total of 55 confection samples were collected from 30 
confectioneries of Isfahan. They were analyzed for the 
presence of Staphylococcus using standard protocols 
for isolation and characterization of the isolates. The 
conventional tests were used for primary identification 
and the sequence analysis of 16S rRNA was used for 
SUMMARY
the species identification. A total of 47 out of 55 samples 
were gram-positive cocci (85.45%). They belonged to 39 
Staphylococcus spp., 7 Macrococcus spp., and one Mic-
rococcus spp. The most prevalent 11 various Staphylo-
coccus species were S. aureus 30.8%, S. warneri 20.5% 
and S. succinus 17.9. Identification and characterization 
of Staphylococcus species can be important for epidemi-
ological investigations and assessment of virulence fac-
tors such as enterotoxin production and development of 
specific management practices to prevent staphylococ-
cal food poisoning.
Keywords: Staphylococcus, confectioneries, DNA se-
quence analysis.
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itive staphylococci (CPS) and coagulase-negative 
staphylococci (CNS) [5]. Staphylococcus aureus, 
the prototype CPS, is enterotoxigenic and re-
sponsible for the majority of SFP cases. However, 
several studies reported that CNS isolated from 
foods can also produce enterotoxins and may be 
involved in food poisoning [3, 6, 8-12]. Accurate 
identification of staphylococci to species level is 
necessary to follow up toxigenic species and for 
epidemiological investigations. Manual and auto-
mated phenotypic identification methods are not 
entirely reliable to accurately identify all staphy-
lococcal species [13, 14]. Most of these methods 
have been designed for detection of frequently 
involved species in human clinical samples and 
cannot identify rare species and atypical strains 
that may exist in food stuffs [13]. In addition to 
routine phenotypic methods, several DNA-based 
methods for Staphylococcus species identification 
have been described. Some studies have demon-
strated that molecular methods are preferable 
to phenotypic methods [15, 16]. One applicable 
molecular method is the evaluation of polymor-
phism in housekeeping genes such as 16S rRNA 
gene by Polymerase Chain Reaction (PCR) and 
sequencing. 
In Iran, national standards are focused only on 
detection of S. aureus in sweets [17]. As previous-
ly mentioned, other Staphylococcus species can 
also be the causative agent of SFPs. Since pastries 
are popular and are widely consumed in many 
countries, isolation and identification of contami-
nating Staphylococcus species can have important 
health ramifications [18]. The diversity of Staphy-
lococcus species isolated from confectioneries has 
not been studied in our region. In this study, we 
aimed to isolate staphylococci from confectioner-
ies in Isfahan using routine phenotypic methods 
and identify bacterial species by partial 16S rRNA 
sequencing.
n MATERIALS AND METHODS
Sampling, isolation and conventional identification
In a descriptive study conducted during Septem-
ber to December 2015, 55 confectionery samples 
including sweet pastries, cakes, and similar baked 
goods were collected from 30 confectionery stores 
in various sections of Isfahan, Iran. The samples 
were processed within 12 h of the collection in 
microbiology laboratory of Isfahan Infectious 
Diseases and Tropical Medicine Research Center. 
To isolate staphylococci, 10 grams of the collected 
samples were suspended in 90 ml sterile phos-
phate buffered saline, pH 7.4 (PBS) for 10 min. Ten 
mL of the suspension was added to 10 mL of Gi-
olitti - Cantoni broth (HiMedia, India). The tubes 
were incubated at 37°C for 18-24 hours. Then, 10 
μL of the enriched cultures were streaked on Baird 
Parker Agar containing egg yolk tellurite emul-
sion (HiMedia, India). The plates were incubated 
at 37°C for 18-24 h. After that, a single colony was 
streaked onto blood agar plates with 5% sheep 
blood (HiMedia, India) and further incubated at 
37°C for 12-18 h. Suspected Staphylococcus colo-
nies were identified using the standard microbiol-
ogy tests including Gram staining, catalase reac-
tion, resistance to bacitracin (0.04 units), modified 
oxidase test, tube coagulase reactions, DNase test 
and growth on mannitol salt agar [3].
n MOLECULAR IDENTIFICATION
DNA extraction
Chromosomal DNA was extracted using a sim-
ple boiling method [18]. In brief, a few colonies of 
each isolate was added to 100 μL of TE buffer (10 
mM Tris, 1 mM EDTA, pH 7.8) and boiled for 10 
minutes at 100°C. After centrifugation of bacterial 
suspensions at 9,000 × g for 30 second at 4°C, the 
supernatant was stored at -20°C for future PCR 
analysis.
Molecular identification of staphylococci isolates
Oligonucleotide primers were synthesized at Bi-
oneer (Daejeon, Republic of Korea) based on uni-
versal bacterial primers 27F (5′-AGA GTT TGA 
TYM TGG CTC AG-3′) and 515R (5′-TTA CCG 
CGG CKG CTG GCA C-3′) [18]. Fifty μl PCR re-
actions were set up each containing 5 μl of 10X 
reaction buffer, 2 μl of 50 mM MgCl2, 1 μl of 2.5 
mM dNTPs, 2 μl of each 20 pmol/μL primer, 0.4 
μl Taq DNA polymerase 5 U/μl (SinaClone, Teh-
ran, Iran) and 35.6 μL distilled water. Each PCR 
reaction was run in a Master cycler (Eppendorf, 
Germany) with the following conditions: 94°C 
for 3 min; 35 cycles of 94°C for 1 min, 58°C for 45 
seconds, and 72°C for 1 min; 72°C for 10 min and 
12°C. PCR products were visualized in 1.5% aga-
rose gels stained with ethidium bromide.
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For DNA sequencing, amplified products of 16S 
rRNA gene underwent bidirectional Sanger se-
quencing using the ABI 3730 XL DNA analyzer 
(Applied Biosystems, USA). The primers used 
for sequencing the 16S rRNA gene were same as 
those used for PCR amplification. The sequenc-
es were blasted against the Staphylococcaceae 
nucleotide database and 16S ribosomal RNA se-
quences of the National Center for Biotechnolo-
gy Information (NCBI) available at http://www.
ncbi.nlm.nih.gov/BLAST.
The staphylococcal sequences were aligned using 
the Clustal W v2.0 software and Phylogenetic tree 
was constructed by MEGA Version 6.0 [19] and 
UPGMA method [20].
Nucleotide sequence accession numbers
Partial 16S rRNA sequences from the 39 isolates, 
representing the 12 species and subspecies iden-
tified in the present study, were registered in 
GenBank under accession numbers KY411652 to 
KY411690.
n RESULTS
Forty-seven Gram-positive cocci with a positive 
catalase reaction were isolated from 37 (67.3%) 
of the 55 confectionery samples. From these iso-
lates, one Micrococcus spp. and seven Macrococcus 
spp. were detected using phenotypic methods 
[resistance to bacitracin (0.04 units) and Modified 
oxidase test]. The other Gram-positive cocci (39 
isolates) belonged to the genus Staphylococcus. 
According to tube coagulase reaction, twenty CPS 
isolates and 19 CNS isolates were detected. Re-
sults of DNase test and growth on mannitol salt 
agar were shown in Table 1.
After performing phenotypic tests, the 39 Staph-
ylococcus isolates recovered from confectionery 
samples were subjected to partial 16S rRNA gene 
sequencing. The alignment of sequences to those 
available in GenBank (nucleotide database) was 
discriminative enough to differentiate 26 Staphy-
lococcus strains at the species and subspecies lev-
el with similarities of 100%. However, 13 strains 
Table 1 - The results of phenotypic methods for detec-
tion of Staphylococcus spp.
CPSc 
(nb=20)
CNSd 
(n=19)
Total
Growth on MSAa Positive 16 15 31
Negative 4 4 8
DNase Test Positive 11 2 13
Negative 9 17 26
aMSA = Mannitol Salt Agar medium. 
bn = Number of isolates. 
cCPS = Coagulase-positive Staphylococcus. 
dCNS = Coagulase-negative Staphylococcus.
Table 2 - Phenotypic and molecular features of Staphylococcus confectioneries isolates.
Isolates Phenotypic features 16S rRNA analysis
Designation Catalase Coagulase DNase MSAa Similarityb (%) Identification
LH (8, 17, 47, 49, 52, 56, 57/2, 
60/1, 65, 67, 69, 75)
+ + + + 100 S. aureus
LH (4, 6, 43, 48, 68, 76) + + - + 100 S. warneri
LH (3/2, 58) + - - + 100 S. vitulinus
LH (5,50) + + - + 100 S. pasteuri
LH 7 + - - + 100 S. succinus
LH (11, 16/1, 60/2, 71, 77, 79) + + - + 100 S. succinus subsp. casei
LH (9, 10) + - - + 100 S. sciuri subsp. sciuri
LH 13 + - - - 100 S. lugdunesis
LH 15/1 + - - + 100 S. saprophyticus subsp. bovis
LH (46, 61/2) + - - - 100 S. epidermidis
LH 54 + - - - 100 S. gallinarum
LH (78, 80, 81) + - - - 100 S. carnosus
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Figure 1 - Phylogenetic trees generated from the multiple alignments of 16S rDNA sequences from the 39 Staphylo-
coccus strain isolates found in confectionery samples and nearest validated species of Staphylococcus species. The 
Clustal W v2.0 software using Mega 6.0 and the unweighted pair group method (UPGMA] were used.
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were not distinguishable between the two or three 
species (Table 2). All strains were distinguished at 
the species and subspecies level with similarities 
of ≥99% using the 16S ribosomal RNA sequences 
database of NCBI (Table 2).
Twelve coagulase-positive isolates were iden-
tified as S. aureus by partial 16S rRNA sequenc-
ing. Of these, 11 and 10 isolates were DNase and 
MSA-positive respectively.
The phylogenetic tree constructed based on the 
16S ribosomal RNA sequences showed a high 
bootstrap value between the validated Staphylo-
coccus species sequences from German Collection 
of Microorganisms and Cell Cultures (DSMZ) and 
our isolates sequences (Figure 1).
Partial 16S rRNA sequences from the 39 isolates, 
representing the 12 species and subspecies iden-
tified in the present study, were registered in 
GenBank under accession numbers KY411652 to 
KY411690.
n DISCUSSION
Staphylococcal food poisoning may not cause 
high mortality but can cause a lot of morbidities 
and economic loss. Confectioneries, particularly 
cream-filled pastries, and cakes, are foods that 
have been frequently considered as SFP agents 
[21]. In this study, among the 55 confectionery 
samples, we detected 6 different species and sub-
species of staphylococcus based on nucleotide 
database and Staphylococcus aureus contamina-
tion rate was 21.8%. This rate in different parts 
of the country varies from 19% to 48.7% [22-25]. 
According to Institute of Standards and Industri-
al Research of Iran report number 2395, colony 
count of Staphylococcus aureus in pastry and con-
fectionaries should be negative [17]. Since after 
cooking the confectioneries are in contact with 
surfaces and worker’s hands, therefore the pres-
ent data imply pastries might be contaminated 
by food handlers and environments. While the 
isolated Staphylococcus spp., carry the enterotoxin 
genes and the environmental conditions such as 
temperature and acidity are suitable for the toxin 
production, epidemic SFP is likely to occur with 
the consumption of these products. Unfortunate-
ly, in this study, testing of humans and surfaces 
that came into contact with the study products 
were not evaluated and therefore we suggest that 
further investigation should be done in this case.
In the present study, with respect to phenotypic 
identification tests, 10 S. aureus isolates were co-
agulase/DNase/MSA positive; one isolate was 
coagulase/DNase positive and one isolate just 
coagulase positive. According to previous stud-
ies, these two isolates with atypical characteristics 
may be methicillin-resistant Staphylococcus aureus 
(MRSA) [26, 27]. In current study, the survey of 
antimicrobial susceptibility pattern of isolates was 
not considered. However, laboratories should be 
considered such atypical strains. 
Identification of Staphylococcus spp., other than S. 
aureus is not routinely conducted in food safety 
reference laboratories. However, the identification 
of these species might be important for epidemio-
logical investigations, the assessment of virulence 
factors such as enterotoxin production and the 
development of specific management practices to 
prevent SFPs caused by CNSs [28]. Not only the 
identification of CNS is important, but also this 
process is difficult and relatively costly. Since in 
our country, limited phenotypic tests were used 
for Staphylococcus species identification in food 
laboratories, most of the isolates were not com-
pletely identified or misdiagnosed. Unfortunate-
ly, we could not properly detect the CNSs using 
phenotypic tests; however, 78.2% of identified 
Staphylococcus species were CNSs by partial 16S 
rRNA sequencing method. With comparing the 
partial sequences of 16S rDNA to the sequences 
available at GenBank database, 14 (52%) strains 
from 27 CNSs were identified at the level of spe-
cies and subspecies while, 13 (48%) strains were 
confirmed as belonging to two or three species 
(similarity 100%). Unlike to our results, Casaes 
Nunes et al. identified 42 strains at the level of 
species and subspecies from 45 Staphylococcus 
strains isolated from Minas Frescal cheeses that 
were submitted to the sequencing of the V5 re-
gion of the 16S rDNA and only three strains were 
confirmed as belonging to Staphylococcus genera 
[28]. Chakravorty et al. determined that V1 re-
gion is the best region to differentiate among S. 
aureus and CNSs [29]. In the present study, we 
also identified 12 Staphylococcus aureus strains by 
partial 16S rRNA sequencing with 100% similari-
ties. We also used 16s ribosomal RNA sequences 
database and all of the CNSs were identified at 
the level of species and subspecies. Even though 
16S ribosomal sequences are widely used for the 
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bacterial species identification and perform taxo-
nomic classification studies, some inadequacy can 
be seen in currently available databases and this 
subject was confirmed in our study and by other 
researchers [15, 30, 31].
n CONCLUSION
In the current study, we isolated a considerable 
number of staphylococcus strains from confec-
tionaries that almost one-third of them were S. au-
reus by partial 16s RNA sequencing method and 
rest of them belonged to different Staphylococcus 
species. According to our findings, using this 
method for detection of S. aureus could be useful 
but not suitable for identification of other species 
of Staphylococcus genera.
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n INTRODUCTION
HIV-associated lymphoma was first classified as an AIDS-defining disease by the Amer-
ican Center for Disease Control and Prevention 
(CDC) in 1985 [1]. Prior to the introduction of 
antiretroviral therapy, the incidence of HIV-asso-
ciated lymphoma was 3 to 4% of all AIDS - de-
termining diseases [2-4]. It has been found that 
without effective antiretroviral therapy 5-10% of 
all HIV-infected patients will develop lymphoma 
as an initial or a subsequent AIDS-defining con-
dition [4, 5]. Non-Hodgkin’s lymphomas (NHL) 
are frequent malignancies in AIDS patients. More 
than 90% of HIV-associated NHL are derived from 
B-cells and the majority are of a high grade [6]. 
Study data show that over time, before the era of 
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HIV-associated lymphoma was first classified as 
an AIDS-defining disease by the American Center 
for Disease Control and Prevention (CDC) in 1985. 
Non-Hodgkin’s lymphomas (NHLs) are frequent ma-
lignancies in AIDS patients. The risk of NHL in the 
case of an underlying HIV infection is estimated to 
be 100 times greater than in the general population, 
and it increases with the progression of the retrovi-
rus-related immunosuppression. Cases of HIV-relat-
ed non-Hodgkin’s lymphoma are widely document-
ed in the literature. In this article we present three 
cases of NHL and HIV hospitalized over a period of 
three years (2013-2016) at our specialized department 
for AIDS patients. Two of them were initially diag-
nosed with NHL and then with HIV infection. In one 
patient, NHL developed despite the patient’s taking 
background antiretroviral therapy. The first case was 
a 38-year-old male diagnosed previously with HIV, 
who developed a palpable mass in the left zygomatic 
bone. The second case was a 52-year-old male who 
SUMMARY
was first diagnosed with a cutaneous lymphoma, and 
subsequently with HIV infection. The third patient 
was a 63-year-old male who presented with two pal-
pable masses: one in the left part of the mandible, and 
the other in the right inguinal region, the latter subse-
quently diagnosed as lymphoma. Following the lat-
ter diagnosis, the patient tested positive for HIV. The 
histological findings of the three lymphomas were as 
follows: an NHL plasmoblastic lymphoma, a cutane-
ous large B-cell anaplastic lymphoma, and a diffuse 
large B-cell lymphoma. The first patient received an-
tiretroviral therapy (ART) and EPOCH (etoposide, 
pharmarubicin, vincristin, endoxane, uromitexan) 
plus radiotherapy, while the second received ART 
and CHOEP (endoxan, epirubicin, vincristin, etopo-
side, prednisolone). The third patient died a few days 
after beginning antiretroviral therapy.
Keywords: AIDS, HIV, non-Hodgkin’s lymphoma, an-
tiretroviral therapy.
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highly active antiretroviral therapy, the incidence 
of NHL has been between 60 and 200 times high-
er in HIV-infected adults compared to the general 
population [7, 8].
The following have been considered to be the 
most important prognostic factors for the devel-
opment of HIV-associated NHLs: patients naïve 
to antiretroviral therapy, men who have sex with 
men (MSM), age of 35 years, and, most signifi-
cantly, a low CD4 cell count [8, 9].
In this article we report all cases of HIV-positive 
patients who have developed NHL at our De-
partment over the past three years (2013-2016). 
The patients have been monitored and treated for 
HIV-infection at the Department for AIDS of the 
Specialized Hospital for Infectious and Parasitic 
Diseases in Sofia. The NHL diagnosis was made, 
and accordingly chemotherapy was administered 
at the National Specialized Hospital for Active 
Treatment of Hematological Diseases in the same 
city.
n CASE REPORTS
Case 1
A 38-year-old male with proven HIV infection 
since 1998. Until May 2014, the patient did not 
appear to be registered and monitored at our 
Department. The patient’s complaints started in 
May 2014 with general malaise, chills, shortness 
of breath, fever, cough, and expectoration. In May 
2014, he was treated for bilateral interstitial pneu-
monia at the Pulmonology Department. After 
that, he was hospitalized at our Department, and 
was treated for pneumocystosis and candidiasis. 
The patient started antiretroviral therapy with 
the 3TC/ABC + ATZ/r combination. One week 
later, a solid formation with an increasing size 
occurred in the area of the left zygomatic bone. 
Following a biopsy and a histological examina-
tion of the formation at the National Specialized 
Hospital for Active Treatment of Hematological 
Diseases, the diagnosis was confirmed as plas-
mablastic non-Hodgkin’s lymphoma. A whole-
body CT scan was performed, and the lymphoma 
was graded stage 4. An infiltrate engaging the 
left maxillary sinus was found. The soft tissues 
of the left cheekbone were also infiltrated. The 
upper border of the formation penetrated into 
the left orbit (72/63/44 mm). A soft-tissue lesion 
in the right anterior diaphragmatic sinus with a 
pore-size of 30 mm was also established. There 
was no evidence of enlarged lymph nodes. The 
trephine biopsy did not reveal involvement of the 
bone marrow. Chemotherapy with 6 courses of an 
EPOCH regimen (etoposide, pharmarubicin, vin-
cristin, endoxane, uromitexan), and radiotherapy 
were conducted. The patient is currently being 
followed-up for progression of his lymphoma. So 
far, it has shown remission.
Since the onset of the antiretroviral therapy (ART), 
an optimal immunological response has been ob-
served: CD4 T+ cell count at baseline being at 79 
cells/μL, and currently standing at 685 cells/μL. 
The initial CD4/CD8 ratio was 0.41, whereas at 
present it is 1.29. The viral load before ART ini-
tiation was 25,000 copies/μL, but following ART 
commencement, an optimal viral suppression has 
been achieved.
Case 2
A 52-year-old man was diagnosed with HIV in-
fection in July 2016. The patient’s complaints dat-
ed back to February 2016, when a cutaneous red 
plaque about 5 cm in size appeared in the right 
temporal area. Subsequently, a “nodular” forma-
tion emerged in the right temporal area, approx-
imately 5 cm in size. Smaller nodes of similar 
appearance developed also on the neck and the 
trunk. A weight reduction of about 6 kg was also 
observed. The diagnosis was established after a 
biopsy and a histological examination of the for-
mation of the calvaria (Figure 1): anaplastic large-
cell lymphoma, which required the ruling out of 
the following differential diagnosis:
a) primary cutaneous anaplastic large cell lym-
phoma;
b) systemic anaplastic large-cell lymphoma with 
skin involvement.
The CT scan of the chest, abdomen and the less-
er pelvis revealed no pathological findings or 
enlarged lymph nodes. The CT scan of the head 
showed a subcutaneous soft-tissue formation in 
the right parietal region, 37/17 mm in size, with-
out destruction of the underlying bone, and a sec-
ond similar lesion, 5/12 mm, in the right occipital 
region. The trephine biopsy showed no involve-
ment of the bone marrow. The patient commenced 
ART in July 2016 with TDF/FTC + RAL at a CD4 
count of 177 cells/μL, a CD4/CD8 ratio of 0.77, 
and a viral load of 265,493 copies/μL. A month 
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later, the patient started chemotherapy with the 
CHOEP regimen (endoxan, epirubicin, vincristin, 
etoposide, prednisolone), and received 8 cours-
es of it. He is currently being followed-up for 
his lymphoma. At present, a remission has been 
achieved. The current CD4 count is 252 cells/μL, 
the CD4/CD8 ratio is 0.77, and the HIV viral load 
is undetectable (<40 μL).
Case 3
A 63-year-old patient was diagnosed as HIV-pos-
itive in August 2016 during his hospitalization at 
the Department of Hematologic Diseases, where 
he was found with diffuse B-cellular NHL. In this 
patient the disease debuted in February 2016 with 
the onset of tumor formations on the left side be-
low the mandible, and in the right inguinal region 
(Figure 2). The patient’s lymphoma was graded 
stage 4. The CT-scan showed a tumor formation 
in the left half of the facial skull: part of the for-
mation was tracked to penetrate into the intrap-
haryngeal space; another lesion was found in 
the left mandible. It involved the regional lymph 
nodes: a mesh-like lymphadenomegaly at the lev-
el of the crura of the diaphragm in the posterior 
mediastinum, 70/26 mm in size. A tumor forma-
tion in the right inguinal fold of 12/8 cm was also 
established.
This patient was admitted to our Department 
for initializing antiretroviral therapy. He start-
ed with 3TC/ABC + MVC at a CD4 count of 221 
cells/μL, a CD4/CD8 ratio of 0.38, and a viral 
load of 1,274,788 copies/μL. On the 15th day of 
ART, a lethal outcome due to cardiac arrest was 
observed. The third patient’s lethal outcome was 
probably related to his advanced age and the 
large tumor mass, and the respective aggressive 
course of the NHL.
n DISCUSSION
Patients infected with HIV are at an increased risk 
of developing NHL. AIDS-related NHL (AIDS-
NHLs) are mostly, but not all, of high-grade and 
B-phenotype, as in the presented cases [8, 9]. The 
risk of developing lymphoma in patients with 
symptomatic HIV infection appears to be approx-
imately 1.6% per annum [9]. The most common 
sites of involvement are the CNS (26%), the bone 
marrow (22%), the gastrointestinal tract (17~25%), 
and the liver (12%) [3]. The exact pathogenesis of 
AIDS-related lymphomas is not fully understood. 
One likely factor is the immune suppression itself. 
Chronic antigenic stimulation of the B lympho-
cytes by antigens, mitogens, or viruses, including 
the Epstein-Barr virus (EBV) and HIV, may play 
a role, but the continued HIV viral burden on B 
cells in association with the EBV and Herpes sim-
plex virus 8 (HHV-8) is also believed to play a 
part [10, 11]. All patients presented in this article 
had IgG antibodies against EBV and CMV. PCR 
and testing for HHV- 8 have not been carried out 
for financial reasons.
Figure 1 - The tumor formation on the head. Figure 2 - The tumor formation in the right inguinal region.
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According to other authors, HCV infection is also 
associated with low-grade lymphoproliferative 
disorders that can progress to NHL. Bacterial in-
fections have also been associated with NHL [16]. 
All the patients presented in this article were neg-
ative for HCV. The second patient was positive 
for HBV and had serological evidence of a past 
infection of syphilis. But in all patients, there were 
no concomitant bacterial infections.
Cutaneous lymphomas are characterized by in-
itial accumulation of mononuclear cells, mostly 
lymphocytic, in the skin [12]. Primary cutaneous 
lymphomas represent 5% to 10% of the total ex-
tranodal NHLs, and rank second in frequency 
after the lymphomas occurring in the gastrointes-
tinal tract [12]. The clinical presentation of cuta-
neous NHL includes single or multiple subcuta-
neous nodes, papules, and ulcerative and infiltra-
tive lesions. Patients with NHL show cutaneous 
involvement in 15% to 20% of cases, and in 5% 
to 10% of them, skin lesions are the first mani-
festation of the disease. The number of lesions is 
a prognostic factor in primary cutaneous B-cell 
lymphomas. Fine Needle Cytology (FNC) com-
bined with ancillary techniques can also provide 
the correct diagnosis in most cases. In patients 
suffering from NHL, FNC also plays an impor-
tant role in the differential diagnosis between a 
relapse of a primary disease and reactive lymph 
nodes enlargement [16].
In the pre-antiretroviral therapy era, the incidence 
of AIDS-related lymphoma remained constant at 
about 6~7 cases per 1000 persons per annum [2, 
4]. The declining incidence following the intro-
duction of HAART is promising; there have been 
significant improvements due to the improved 
immunity status in the cases of boosted patients, 
and this has been highlighted by the increase in 
CD4 T - cells counts [13]. In the early years of 
treatment, the recommended optimal first choice 
of therapy for AIDS-related lymphoma was a 
combination chemotherapy that consisted of high 
doses of cytosine arabinoside, methotrexate, and 
cyclophosphamide [14]. However, the combina-
tion chemotherapy regimens that are commonly 
used for the treatment of intermediate or high-
grade lymphomas are so toxic that the occurrence 
of hematologic complications and opportunis-
tic infections has generally resulted in a poor 
outcome for patients, especially for those with 
AIDS-related lymphomas. A recent study using 6 
courses of a dose-adjusted EPOCH regimen has 
shown a complete response rate of 74% [4, 14, 15].
The first two patients in our case, treated with EP-
OCH and CHOEP, respectively, responded well to 
chemotherapy. The first one received also radio-
therapy. The third patient died before starting the 
chemotherapy. The response to the chemotherapy 
and the patient survival were related to the existing 
comorbidities and the patients’ overall state. The 
CD4 count has been considered one of the most im-
portant predictors in AIDS-related lymphoma pa-
tients. The invasion of the tumor elsewhere than in 
the lymph node, the performance status, the histo-
logical subtype, and the clinical stage could also be 
useful as predictors [14, 15]. The adverse prognos-
tic factors for AIDS-related lymphomas include a 
CD4 count of <100/mm3, an age of >35 years, stage 
III or IV disease, an elevated LDH-level, and a his-
tory of drug injection abuse (11). AIDS-related lym-
phoma patients exhibit various degrees of immune 
suppression. At the time of the lymphoma diagno-
sis, the CD4 counts of our patients were 79/mm3, 
177/mm3, and 221/mm3, respectively. The CD4/
CD8 ratios were 0.41, 0.77, and 0.31, respectively. 
All three patients were diagnosed with advanced 
HIV/AIDS disease with severe immunosuppres-
sion and low CD4 T - cell counts at the time of the 
neoplasm diagnosis, age >35 years, and stage IV 
disease. The 1-year survival rate of AIDS-related 
lymphoma patients is 30%, which is lower than in 
the general lymphoma population. The survival 
period for our two patients to date is three years, 
and one year, respectively.
n CONCLUSION
We present three cases of NHL that developed 
in HIV-infected patients. This is a brief report on 
these HIV-infected lymphoma patients; the lym-
phomas had a different anatomical location, and 
distinctive clinical signs at the time of presenta-
tion. In two of the cases reviewed in this study, 
combined antiretroviral therapy and chemo-
therapy was administered, and these treatments 
proved to be effective for improving the progno-
sis of these patients. The third patient died before 
starting the chemotherapy. The tumor invasion, 
together with the performance status and the age 
were the most important factors for the poor out-
come in the third patient.
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n INTRODUCTION
Progressive multifocal leukoencephalopathy (PML) is a rare, deadly demyelinating disease 
of the central nervous system (CNS), caused by 
the John Cunningham virus (JCV) and classically 
observed in advanced stages of human immuno-
deficiency virus (HIV) infection [1, 2]. However, 
in the last decades, PML has been increasingly re-
ported among patients with haematological and 
solid malignancies, organ transplant recipients 
on immunosuppressive drugs and most recent-
ly among patients receiving immunomodulating 
drugs, like natalizumab [1, 2]. Surprisingly, PML 
may also develop occasionally in individuals 
with minimal immunosuppression, such as in 
those affected by sarcoidosis [1, 2]. In HIV-nega-
tive patients, the main therapeutic strategy is to 
decrease the immunosuppression, whenever pos-
sible; serotonin reuptake inhibitors (by blocking 
5-HT2a, used by JCV for cell-to-cell spread) and 
the CCR5-antagonist MVC (for its immune-mod-
ulating properties) have shown promising results 
in limited case series [3-7].
Here we describe a case of PML in an HIV-neg-
ative patient with mixed connective-tissue dis-
ease (MCTD) on a minimally immunosuppres-
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A case of progressive multifocal leukoencephalopathy 
(PML) is described in an HIV-negative patient with 
mixed connective-tissue disease (MCTD) on a mini-
mally immunosuppressive treatment with hydroxy-
chloroquine. The patient presented with right-sided 
weakness, episodes of disorientation and loss of short-
term memory and of vision in her right eye. PML was 
diagnosed by JCV DNA on cerebrospinal fluid and ra-
diological criteria. She was treated with off-label mar-
aviroc and mirtazapine but died two months after hos-
SUMMARY
pital admission, despite a surprising decrease in the 
viral load of cerebrospinal fluid three weeks after start-
ing therapy. Prompt diagnosis and antiviral treatment 
of PML even in low-risk patients are warranted. Future 
studies are required to define the therapeutic role of 
maraviroc (MVC) and mirtazapine in this setting.
Keywords: Progressive multifocal leukoencephalop-
athy, maraviroc, mirtazapine, hydroxychloroquine, 
Sjögren’s syndrome, IRIS, JCV.
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sive treatment with hydroxychloroquine. To our 
knowledge this is one of the fewest cases treated 
with off-label maraviroc and mirtazapine, result-
ing in a divergent clinical, radiological and viro-
logical outcome.
n CASE REPORT
A 50-year-old Caucasian woman with autoim-
mune thyroiditis and MCTD was admitted to our 
clinic for right-sided weakness, episodes of disori-
entation and loss of short-term memory and right 
eye’s vision. In the previous months she reported 
significant difficulty in driving, weakness and 
visual disturbances. MCTD was diagnosed 5 years 
before with a clinical and serologic pattern over-
lapping Sjögren syndrome. She started hydroxy-
chloroquine (200 mg) and low-dose corticoster-
oids (withdrawn after 3 years). At the admission, 
she was on oxycodone, hydroxychloroquine and 
levothyroxine. Neurological examination revealed 
right hemi-paresis, bilateral ophthalmoplegia and 
right hemi-spatial neglect. Blood tests were unre-
markable, but total lymphocyte count of 236 cells/
μL with 217 CD4+ T-cell (68,5%). HIV test was 
negative. Brain magnetic resonance (MRI) showed 
extensive T2/FLAIR non-enhancing signal ab-
normalities involving subcortical white-matter of 
both parietal-occipital lobes, corpus callosum and 
the rear frontal lobe (Figure 1). Cerebrospinal flu-
id (CSF) analysis were within the normality range 
(proteins, glucose, cells and CSF-serum albumin 
ratio). CSF opportunistic infections were ruled 
out (Cryptococcus spp, Toxoplasma, herpetic virus-
es and Mycobacterium tuberculosis), but JCV-DNA 
was 119370 copies/mL. After informed consent 
and the approval by the off-label committee of 
the hospital, maraviroc (300 mg twice daily) and 
mirtazapine (15 mg once-daily; then twice-daily) 
were started, while hydroxychloroquine was con-
currently withdrawn. Nevertheless, her clinical 
conditions worsened: after treatment was started, 
her neurological status continued to deteriorate 
with a new onset of dysarthria, temporo spatial 
disorientation and progressive development of 
tetraplegia. After three weeks of treatment, a brain 
MRI revealed slightly increased white-matter le-
sions (Figure 1), while CSF JCV-DNA was reduced 
to 459 copies/mL. Plasma and CSF maraviroc 
concentrations were 85 ng/mL and <1 ng/mL, 
respectively (ultra high performance liquid chro-
matography coupled to tandem mass spectrome-
try methods SE, Waters, Milan, Italy). Eventually, 
the patient went into a coma and passed-out two 
months after hospital admission.
n DISCUSSION
Nowadays, an increasing number of HIV-nega-
tive individuals are at risk for developing PML, 
Figure 1 - Brain Magnetic 
Resonance Imaging. Axi-
al T2-weighted sequence 
(left) and axial fluid-at-
tenuated inversion recov-
ery (FLAIR, right). Typical 
progressive multifocal 
leukoencephalopathy-as-
sociated lesions are seen 
in parietal-occipital lobes 
and corpus callosum. The 
lesions were hyper intense 
on T2/FLAIR sequences 
and did not enhance with 
contrast.
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due to the broader use of immunosuppressive/
immunomodulatory treatment in different clin-
ical settings [1, 2]. In these cases, the new onset 
of subacute neurologic signs or symptoms should 
raise the suspicion for PML, even in minimally 
immunosuppressed patients suffering from he-
patic cirrhosis, chronic renal failure, pregnancy, 
dementia or idiopathic CD4+/CD8+ lympho-
cytopenia [1, 2]. While for HIV-positive patients 
highly-active antiretroviral therapy may add ad-
junctive help, in HIV-negative patients the prog-
nosis remains poor, with a median survival of 3 
months [3]. For the latter, the only strategy is the 
reduction of immunosuppressants’ doses, when-
ever possible, or the removal of biological agents 
through plasmapheresis [4, 5].
Several medications have been used to treat PML 
with anecdotal success (e.g., cytarabine, cidofovir, 
mefloquine), although these drugs have failed to 
show efficacy in randomized trials or prospective 
studies [8, 9]. On the contrary, no randomized 
trials or prospective studies on large cohort have 
been carried on about MVC and mirtazapine use 
in PML [10-12].
We observed a significant decrease in CSF JCV-
DNA (2.4 log10 copies/ml within three weeks) 
using MVC plus mirtazapine. In vitro studies 
have showed that JCV may entry into target cells 
through the serotonin receptor 5-HT2a, suggest-
ing a potential role for mirtazapine, a serotonin 
reuptake inhibitor licensed for major depression 
[6]. Some evidence claimed beneficial effects of 
mirtazapine for PML treatment, showing con-
current clinical improvement and CSF virologi-
cal clearance due to the restriction of viral cells 
spread [6, 7, 11]. On the other side, MVC is a 
CCR5 receptor antagonist, approved for R5-tropic 
HIV infection. Evidence regarding the usefulness 
of MVC in PML is limited and conflicting. It has 
been shown that CCR5+ lymphocytes may play 
a pivotal role in the pathogenesis of a subgroup 
of PML cases, associated with immune reconsti-
tution inflammatory syndrome (IRIS), an over-
whelming and life-threatening inflammatory re-
action occurring during immune recovery [13, 14]. 
High percentages of CCR5 + cells, predominantly 
CD8+ cytotoxic T-cells, has been found in natal-
izumab-associated PML-IRIS, as well as in other 
cases of inflammatory PML lesions, suggesting a 
role in tissue damaging for this T-cell subpopu-
lation [15, 16]. In an inflammatory milieu, MVC 
may directly hamper the exaggerated inflamma-
tory reaction by decreasing the influx of lympho-
cytes and macrophages into the infection site and 
modulating immune activation [16]. Recently, 3 
HIV-negative patients diagnosed with PML were 
treated with MVC and mirtazapine, showing a re-
duction up to undetectable CSF JCV-DNA value, 
as well as long-term clinical and radiological im-
provements [17]. However, compared to our pa-
tient, these cases presented lower CSF viral loads 
at the diagnosis, which has been associated with 
a better prognosis [18]. In addition, the absence 
of inflammatory components in our patient, as 
evidenced by the lack of enhancing lesions at the 
MRI, may have made MVC vain. Scarce data are 
available regarding CCR5 inhibitors usefulness or 
risks in PML cases without IRIS [19, 20]. In this 
setting, MVC may potentially aggravate immune 
suppression, leading to the inhibition of innate 
and adaptive responses; additionally, the appro-
priate dose is uncertain [21, 22]. Considering the 
conflicting evidence from scant reports and the 
observed discrepancy between virological and 
clinical outcome, further studies are needed to 
assess the real efficacy of MVC and mirtazapine 
and their eventual association for different PML 
subtypes.
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n INTRODUCTION
Cytomegalovirus (CMV) is a double strand-ed DNA virus that belongs to the family 
of Herpesviridae. In immunocompromised pa-
tients can cause serious disease through prima-
ry CMV infection or re-activation secondary to 
immune dysfunction [1]. In healthy individuals 
CMV infection follows an initially asymptomat-
ic benign course with a flu like illness and mild 
symptoms [1].
It has been reported that CMV seroprevalence in 
the United States varies widely, ranging from 21% 
to 95% of the population [2]. Additionally, CMV is 
considered the most common cause of congenital 
infection in the developed countries, affecting 0.1-
2% of live born infants [3, 4]. In the vast majority 
of immunocompetent hosts CMV remains latent 
for years [1]. Here we present an unusual case of 
fatal CMV disease in a previous healthy young 
woman.
n CASE PRESENTATION
A 40-year-old previous healthy woman was re-
ferred by his general practitioner to the Saint 
George General Hospital of Chania, Crete, Greece 
reporting sudden weakness of the lower limbs 
with sensory alterations. A history of lower res-
piratory tract infection, with high fever was re-
ported 1 week before admission. Her vital signs 
at admission were as follows: blood pressure, 
140/60 mmHg; heart rate 90 min; body tempera-
ture, 36.2 C; respiratory rate 12 min; oxygen satu-
ration 97% on ambient air. Abdomen was soft in 
palpation and electrocardiogram revealed sinus 
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Cytomegalovirus can cause severe disease with adverse 
outcome in immunocompromised patients. Severe cyto-
megalovirus infection in previously healthy individuals is 
rare. Here we present an unusual case of cytomegalovirus 
infection with neurological and pulmonary involvement 
in a previously healthy young woman with no history of 
immuno-suppression. Unfortunately, the disease followed 
a malignant course and despite the efforts of the medical 
staff the patient died. CMV infection should be considered 
SUMMARY
in the diagnostic work-up of immunocompetent patients 
with fever and unexplained neurological or pulmonary 
manifestations. Although uncertainty exists regarding the 
optimal treatment of CMV in healthy individuals, early 
recognition and administration of ganciclovir may pre-
vent a fatal outcome.
Keywords: Cytomegalovirus, pneumonitis, neurological 
impairment, immunocompetent
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rhythm. Neurological examination showed di-
minished muscular strength in the lower limbs 
(grade 3/5) and reduced pain sensations bellow 
L1. Cranial nerves examination was normal.
Blood tests revealed a normal white blood cell 
count (WBC) of 7.1×109/L (4-9.5). Liver func-
tions tests disclosed a 2-fold elevation of hepatic 
transaminases, with alanine aminotransferase 122 
U/l (normal range: 0-45) and γ glutamyl trans-
ferase 133 U/l (normal range: 0-55). Due to the 
neurological deficit a lumbar punction test was 
consequently performed.
Polymerase chain reaction assay in cerebrospinal 
fluid (CSF) for CMV was positive in two consec-
utive tests. Further analysis for human immuno-
deficiency virus, varicella zoster virus, measles, 
mumps and mycoplasma pneumonia was neg-
ative. The patient was treated with ganciclovir 
(5 mg/kg twice daily for two weeks) and meth-
ylprednisolone due to the neurological deficit of 
the lower limbs (500 mg once daily for 7 days). 
A progressive clinical improvement of the neu-
romuscular deficit was recorded and the patient 
was discharged home 4 weeks later. Serum tests 
including antinuclear antibody (ANA), antiJo-1 
antibody, anti-DNA antibody, anti-CCP, anti-RNP 
antibody, rheumatoid factor, and thyroid tests 
were all negative.
After two months, she was readmitted to the Pul-
monology department of our hospital with acute 
respiratory distress. Her oxygen saturation was 
88% on ambient air. Arterial blood gases showed 
pH 7.5, pCO2 31 mmHg and pO2 76 mmHg. The 
chest X ray showed butterfly pulmonary opaci-
ties bilaterally (Figure 1). C-reactive protein was 5 
mg/dl with normal white blood cells count. Poly-
merase chain reaction serum test was positive for 
CMV DNA with high viral load. A diagnosis of 
CMV pneumonitis was made. Since the respirato-
ry status continued to deteriorate the patient was 
transferred to the Intensive Care Unit of our Hos-
pital and was intubated. Treatment with ganciclo-
vir 500 mg twice daily was initiated. Response to 
antibiotic therapy was poor and the patient died 
4 days later.
n DISCUSSION
Although CMV infections in immunocompro-
mised patients is well documented, those ob-
served in immunocompetent individuals have 
not been well described [1]. A literature review by 
Rafailides et al., reported that CMV infections in 
healthy patients may not be so unusual as previ-
ously believed [1]. It can be manifested as a wide 
range of conditions, from asymptomatic to inva-
sive disease [5].
Almost every anatomical region can be involved 
[1]. Gastrointestinal tract is the location most fre-
quently affected, following by the central nervous 
system, blood cells, eye, liver and last by pulmo-
nary and vascular system [1, 6].
More specifically, gastrointestinal manifestations 
include gastroenteritis, colitis, duodenitis and 
proctitis [1]. Fever, abdominal pain in the lower 
abdomen, anorexia, nausea and vomiting are the 
main symptoms patients admitted while abdom-
inal and rebound tenderness are the principal 
signs during palpation [1].
Central nervous system is the second prevalent 
site of CMV infection in immunocompetent in-
dividuals [1]. It is often presented with myelitis, 
encephalitis, and meningitis [1]. Fever, myalgia, 
muscular weakness, paraplegia are the principal 
symptoms while numbness, hypoesthesia, dis-
orientation, confusion, visual loss are the main 
signs recorded during neurological examination. 
Advanced age is an aggravating factor for a fa-
vorable outcome [7]. Two types of meningo-en-
cephalitis have been described in immunocom-
petent patients: the paroxysmal type with benign 
outcome and the monophasic type characterized 
by seizures and an adverse prognosis [7].
Remarkably in a retrospective study of 116 im-
Figure 1 - Chest X-ray showing pulmonary opacities in 
both lungs.
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munocompetent adults (range 19-68 years old), 
only two presented with interstitial pneumonitis 
and encephalitis [8]. Similarly in a cohort study 
by Wreghitt et al. among 124 immunocompetent 
patients with a diagnosis of acute CMV infection, 
aged from 16 to 86 years old, almost 3 out of 10 
suffered from respiratory symptoms, about 1 out 
of 4 had jaundice and 3% were reported to be con-
fused [9].
The traditional method for the diagnosis of CMV 
infection is by virus isolation from culture of the 
human specimen [10]. Similarly, serological tests 
are useful for determining whether a patient has 
had CMV infection in the past, by the presence or 
absence of CMV IgG [8]. Remarkably, polymerase 
chain reaction (PCR) is considered a fast method 
for CMV detection characterized with a high sen-
sitivity [10].
We presented an unusual case of CMV multi-or-
gan infection in an apparently immunocompetent 
patient. Our case is unusual since it represents 
concurrent manifestation of severe CMV disease 
with neurological and pulmonary involvement 
in a healthy young female. We presume that the 
resistance of the virus to ganciclovir was respon-
sible for the unfavorable outcome.
Furthermore, compelling evidence suggests that 
unknown genetic parameters may influence the 
clinical expression of the disease [11]. It has been 
reported that natural killer (NK) cells play a crucial 
role in host defense against CMV infection and few 
studies demonstrated the KIR and HLA repertoire 
may influence the risk of developing symptomatic 
or asymptomatic disease after primary CMV infec-
tion in the immunocompetent host [12].
n CONCLUSION
Despite the rarity of CMV infections with neu-
rological and pulmonary involvement, clinicians 
involved should have high index of suspicion in 
order to make an early diagnosis of the disease. 
Timely and appropriate antiviral therapy may im-
prove prognosis and prevent lethal eventualities.
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n INTRODUCTION
Mycetoma or Madura foot is a chronic gran-ulomatous infection involving cutaneous 
and subcutaneous tissue, with possible and grad-
ual extension to fascia and bone, becoming even a 
large and mutilating lesion [1].
The development of the disease seems to be cor-
related also to the patients’ immune system and, 
in particular, to some single nucleotide polymor-
phisms and Th2-response, that predisposes to the 
evolution of the infection. It is caused by bacteria 
(Actinomycetoma) or fungi (Eumycetoma), both 
found in the soil, which enter the body by a lesion 
of the skin caused by thorn pricks, splinters, stone 
cuts or insect bites. The principal species involved 
is Actinomadura spp a bacterium that belongs to 
the genera of actinobacteria [1, 2].
Actinomycetoma and eumycetoma have a simi-
lar clinical presentation: the affected part of the 
body appears increased in volume, deformed and 
firm, characterised by the presence of nodules 
and multiple sinus, with a seropurulent discharge 
containing grains. The lesion is typical painless. 
The foot and the hand are the parts of the body 
more involved (more than 80% of cases), followed 
by the other parts of the leg and arm, and back 
[3]. Nevertheless, unlike eumycetoma, actinomy-
cetoma has a more aggressive clinical course with 
early bone involvement and frequent lymphatic 
spread.
In order to establish the correct treatment, it is 
mandatory the identification of the causal micro-
organism, since actinomycetoma and eumyceto-
ma are treated differently.
The diagnostic tools should be employed on deep 
surgical biopsy material. Direct examination and 
histopathology aim at identifying the filaments 
and grains characteristics using special stains: in 
actinomycetoma, the filaments can be identified 
with Gram stain and are weekly stained by hae-
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from the cutaneous layer to the underlying fascia, and an 
indolent course. A number of fungal or bacterial agents 
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among the most common agents of mycetoma occurring 
worldwide. We report a case of madura foot caused by 
A. madurae in an immunocompetent young Somali man 
who was admitted with a diagnosis of skin and soft tissue 
infection of the left foot with osteomyelitis. The present re-
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matoxylin and eosin; in eumycetoma, the fila-
ments stain with periodic acid-Schiff and, strong-
ly, with haematoxylin and eosin [4]. Nevertheless, 
it is hard to distinguish the species because of their 
similar appearance. Even the culture of grains, 
carried out using recommended media (Colum-
bia agar, Brain Heart Infusion, Lowenstein-Jensen 
and Sabouraud glucose agar) for at least 10-15 
days, is difficult and time-consuming [4].
Molecular methods applied on biopsy specimens, 
based on PCR and sequencing, even if more ex-
pensive, result more reliable in species identifica-
tion and more rapid [5].
Once the microorganism is identified, the main 
challenges of the therapy are the long duration, 
the possibility of collateral effects and the poor 
availability of alternative effective drugs.
n CASE REPORT
A 24-year-old immunocompetent Somali man 
was admitted to the Infectious Diseases Unit of 
the University Hospital of Palermo (Sicily, Italy) 
in May 2017 because of a skin and soft tissues in-
fection of the left foot with osteomyelitis. He had 
arrived in Lampedusa one week before, after a 
migratory route that lasted seven years, crossing 
Sudan, Kenya and Libya. He reported the first le-
sion in the left sole at the age of 13, with a slowly 
progressive deformation of the foot. On admis-
sion, the foot was swollen, warm and tender with 
limitation of the IV and V toes movement and 
multiples, poorly draining sinus on the dorsal 
face (Figure 1). The rest of the physical examina-
tion showed no anomalies. He had no pain. No 
fever or any other systemic symptom appeared.
Laboratory tests showed a modest leukopenia 
(WBC 3010/mmc, N 63% and L 29%) and an in-
creased C- reactive protein (76 mg/L).
A plain radiography and CT scanning of the foot 
revealed marked soft tissue swelling of the meta-
tarsal and between III-V toes, with bone sclerosis 
and cavities of the metatarsal and V toe.
The blood cultures were sterile. Quantiferon TB 
Gold Plus test was positive, but an active tuber-
cular infection was excluded. The patient signed 
an informed-consent form before biopsy analysis.
We performed a surgical biopsy of the sole: pa-
thology showed chronic, granulomatous inflam-
mation with PAS positive grains; the specimen 
ZN coloration and cultures for common aerobic 
and anaerobic bacteria were negative.
The biopsy, before and after decontamination 
by N-acetyl L-cysteine (NALC) sodium hydrox-
ide (NaOH) method, was inoculated on Löwest-
ein-Jensen (L-J) and Blood Agar and incubated at 
37°C for 8 weeks.
On the basis of epidemiology, clinical aspect and 
pathology result, under the hypothesis of eumy-
cetoma, waiting for the microbiological results, 
we started a therapy with itraconazole.
Figure 1 - A. Madura 
foot on admission and 
B. after one month of 
treatment.
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Two weeks later, the colonies grown (Figure 2), 
were identified as Actinomadura madurae by PCR 
and sequencing of 16S rRNA and hsp65 genes.
In June, we switched therapy to trimethop-
rim-sulfamethoxazole (TMP/SMX) 240/1200mg 
BID and 1g of amikacin for the first month. No 
renal dysfunction or ototoxicity occurred, but 
a worsening of leukopenia led us to using folic 
acid permanently and filgrastim twice, with sta-
bilisation of the WBC count. At the discharge, the 
patient was given custody by a community one 
hour far from Palermo. In order to avoid the lack 
of adherence due to the daily intramuscular ad-
ministration of amikacin, we decided to continue 
the therapy with TMP/SMX in association with 
rifampicin and isoniazid, in consideration of the 
latent tuberculosis infection. Nevertheless, two 
days later the patient had vomit and abdominal 
pain probably rifampicin-correlated, so rifampic-
in was stopped, and treatment with TMP/SMX, 
in association with folic acid and isoniazid was 
continued monitoring WBC count twice week.
After four months of treatment, the swelling sub-
sided and the foot decreased in dimension. The 
patient carries on the follow-up and the treatment 
is currently on going.
n DISCUSSION
Mycetoma is a rare neglected tropical disease. 
According to the first and last biggest worldwide 
meta-analysis on the global burden of mycetoma, 
carried on in 2013 by van de Sande and reporting 
8673 cases since 1944, the most endemic countries 
are Sudan, Senegal and Togo in Africa, India in 
Asia and Mexico in North America [6].
Nevertheless, lacking established surveillance 
programs, the real global incidence and preva-
lence are not known.
In Europe, thirty autochthonous cases were de-
scribed in immunocompetent hosts, coming from 
Bulgaria, Albany, Italy, Greece, and Turkey [7, 8]. 
The only species found on all continents in equal 
amount is A. madurae [6].
In consideration of the increasing number of ref-
ugees from endemic areas observed in Europe 
since 2014, we underline the need to improve the 
awareness on this disabling disease [8, 9].
In Italy, only few cases are reported: among 
them, three cases are autochthonous and all of 
them by A. madurae. In Italy, was reported also 
an imported case of mycetoma due to Actinoma-
dura pelletieri [8-10].
It is not known the entity of the national and Eu-
ropean burden of imported cases that is likely to 
be increased due to the growing number of mi-
grants.
Actinomycetoma is well responsive to antibiotic 
treatment, even if continued for a long period. 
The recommended first-line regimen is based on 
trimethoprim/sulfamethoxazole 240/1200 mg 
BID in cycles of 5 weeks, with the possible asso-
ciation of amikacin 15 mg/kg per day divided 
in 12 hours im or ev for 3 weeks, that seemed to 
increase the efficacy of the treatment [6]. Amox-
icillin-clavulanate, rifampicin and carbapenems 
could be used in case of allergy to co-trimoxa-
zole or amikacin or in refractory cases [11-13]. 
Amoxicillin-clavulanate is generally not effec-
tive against A. madurae [14]. The duration of the 
therapy is not well established: among all the 
studies, none lasts less than five months, until a 
maximum of one year.
Eumycetoma requires surgical management in as-
sociation with a long period of antifungals.
In our case, despite a prompt diagnostic suspi-
cion, we delayed the correct treatment because of 
initial misunderstanding of the causal agent wait-
ing for the slow growth of microorganism.
In conclusion, international and national surveil-
lance programs are necessary to establish the real 
burden of mycetoma. It is important to improve 
the awareness on mycetoma of physicians, pa-
thologists and microbiologists, above all in those 
centres more involved in the increasing of migra-
tory routes. All of these figures should have to 
work in strict collaboration to reach rapidly the 
correct diagnosis and promptly start a long and 
difficult treatment.
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Figure 2 - A. madurae on Löwenstein-Jensen Agar.
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We present four cases in which probable sexual trans-
mission of Giardia lamblia was suspected. 
Diagnosing this mode of transmission in endemic ar-
eas is often difficult and should be considered only 
as possible, because exposure to poor sanitation and 
a potentially contaminated environment are always 
latent. However, as patients reported, there was no 
history of drinking tap water, exposure to recreation-
al water, eating contaminated food, or other potential 
sources of infection but anilingus with an infected 
partner. We consider that in endemic countries, even 
SUMMARY
when other more frequent modes of transmission 
could be playing the main role, the possibility of (re)
infection due to sexual transmission should not be 
forgotten. 
Talking openly with patients, strengthening pa-
tient-specific preventive measures and counselling 
appear to be needed to reduce risks of Giardia infec-
tion transmission due to this often neglected route.
Keywords: Giardia, giardiasis, sexual transmission, HIV, 
diarrhoea, combination therapy.
n INTRODUCTION
Giardia lamblia, the aetiological agent of hu-man giardiasis, is a protozoan widespread 
throughout the world and it is estimated that in-
fects approximately 5-10% of the world´s popula-
tion, especially in low- and middle-income coun-
tries where the prevalence rates may range from 
4-43% [1, 2]. Giardia transmission mainly occurs 
when faecal excretion of cysts by ill persons or 
healthy carriers is followed by oral ingestion of 
contaminated water or food by a susceptible host. 
In the same way, faecal-oral transmission can occur 
within households, daycare centres and custodial 
institutions, and in those people who include and 
practice anilingus in their sexual repertoire, espe-
cially in men who have sex with men (MSM) [3-6].
Giardia is often an asymptomatic -or self-limited- 
infection of the upper small intestine. When symp-
tomatic, this infection presents with non-specific 
manifestations like diarrhoea, abdominal pain, 
anorexia, nausea, vomiting, weight loss, and in-
creased flatulence [7]. Were these reasons not 
enough, the value of the recent Giardia research is 
increased by the recognition that this protozoan 
has been linked to irritable bowel syndrome and 
chronic fatigue [8].
Relatively non-specific clinical features of this dis-
ease lead to diagnostic difficulties. High indexes of 
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suspicion by clinicians, as well as thorough eval-
uation using sensitive techniques, are essential to 
diagnose this infection. Treatment of giardiasis is 
based on 5-nitroimidazole compounds (mainly 
metronidazole and tinidazole), nitazoxanide and 
albendazole (ABZ). When treatment fails to cure, 
a number of factors must be considered, includ-
ing re-infections, medication non-compliance, re-
sistance, etc. [7].
While in endemic areas the main sources of Gi-
ardia infection seem to be water- or food-borne, 
other modes of infection including sexual trans-
mission could have a role in transmission. Herein 
we report our experience with 4 cases, living in an 
endemic region in which the sexual transmission 
was considered as possible.
n CASE REPORTS
Case 1: A 35-year-old healthy woman started 
with diarrhoea, hives, abdominal pain of several 
days’duration; mild nausea and a decreased ap-
petite. On physical exam her abdomen was dif-
fusely tender to palpation. There was no obvious 
rash seen. Up to three faecal specimens were re-
quested and Giardia cysts were observed. She was 
treated with secnidazole (SCZ) with resolution of 
symptoms and three negatives faecal specimens 
in follow up consultation. Four weeks later, she 
started with similar symptoms and Giardia cysts 
were found in faecal specimens again. On repeated 
questioning, exposure to persons with diarrhoeal 
illness or to contaminated food and water were 
ruled out. However, she stated that had heard that 
Giardia could be transmitted sexually -by receptive 
vaginal intercourse-, and someone told her that if 
she had giardiasis, maybe her husband should re-
ceive treatment at the same time. We denied this 
route of transmission, but on continued question-
ing, she stated that she enjoyed actively perform-
ing anilingus during the sexual intercourse with 
her husband. Her husband was invited to attend to 
the consultation. He was asymptomatic but when 
he was parasitologically examined, Giardia infec-
tion was confirmed, too. Other family members, 
who lived in the same house, were parasitologi-
cally examined and were negative for Giardia cysts 
in faecal specimens. The patient and her husband 
were given giardiasis treatment at the same time 
with a single dose of SCZ, which resulted in parasi-
tological cure. She had completely recovered, with 
resolution of her symptoms and both, she and her 
husband remained well.
Case 2. A 24-year-old healthy MSM noticed a 
change in bowel habits, with increased frequen-
cy and decreased consistency of faeces. Yellowish 
foul watery diarrhoea, 3-4 times a day, abdomi-
nal pain and a decreased appetite were the main 
clinical manifestations. These started around 10 
days after a sexual encounter with an adult male 
with whom he sporadically had sexual encoun-
ters. He was very concerned about the possibility 
of Giardia infection because his occasional partner 
had had giardiasis no less than 4 times before. 
He denied both receptive and insertive anal in-
tercourse; however, they practiced fellatio and 
anilingus without protection, considering these 
less risky practices in relation with HIV infection. 
Exposure to contaminated food and water were 
ruled out. The findings of a physical examina-
tion revealed moderated periumbilicar tender-
ness. Faecal specimens for ova and parasites, and 
modified acid-fast staining were requested. HIV 
testing was also offered. HIV tests were negative 
and modified acid-fast staining was negative for 
intestinal coccidia. After microscopic detection of 
Giardia cysts in faecal specimens, metronidazole 
(MTZ) was prescribed for 5 days to the patient 
and he received the recommendation of abstain-
ing anilingus without protection. In the follow up, 
his faecal examination were negative for ova and 
parasites. He improved clinically with resolution 
of diarrhoea, and weight gain. Despite history of 
recurrent giardiasis, his sporadic sexual partner 
had been asymptomatic throughout the patient’s 
evaluation and management. He was invited to 
attend to the doctor office and to be examined 
for intestinal parasites. He was also confirmed to 
be infected with Giardia and successfully treated 
with a 7-day course of MTZ.
Case 3: A 56-year-old, HIV-infected MSM (11 
years diagnosed, receiving treatment with 
HAART the last 5 years with apparent adher-
ence) with a past medical history of hyperten-
sion and asthma, started complaining with ab-
dominal pain, diarrhoea, flatulence and weight 
loss. The findings of a physical examination 
were unremarkable, only diffuse abdominal ten-
derness. At the faecal examination it was found 
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Giardia and Entamoeba coli cysts. Modified ac-
id-fast staining of faecal specimens was negative 
for intestinal coccidia. A thorough history re-
vealed no potential source of infection other than 
sexual. He protected himself avoiding drinking 
unboiled water or eating food out of his house 
in order to prevent enteric parasitic infections 
that may complicate his HIV seropositive status. 
He practiced protected anal intercourse (both re-
ceptive and insertive). He participated in group 
sex, used sex toys and also practiced anilingus 
without protection. He had been previously di-
agnosed with intestinal amoebiasis, enterobiasis 
and hepatitis A. He was asked about the health 
of his most recent partner and he stated he used 
to have recurrent Giardia infection. The patient 
was initially and successfully treated with MTZ 
for 5 days, parasitologically confirmed by faecal 
tests for ova and parasites, three weeks later, on 
the day of their follow-up visit. A month later, 
symptoms reappeared, he reported being with 3 
nights history of severe pruritus ani; enterobiasis 
was suspected; however, it was not confirmed. 
The patient reported a sexual encounter with 
the same last partner and having had active an-
ilingus with him, again. Three additional faecal 
specimens were requested. Once again exposure 
to contaminated food and water were ruled out. 
Giardia cysts were found again and he was suc-
cessfully treated with MTZ and ABZ, both for 5 
days and repeating 200 milligrams of ABZ after 
15 days, according to the guidelines for the treat-
ment of Enterobius vermicularis infections. Addi-
tionally, he was recommended abstaining anilin-
gus without protection. Apart from mild nausea 
and bitter taste he tolerated the treatment well. 
Within several days after therapy, he improved 
clinically with resolution of diarrhoea, and 
weight gain. He achieved a complete parasito-
logical cure. His occasional partner was invited 
to attend to the consultation but he never came.
Case 4: A 21-year-old healthy MSM attended with 
his 28-year-old male partner to the doctor´s office. 
Both were complaining with recurrent abdomi-
nal pain with moderate intensity, increased flatu-
lence, diarrhoea and weight loss. They had visited 
a camping in the countryside and drank unboiled 
water a month before. They stated anilingus with-
out protection as a common sexual practice. The 
findings of their physical examination were nor-
mal. HIV testing was offered to both, and was 
negative. Up to three faecal specimens were re-
quested and Giardia cysts were observed. Once 
etiological diagnosis was established, they were 
counseled about Giardia and its mode of transmis-
sion. Also, it was prescribed MTZ for 7 days for 
the patient and his partner, and the recommen-
dation of drinking boiled water and abstaining 
anilingus until three negative faecal specimens 
after completion of a 7 day course of MTZ were 
obtained. Only the 21-year-old patient attend-
ed to follow up and the three faecal specimens 
requested revealed the complete parasitological 
cure. However, three weeks later, he re-attended 
with symptoms again. The findings of his faecal 
examination revealed Giardia cysts again. On re-
peated questioning, it appeared that the 28-year-
old male partner had only taken MTZ for three 
days, time in which resolution of abdominal pain 
and diarrhoea occurred and he stopped taking the 
drug. So, they recommenced their sexual activi-
ties including mutual anilingus without protec-
tion. A repeat course of the same therapy led to a 
complete parasitological cure in both men. They 
improved clinically with resolution of diarrhoea, 
and weight gain. The complete parasitological 
cure was achieved.
n DISCUSSION
Giardia is a common and globally distributed 
intestinal protozoan, although this infection is 
mainly observed in developing countries. It is the 
commonest intestinal parasitic protozoan infec-
tion in Cuba, where the highest prevalence has 
been found in children [9]. According to Cuban 
studies, despite the high proportion of the pop-
ulation who lives with improved water supplies, 
water seems to play a major role in the transmis-
sion of this protozoan [10]. In the present case 
series, the mode of transmission in each instance 
was thought to be probably via faecal oral contact 
during anilingus, a common risk factor found in 
the cases reported.
Direct transmission from person to person is an 
established mode of transmission for some enteric 
pathogens including Shigella, Entamoeba, Enterobi-
us, and Giardia when there is an oral contact with 
the perianal area, previously contaminated with 
faeces [6, 11-13]. As our cases live in endemic areas, 
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diagnosing this mode of infection is often difficult 
and should be considered only as possible; howev-
er, the sexual route appears to have provided the 
necessary link for transmission in each one of our 4 
cases, according to the each case history.
In endemic areas, sexual transmission of Giardia 
infection may be underappreciated, due to the 
continuous exposure to a potentially contam-
inated environment because of poor hygienic 
conditions. That is why in these regions, the sex-
ual transmission of Giardia infection is hard to 
be distinguished from other routes of transmis-
sion. However, it might be more common than 
is currently recognized, especially if the sexual 
repertoire of couples is taken into consideration. 
In addition, although this route has been mainly 
reported in homosexual males, anilingus may be 
a practice carried out independent of sexual ori-
entation, as in our first case.
It is important to highlight that our 4 cases were 
highly motivated and we were able to form a close 
doctor-patient relationship throughout their period 
of diagnosis, treatment and follow up to talk in an 
open manner. We were therefore almost confident 
of excluding other potential sources of reinfection 
but anilingus. They denied history of exposure to 
drinking tap water, eating contaminated food or 
contact with diaper-age children, neither exposure 
to recreational contact with fresh water.
HIV/AIDS awareness may have a side-effect 
on the transmission of Giardia and other enteric 
parasitic infections, due to the HIV transmission 
through the oral route is considered uncommon 
[14]. In this way, because of the perceived “rel-
ative safety” of oral sex, in comparison to other 
types of sexual behaviour, oral sexual practic-
es have been prevalent among many high-risk 
groups and this could increase the possibility of 
sexual transmission of this protozoan, mainly if it 
is considered the high number of asymptomatic 
cysts passers, the high cyst excretion rate and the 
long-term faecal shedding from infected human 
host, the immediate infectivity of cysts released in 
the faeces, and the low infectious dose necessary 
to initiate an infection (10 organisms) [7, 15].
From a public health perspective, the major chal-
lenge is how best to avoid acute infections in at-
risk populations, and for those already infected, 
how to prevent consequent morbidity and trans-
mission to other members in the community. A 
combination of both prevention and treatment is 
required to minimize the ongoing transmission 
of Giardia in the general population. For giardi-
asis, primary prevention is difficult, because a 
human vaccine is not available nor is one likely 
to be available in the near future. It seems neces-
sary that providers have open and non-judgmen-
tal conversations with patients about the varying 
levels of risk for Giardia infection also based on 
sexual activity. Providers can intervene with ed-
ucation about harm reduction techniques; for 
instance, messages that include information that 
individuals with giardiasis are infectious during 
the cyst shedding. These patients should be coun-
selled to avoid oral-anal contact during this time, 
and it should be explained that being asympto-
matic, improvement of abdominal pain or the 
achievement of diarrhoea resolution do not une-
quivocally mean parasite clearance neither cessa-
tion of infectivity. 
The present case series highlights some important 
points; firstly, the importance of considering the 
possibility of sexual transmission of Giardia infec-
tion in endemic countries, at least in those with 
recurrent Giardia infection or when other causes 
of treatment failures were ruled out, even among 
heterosexual couples: in this way the patient can 
be appropriately investigated and promptly - and 
properly - treated. Secondly, it is an important 
reminder that the human factor of compliance to 
therapy and preventive measures are at least as 
relevant, if not more so, than the drugs we choose 
for a regimen after failure of first-line therapy. 
Thirdly, the importance of tailoring messages ac-
cording to the route and mode of transmission; 
patients could be receiving counselling messages 
sufficiently tailored to the epidemiological reality 
of the local endemicity regarding Giardia trans-
mission that emphasize drinking unboiled water, 
eating contaminated food or swimming in con-
taminated pools, etc., forgetting other important 
modes of transmission that could be implicated.
While the importance of sexual transmission of 
Giardia infection in an endemic region need not 
to be overemphasized, its inadequate assessment 
makes re-infections possible. So, it is necessary to 
find an easy route into discussion about sexual 
transmission of this protozoan, avoiding moral 
judgments. Additionally, patients and their cou-
ples should be warned to use protection during 
this kind of sexual practice or abstain from it until 
a negative ova and parasites control after comple-
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tion of a course of antigiardial drug was obtained.
In the field of sexually transmitted infections 
(STIs), the effective management of these infec-
tions depends on appropriate testing, treatment, 
partner management, complete and timely re-
porting of positive the sexually transmitted dis-
ease tests and the implementation of preventive 
measures. However, in the case of Giardia infec-
tion, it is non-notifiable disease in many coun-
tries and it is not considered in the STIs setting, 
so the health department takes no action to noti-
fy partners. If sexual transmission is suspected, 
the responsibility mostly lies with the patient 
and most likely most physicians rely on the pa-
tient to notify his/her partner(s), which could 
persuade him/her to look for diagnosis and care, 
but probably not.
n CONCLUSIONS
Although Giardia is mainly transmitted through 
contaminated water or food, and sexual transmis-
sion is not the primary route of transmission in 
endemic countries, the potential of sexual trans-
mission of this protozoan should be ruled out, 
mainly in patients who actively report anilingus 
or those who report after questioning. Increased 
public awareness is essential for the treatment and 
control of this disease in different settings. People, 
in general, should be counselled accordingly with 
clear-designed messages about the relative con-
tributions of the main modes of transmission of 
Giardia, so that they can make informed choices 
about the preventive measures they should take. 
As no immune protection can be expected from 
previous Giardia infections, infections may repeat-
edly occur, as long as high-risk practices or expo-
sure to an ongoing source continue. Thus, consid-
ering Giardia in the STI setting, sexual partners 
should be screened for this protozoan infection 
and treated if necessary.
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Dear Editor, A 24-year-old man came to our outpatient 
clinic due to epigastric abdominal pain which mi-
grated to the right lower quadrant during the next 
few days. The patient also presented persistent 
watery and non-bloody diarrhea. On physical ex-
amination, the patient was afebrile (body temper-
ature, 36.5°C). He had right lower abdominal ten-
derness with rebound pain and guarding. Physi-
cal signs suggestive of acute appendicitis, such as 
McBurney’s or Lanz’ point tenderness, Rovsing’s 
and obturator signs, were all positive. However, 
the patient was afebrile and the laboratory data 
indicated the absence of inflammatory findings 
(peripheral white blood cell count, 6,600/µl; C-re-
active protein level, 0.08 mg/dL). Plain abdomi-
nal computed tomography (CT) scanning demon-
strated a normal appendix, but a severely swollen 
ascending colon with prominent thickening of the 
bowel walls (Figure 1, arrow heads). It appeared 
to totally occlude the luminal space, showing the 
appearance of a pseudoabscess-like formation 
with stratified structures inside. Since there was 
no diverticulum in the colon, acute diverticulitis 
was not likely the diagnosis. Additionally, an ab-
dominal X-ray revealed the absence of mechani-
cal bowel obstruction (Figure 2), which suggested 
the unlikeliness of carcinoma or intussusception. 
The lesion extended continuously in the right 
lower abdominal area (Figure 1A to B), which 
strongly supported a diagnosis of acute entero-
colitis in the ascending colon. Oral rehydration 
was initiated with the administration of empiric 
antibiotics together with probiotics. Intravenous 
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administration of ceftriaxone (1 g/day) was ini-
tially started, followed by oral administration of 
cefcapene pivoxil (300 mg/day) for seven days. 
The patient remained afebrile, but his symptoms 
and signs, including watery diarrhea and right 
lower abdominal pain, subsided several days af-
ter the initiation of the treatment.
Abdominal imaging is not usually warranted in 
patients with acute diarrhea. However, in patients 
who have significant peritoneal signs, CT scan-
ning is a useful diagnostic approach to evaluate 
undifferentiated abdominal pain. The typical CT 
findings of acute enterocolitis include thickening 
of the bowel walls due to intramural edema and 
pericolic fat stranding, sometimes showing the 
appearance of a pseudoabscess-like formation 
(Figure 1) [1, 2]. There are many causes of infec-
tious acute enterocolitis, such as bacterial, fungal, 
viral, parasitic causes and sometimes by amebia-
sis and tuberculosis [1, 3]. In our case, however, 
the affected portion of the ascending colon sug-
gested infection with specific organisms, such 
as Shigella, Salmonella, Campylobacter or Yersinia 
enterocolitica [4]. Since initial stool culture results 
for routine organisms, such as Shigella, Salmonella 
and Campylobacter, revealed negative, Yersinia en-
terocolitica, which usually grows more slowly on a 
separated culture media, was most likely to be the 
causative pathogen.
In young adult males, the differential diagnoses 
of right lower quadrant abdominal pain include, 
appendicitis, diverticulitis, mesenteric lymphade-
nitis, inguinal hernia, testicular torsion or nephro-
lithiasis [5]. In our case, except for the persistent 
watery diarrhea and the absence of inflammatory 
findings, the patient’s symptoms and signs mim-
icked those of acute appendicitis. As we previ-
ously reported in a patient with Fitz-Hugh-Cur-
tis syndrome complicated by appendicitis, the 
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extension of pericolic inflammation into the right 
lower quadrant was likely to be responsible for 
the parietal pain stimuli [6]. In our case, an ab-
dominal X-ray revealed the absence of mechani-
cal bowel obstruction (Figure 2), which suggested 
the unlikeliness of carcinoma or intussusception. 
However, it does not totally exclude the possibil-
ity of the malignancy in the right colon, although 
it is unlikely from the patient’s history and age. In 
this regard, further investigations, such as colo-
noscopy and repeated CT scan, should be neces-
sary in the future, once the enterocolitis has been 
resolved.
Figure 1 - Plain abdominal computed tomography (CT) scanning at the umbilical (A) and pelvic (B) levels. It demon-
strated a severely swollen ascending colon with prominent thickening of the bowel walls (arrow heads), showing the 
appearance of a pseudoabscess-like formation with stratified structures inside. The lesion extended continuously in 
the right lower abdominal area (A to B). There was no diverticulum in the colon and the appendix was normal.
Figure 2 - An abdominal X-ray film revealed the ab-
sence of a mechanical bowel obstruction.
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Dear Editor,Zika epidemics have significantly impact-
ed in the Americas region [1]. Countries such as 
Brazil and Colombia had regions with high inci-
dence [2, 3]. Nevertheless, there is still a lack of 
epidemiological studies showing the spatial pat-
tern of distribution, with their implications for 
public health and infectious diseases practition-
ers [2-4]. Also, travelers to those endemic areas 
should be aware about the risk of infective biting 
exposure when visiting for different purposes 
these areas [3]. In order to help in the advice to 
travelers and public health, epidemiological in-
formation is of utmost importance, including the 
availability of detailed maps in order to assess 
the risk when visiting specific destinations [2, 
5, 6]. For these reasons, we have developed and 
published epidemiological maps for Zika in Co-
lombia using geographical information systems 
(GIS) for different regions, in this case at one of 
the largest departments, Antioquia, constituted 
by 125 municipalities [2-6].
Use of GIS for development of epidemiological 
maps in Zika and other emerging arboviral dis-
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eases has not been used enough in Colombia and 
Latin America [2, 3, 6].
Surveillance cases data (2015-2016) (official report-
ed by the National Institute of Health of Colombia) 
were used to estimate cumulative incidence rates 
using reference population data, on Zika RT-PCR 
and clinically suspected cases (both estimated as 
cases/100,000 pop.) to develop the first maps of 
Zika in the department of Antioquia (constituted 
by 125 municipalities). GIS used was Kosmo® 3.1. 
Four thematic maps were developed according 
municipalities. Determination of ZIKV infection 
includes either laboratory and syndromic surveil-
lance (clinical definition of fever, rash, conjuncti-
vitis and arthralgias in a municipality with previ-
ously ZIKV circulation, at least one case confirmed 
by RT-PCR). The clinical definition has been rec-
ommended by World Health Organization, Pan 
American Health Organization as well the US 
Centers for Disease Control and Prevention.
Total number of cases also included those in 
which clinical diagnostic criteria, i.e., the case 
definition was met, but which were reported in a 
municipality without RT-PCR confirmation. After 
one case is confirmed by RT-PCR in a municipali-
ty, patients not classified as risk groups (pregnant 
women, children <1 y-old, people >60 y-old and 
patients with comorbidity), can be diagnosed by 
clinical definition.
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Since September 1, 2015 up to April 23, 2016, 
1,965 cases were reported in Antioquia, Colom-
bia (Figure 1), corresponding to: 139 RT-PCR con-
firmed and 1,826 clinically suspected (1,479 from 
municipalities with RT-PCR confirmed cases and 
347 from other municipalities, without previous 
confirmed cases) (Figure 1), for a cumulative rate 
for the department of 30.43 cases/100,000 pop. 
Highest incidence rate was estimated in Chigor-
odó (208.58), followed by Carepa (188.75), Apar-
tadó (186.16), Zaragoza (173.47) and Mutata 
(161.31) (Figure 1). Seventy-nine (out of 125) mu-
nicipalities reported cases. Medellin (the capital 
city) reported 323 cases (16.4%) for a rate of 12.99 
cases/100,000 pop. Eleven municipalities (high 
incidence at maps), reported >100 cases/100,000 
pop. (Figure 1). The disease is concentrated in 
northwest municipalities (the whole central 
Urabá) of the department (neighbor municipal-
ities) (Figure 1).
Data derived from these maps can be used to guide 
decisions for prevention and control of emerging 
health problems. Undoubtedly, Zika represents a 
significant issue in the region and the country, par-
ticularly in pregnant women and newborns [2, 3, 
7]. And these maps should be used for counseling 
of travelers and pregnant patients who should be 
aware about the risk of infective mosquito biting. 
But also about the possibility of asymptomatic dis-
ease and the risk of disease transmission through 
sexual intercourse that should lead to the use of 
contraceptive barrier methods even weeks after 
visiting these areas, such as Antioquia [2, 3, 7]. A 
previous study assessed the basic reproduction 
Figure 1 - Geographic distribution of Zika incidence rates (cases/100,000pop) in Antioquia department, Colombia, 
2015-2016. A. Based on all notified cases. B. Based on clinical syndromic surveillance (clinical definition of fever, 
rash, conjunctivitis and arthralgias in a municipality with previously ZIKV circulation, at least one case confirmed 
by RT-PCR). C. Based on RT-PCR-confirmed cases. D. Suspected cases (clinical definition of fever, rash, conjunctivi-
tis and arthralgias in a municipality without previously confirmed ZIKV circulation).
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number (R0) in Antioquia for this epidemic peri-
od, which was found as 1.12, but did not devel-
op incidence maps [8]. For Colombia, a previous 
report indicated a R0 ranging from 3.0 to 6.6, that 
study found that the Urabá had a R0 between 1.1 
to 5.0, consistent to the high incidence we found 
of >140 cases/100,000 pop [8] (Figure 1).
Colombia officially reported during 2015-2016, a 
total of 106,659 cases; 2.4% were from Antioquia 
department. Given the ecoepidemiological con-
ditions of the department and particularly of the 
northwestern municipalities, these are becoming 
now endemic for Zika. Other factors, including 
environment and climate, as have been studied 
in another Aedes-borne disease, such as Den-
gue, are important in future studies [3, 9]. Public 
health policies and strategies, considering these 
conditions, for an integral control of Zika in peo-
ple living, but also in travelers, in these areas, 
should be developed and urgently implemented 
[3, 5, 7, 8].
Use of GIS-based epidemiological maps allows to 
integrate preventive and control strategies, as well 
as public health policies, for joint control of this 
vector-borne disease in this area of the country [2, 
6]. As Zika is transmitted primarily by A. aegypti, 
the Dengue and Chikungunya virus vector, maps 
of both infections as well for coinfections will be 
also needed [10, 11]. Finally, the availability of rel-
evant information, to assess the risk of travelers 
with specific destinations, in highly transmission 
areas, is highly important for prevention advice. 
Even more, because they play also an important 
role in the virus spread, as occurred in Colombia 
and the Antioquia department during 2015-2016 
[2, 3, 6, 10].
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n INTRODUCTION
Louse infestation, called pediculosis, one of the oldest pestilential diseases of humankind, is 
very contagious and easily transmitted by close 
body-to-body contact or contact with infested lin-
en, brushes, or clothes, according to the species 
of louse. Pediculosis capitis, caused by head lice, is 
the most common louse infestation; it particular-
ly affects school-children 3-11 years of age and its 
clinical hallmark is scalp pruritus [1]. Pediculosis 
corporis, caused by body lice, represents a major 
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public health concern. It is strongly associated 
with close body-to-body contact, and occurs only 
when clothes are not changed or washed regular-
ly. These conditions are more prevalent in indi-
viduals living in crowded and unhygienic envi-
ronments, such as refugee camps or shelters for 
the homeless and migrants.
Clinical manifestations include generalized pruri-
tus associated with scratching and lesions are typ-
ically localized to the neck, thorax, waist, and an-
kles. Diagnosis is based on a finding of adult lice 
and, more importantly, eggs in clothing seams.
Three types of louse can affect humans, but only 
body lice act as vector for human pathogens such 
as Rickettsia prowazekii, Borrelia recurrentis and 
Bartonella quintana, which are known to cause 
epidemic typhus and louse born relapsing fever 
Louse infestation is one of the oldest contagious pes-
tilential diseases of humankind, which has recently 
re-emerged in several developing countries as well 
as in homeless individuals and migrants. The present 
work provides the first phase of an historical excursus 
of louse remedies based on the classics of pharmaceu-
tical literature, codes, pharmacopoeia and treatises. 
The second phase involves a literature search, based 
on the principal medical databases (SciFinder, Pu-
bmed, Google Scholar, ISI-Web of Science and Scopus), 
to match ancient raw materials and active principles 
for the treatment of pediculosis and their possible ap-
plications, with other current infectious pathologies 
transmitted by different carriers. In this regard, Rho-
dodendron tomentosum has revealed repellent insect 
activity, particularly against Aedes aegypti, responsible 
SUMMARY
for Dengue fever, Chikungunya, Zika fever, Mayaro, 
yellow fever and other infectious diseases. Petroseli-
num crispum is an insecticide employed for resistant 
strains of A. aegypti. In the case of Delphinium staphis-
agria, the phytochemical profile was further investi-
gated with the identification of further molecules in 
addition to delphinine. The latter shows interesting 
activities against Trypanosoma cruzi and Leishmania. 
Anthemis pyrethrum, now renamed as Anacyclus pyre-
thrum, although not containing pyrethrins present in 
several plants of the genus Chrysanthemum, revealed 
pediculicidal activity but did not produce satisfactory 
results in antiprotozoal activity.
Keywords: louse, remedies, typhus, mosquito-borne dis-
eases, trypanosomiasis, Chagas disease, leishmaniasis.
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(LBRF) which must be considered in any febrile 
refugee regardless the country of origin, and 
trench fever, respectively.
These infections particularly affect populations 
living in poor-hygiene conditions where body 
louse infestations are prevalent. Whereas epi-
demic typhus and epidemic relapsing fever are 
particularly prevalent in vulnerable populations 
in developing countries, trench fever is common 
worldwide, especially in homeless individuals.
Louse-borne diseases are associated with a high 
prevalence of body louse infestation, and have 
recently reemerged in jails and refugee camps in 
central and eastern Africa, Peruvian Andes and in 
rural louse-infested populations in Russia [2, 3]. 
LBRF, a neglected and forgotten disease by west-
ern physicians has recently reemerged among 
East African migrants seeking asylum in Europe 
[4]. Migrants from endemic areas can carry the 
vector with them; healthcare providers should be 
aware of this condition to implement adequate di-
agnostic, therapeutic, and public health measures.
The historical path that has led to today’s reme-
dies against pediculosis has been long and labo-
rious, although it is worth recalling that the in-
secticide action on the common louse can now be 
exploited against the carriers of severe infectious 
diseases now rapidly spreading from a continent 
to another.
In 1939, the dichlorodiphenyltrichloroethane 
(DDT) came into pratical use revolutionizing the 
cornerstones of disinfestation although it was 
banned in 1978 for its adverse health effects. After 
DDT benefit, treatment of pediculosis has been 
continued since the late 1970s by the employment 
of synthetic pyrethroids developed from natural 
molecules drawn from Chrysanthemum cinerar-
iaefolium. Among them, permethrin has shown 
to be the most effective product. Other synthetic 
pyrethroids are phenotrine, deltamethrin and su-
mitrin. A second choice treatment consists of mal-
athion, an organophosphorus pesticide.
The present work provides a first part on an his-
torical excursus of pediculosis remedies based on 
the classics of pharmaceutical literature, codes, 
pharmacopoeia and treatises (Figure 1).
A second phase part will involve a literature 
search, based on the principal medical databases 
(i.e., through SciFinder, Pubmed, Google Scholar, 
ISI-Web of Science and Scopus), to match ancient 
raw materials and active principles for the treat-
ment of pediculosis and their possible applica-
tions, with other current infectious pathologies 
transmitted by different carriers.
Figure 1 - De Animalibus: 
Pediculus, Ortus sanita-
tis, 1517.
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Historical notes
The role of Pediculus as a vehicle of epidemic ty-
phus infection was established in 1909 by the No-
bel Prize in Medicine Charles Nicolle who discov-
ered that epidemic typhus is transmitted by body 
lice (Pediculus humanis corporis) [5]. The epidemi-
ology of head louse and body louse infestations, 
and of louse-borne epidemic typhus, indicates 
that the head lice are potential vectors of R. prowa-
zekii in the field [6].
Epidemics occurred during wars and famine and 
epidemic typhus has been one of the earliest pes-
tilential diseases that have strongly influenced 
humanity [7].
Paleomicrobiology enabled the identification of 
the first outbreak of epidemic typhus in the 18th 
century in the context of a pan-European great 
war in the city of Douai, France, and supported 
the hypothesis that typhus was imported into Eu-
rope by Spanish soldiers returning from America. 
R. prowazekii was also detected in the remains of 
soldiers of Napoleon’s Grand Army in Vilnius, 
Lithuania, indicating that Napoleon’s soldiers 
had epidemic typhus [8]. It is estimated that, of 
the 25,000 soldiers who reached Vilnius, only 3000 
survived (Figure 2). The majority of them were 
infected with louse-transmitted diseases and re-
cently, DNA from soldier’s dental pulp gave ev-
idence of infection with either R. prowazekii or B. 
Quintana [9, 10].
Remedies
Mercurials
Mercurials have been used in traditional med-
icine. Mercury and most of its compounds are 
extremely toxic. They have been used in antisep-
tics, laxatives and antisyphilitics. Topical mercury 
treatment was used to treat pediculosis.
In the Lemery’s pharmacopoeia (1720) Unguen-
tum Neapolitanum simplex made of quicksilver, 
Venice turpentine and lard is reported. It can be 
employed for treatment of scabies, phthiriasis, 
bedbugs, crabs. It is called Neapolitanum, and was 
also used against syphilis [11].
Campana in the Farmacopea ferrarese (several edi-
tions) recommends mercurial ointment of white 
or red precipitate of quicksilver [12].
The same remedy is reported in Porati’s Manuale 
Farmaceutico (1820): Unguentum ad pediculos co-
eruleum and Unguentum ad pediculos rubrum and 
in Orosi’s pharmacopoeia (1856-57): Pomata An-
tipedicolare: prec. Rosso o bianco and lard [13, 14]. 
In the De Bruc’s Formulario (1863), including many 
international pharmacopoeial preparations, sim-
ple mercurial ointment, mercurial rose-water and 
lotion of the bichloride of mercury (Pomata mercu-
riale semplice, Acqua contro i pidocchi, Lozione mon-
dificante) are reported [15].
Brugnatelli in Pharmacopeia Generale (1817) cited 
red precipitate of mercury, also named red nitrat-
ed quicksilver, and mercurial creme, Precipitato 
rosso e manteca mercuriale [16].
In Manuale di Pharmacopeia generale e speciale su 
Farmacopea Prussiana e lavori Alemanni e stranie-
ri (1871) Posner recommended the powder of 
bichloride of mercury mixed with starch and sug-
ar [17].
Figure 2 - A, Map showing the location of Vilnius. The 
“Grande Armée” retreated from Moscow to Paris. B, Gen-
eral view of the grave in Vilnius (from Raoult D. et al., 2006. 
Photo by P. Adalian, Centre National de la Recherche Sci-
entifique, Unité Mixte de Recherche 6578) [10].
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Stafisagria - Delphinium Staphisagria
The Ortus Sanitatis, a treatise published since the 
end of 15th century, attributed the spread of pe-
diculosis to … balnei paucitatem … and indicates 
hygiene as the main remedy … precipuum reme-
dium esse dicit frequens ablutio corporis (Figure 3). 
As remedies it includes, in addition to mercury, 
staphisagria with arsenic, as Avicenna said [18].
Antonio Musa Brasavola, in Examen omnium sim-
plicium medicamentorum, quorum in officinis usus 
est (1539), states that it is used by women ad ne-
candos pediculos. The name comes from them in 
strafusarium. The name Staphisagria derived from 
the Greek and means wild raisin. It is the herba 
pedicularis of the Romans [19]. In Librum quar-
tum Dioscoridis Cap. CL (Commentarii, Latin Edi-
tion of I Discorsi, 1554) it is illustrated according 
to Dioscorides Staphys Agria: Trita, & ex oleo illita 
phthiriasi prodest. Mattioli points out that Latini ab 
effectu, quod pediculos necet, herba pedicularis dicitur. 
Oil is effective agaist phthiriasis, Mattioli remem-
bers that it is called by Latini herba pedicularis for 
its effect on lice. It is frequent in Istria, Dalmatia, 
Apulia and Calabria. It also has harmful effects on 
humans (Figure 4) [20].
Lemery in Farmacopea Universale reports lotion 
pediculicide Lotio ad pediculos capitis enecandos 
(Staphysagria, Seminis contra, assenzio, tanaceti, be-
tonica, centauria minor). Hot decoction is used to 
wash the head. It kills lice and crabs [11].
As reported in Jourdan’s Parmacopea Universalis 
(1837) stafisagria is a component in Pulvis Cap-
ucinorum, made of sabadilla, parsley and tobacco 
[21].
Orosi proposed an ointment: stafisagria powder 
mixed with lard in 1:8 ratio [14].
Ferrarini in the Farmacopea (1825) for the Erba 
de Pidocchi indicates the habitat in Linguadocca, 
Provence, and in the mountains of Spouthern Eu-
rope. He also suggests its use as powder, infusion, 
ointment [22].
Brugnatelli recommended its use as powder, de-
coction and ointment. An infusion of staphisagria 
may be made with vinegar [16].
The Dizionario delle Droghe semplici e composte 
(1831) and Dizionario classico di Medicina interna ed 
esterna (1838) report an ointment (Pomata) made 
of powder of stafisagra (fr. Staphisaigre) and lard 
[23,24]. Seeds can be macerated in vinegar. The 
isolation from the seeds of the active component 
is also cited: Lassaigne and Feneulle report that 
the seeds contain a basic substance, named Delfin-
ia, with an excess of malic acid. The water-soluble 
fraction is more toxic to animals. Powdery seeds 
Figure 3 - De Herbis: Staf-
isagria, Ortus sanitatis, 
1517.
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are poisonous for ingestion in animals [23].
Campana itself mentions the isolation by Feneulle 
and Lassaigne of Delfina, its characterization and 
toxicity [12].
Posner suggests its use as powder, decotion and 
ointment, even in association with mercurials, 
and report that the seeds contain Delfinia, an acre 
alkaloid similar to veratrina [17].
Delfina, whose properties are attributed as a reme-
dy, is described for its tossicity in treatise of Legal 
Medicin (1840) [25].
Sabadilla - Veratrum sabadilla L.
Sabadiglia Veratrum sabadilla L. is recommended 
in the treatment of pityriasis, as reported in Brug-
natelli’s pharmacopoeia [16].
The Jourdan’s Farmacopoea Universalis contains 
many preparations of Sabadilla. Sabadilla is de-
rived from the seeds of V. sabadilla, which grows 
in Mexico. Jourdan reported that the sabadilla’s 
components isolated by Meissner, Pelletier Caven-
tou are acido cevadico and veratrina o sabadiglina. 
The Galenical preparation are: Pulvis capucinorum, 
Polvere dei Cappuccini, made of Seminum sabadil-
lae, Staphydis agriae, Petrosellini, Foliorum nicotianae 
(seeds of sabadilla, staphisagria, parsley, tobacco); 
Unguentum ad s. contra pediculos (Ointment against 
lices) made of Pulveris sabadillae, Synapis, Pyretri, 
Axungiae preparatae (sabadilla in powder, mustard, 
pyrethrum, lard). The Infusum ad cimices is also re-
ported, against the bedbugs, per la distruzione delle 
cimici, lavando con questo le lettiere [21].
Pulvis Capucinorum is well-known, reported also 
in Orosis’s Farmacopea [14].
Antonio Campana in the Farmacopea ferrarese says 
that veratrina is an alkaline substance contained in 
sabadiglia and also in autumn crocus [12].
Meyer in Manuale di Farmacologia (1841) recom-
mends that, if any excoriations exists, care must 
taken not to use the powder too freel [26].
As reported by Posner, Sabadilla in powder or 
infusion is a very good preparation. As ointment 
made mixing powder, lard and an essential oil of 
lavandola, can improve the odour (Pharm austria-
ca is cited). Instead, sabadilla’s vinegar, obtained 
moisten the powder with diluted acetic acid, is 
not recommended as it causes skin irritation [17].
Galla del Levante, Menispermum cocculus Lin. o Coc-
culo o Coccola del Levante (fruit, powder) has been 
a substitute of sabadilla, as claimed by Ferrarini 
and Campana [12, 22]. Orosi reports that picrotox-
in was first isolated by Couerbe and Pelletier and 
it is extremely toxic. [12]. As pediculicide, it may 
be applied in the form of ointment, according to 
Farmacopea prussiana [17].
Petrosellino nostrale - Apium petrosellinum L.
A treatise comprehensive of the Codice Farmaceu-
tico Francese and the Farmacopea austriaca (1838) 
praises the virtues of the parsley. The Petroselli-
no nostrale, Apium petrosellinum, which grows in 
Greece and Sardinia, contains olio etereo and can-
fora. The seeds were employed to prepare a oint-
ment [27].
The powder is suggested by Brugnatelli and is a 
component in Pulvis Capucinorum previously de-
scribed [16, 21].
Rosmarino silvestre - Ledum palustre L.
In Farmacopea ferrarese, it is reported that decotion 
of leaves of wild rosemary, Rosmarino silvestre 
Figure 4 - Lib. quartum Dioscoridis Cap. CL: Staphys 
Agria, Mattioli P.A., Commentarii, 1554.
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Ledum palustre Lin., which grows in swamps in 
North Europe, is also effective [12].
Other compounds
For treatment of phthiriasis, Brugnatelli makes 
a list of Vegetabili e loro preparazioni: Stafisagria 
(powder), Sabadilla (seeds) and also Colchico au-
tunnale Colchicum autumnale L. (sugo), Lauro ric-
cio Laurus nobilis L. (oil from berries and leave), 
Pepe nero Piper nigrum L. (powder), Tabacco Nico-
tiana latifoglia L. (powder or infusion) [16].
Campana suggested as insecticidal Colchic Col-
chicum autumnale Lin. and oil of Carapa, Persoonia 
Guareoides Vild. Carapa oleifera Aubl. [12].
As reported by Posner, decotion of Evonimo Eu-
ropeo, european spindletree, and powder of seeds 
of Datura stramonium containing daturina are ef-
fective in the treatment of phthiriasis [17].
Throughout history, the treatment of phthiriasis is 
abundantly simple. Many are the medicines and 
varied the forms which are used for this purpose. 
The preparations of mercury, staphisagria and sa-
badilla are predominantly employed.
A number of these has been considered as ho-
meopathic remedies: S. staphisagria, V. sabadiglia, 
Petrosellinum, L. palustre, C. autumnale, Tabacum, 
mercury [28, 15].
The lesson of past remedies  
for future remedies
The virtues boasted of raw materials conceived in 
past remedies in popular use or pharmacopoeia, 
can be certified with today’s advanced techniques 
and tools. The insecticide action on the banal louse 
can now be exploited against vectors of danger-
ous infectious diseases, now rapidly spreading 
from one continent to another and often in a very 
short time. Some raw materials may cause high 
toxicity not compatible with their use, but others 
may reveal unexpected properties.
Mosquito-borne diseases
Mosquitoes are responsible for the transmission 
of several pathogenic microorganisms to hu-
mans, causing mosquito-borne diseases, such 
as malaria, dengue, yellow fever, West Nile vi-
rus (WNV) disease, Chikungunya fever, and Rift 
Valley fever (RVF). Although there are numerous 
native mosquito species present and thus able to 
transmit pathogens in Europe, other mosqui-
to species (e.g. Aedes spp.) have recently been 
introduced and become established in the con-
tinent. Among them, the tiger mosquito, Aedes 
albopictus, is probably the major threat to public 
health in Europe. 
The presence of these tropical species means that 
there is a risk of the appearance of autochthonous 
mosquito-borne diseases that have previously 
never or rarely been seen in Europe, acquired af-
ter importation from endemic countries [29].
Mosquito-borne diseases, remain a major source 
of illness and death worldwide, particularly in 
tropical and subtropical climates [30].
Although surveillance and diagnostic methods 
are available, control and preventive measures 
are still limited.
Protection against insect bites is best achieved by 
avoiding infested habitats, wearing protective 
clothing and applying insect repellent [31, 32].
Repellents that can be used anywhere at any time 
are the only feasible measure for preventing ar-
thropod attacks in some situations. Economical 
and practical insect repellents have, therefore, 
become a viable and attractive alternative that is 
widely sold on the market. Commercially availa-
ble insect repellents can be divided into three cat-
egories, synthetic chemicals, botanicals and alter-
natives such as the combination of synthetic and 
natural compounds [33].
Therefore, there is an urgent need to develop 
more efficient surveillance and control tools, and 
to support coordinated monitoring programmes, 
particularly in the Mediterranean region, to ena-
ble prompt recognition of the threat of potential 
introduction of some arbovirus into Europe.
Remedies
Ledum palustre L.
Rhododendron tomentosum Harmaja
Insect repellent activity
Rhododendron tomentosum Harmaja (previously: 
L. palustre) is a fragrant evergreen shrub found in 
peaty soils in northern Europe, Asia and North 
America, commonly referred to as wild rose-
mary, marsh tea, marsh rosemary or northern 
Labrador tea. 
At least, since in the eighteenth century it has 
been used in ethnomedicine for the treatment 
of various sicknesses, such as rheumatism, 
cough, cold and insect bites, as well as a repel-
lent. The essential oil of wild rosemary with the 
rich polyphenolic fraction possesses analgesic, 
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anti-inflammatory, antimicrobial, antiviral, anti-
fungal, promising antidiabetic, antioxidant and 
anticancer properties. Its insecticidal potential 
has been demonstrated by in vivo and in vitro 
studies.
The ethyl acetate extract of R. tomentosum from 
southern Sweden, significantly reduced biting 
by Aedes aegypti L. mosquito in laboratory tests. 
The main volatile compounds, collected by sol-
id phase microextraction (SPME) from leaves of 
wild rosemary, i.e. p-cymene, sabinene, and ter-
pinyl acetate, were suggested to be responsible of 
this effect.
R. tomentosum may be a useful source of chemical 
compounds of medical, veterinary or agricultural 
importance for the control of insects [34].
Apium petroselinum L.
Petroselinum crispum (Mill.) Fuss
Insecticidal activity
The increasing and widespread resistance to con-
ventional synthetic insecticides in vector popula-
tions, has underscored the urgent need to estab-
lish alternatives in the mosquito management 
system. The study was carried out with the aim 
to investigate the antimosquito property, larvi-
cidal and adulticidal potential, of plant products 
against both the pyrethroid-susceptible and re-
sistant strains of A. aegypti.
Seventeen plant products, including essential oils 
and ethanolic extracts, were obtained by steam 
distillation and extraction with 95% ethanol, re-
spectively. Potential toxicity of the plant candi-
date was compared with that of synthetic teme-
phos, permethrin, and deltamethrin. The highest 
efficacy was established from P. crispum fruit oil.
The profound larvicidal and adulticidal potential 
of P. crispum oil promises to form a new larvicide 
and adulticide against either the pyrethroid-sus-
ceptible or resistant strains of A. aegypti. Conse-
quently, P. crispum oil and its constituents can be 
used or incorporated with other chemicals/meas-
ures in integrated mosquito management for con-
trolling A. aegypti, particularly in localities with 
high levels of pyrethroid and organophosphate 
resistance.
GC-MS analysis of P. crispum oil demonstrated 
that 19 compounds, accounting for 98.25% of the 
whole oil, were identified as the main constitu-
ents such as thymol (42.41%), p-cymene (27.71%), 
and γ-terpinene (20.98%) [35].
Veratrum sabadilla - Schoenocaulon officinale
Insecticidal activity
Sabadilla is derived from the seeds of plant Schoe-
nocaulon officinale, which grows in Venezuela. Sa-
badilla is one of the least toxic registered botanical 
insecticides, with mammalian LD50 of 5,000 mg/
kg bw. Similar to other botanical insecticides, it 
has minimal residual activity and degrades rap-
idly in sunlight and moisture (rainfall). Purified 
veratrine alkaloids, however, are considered on 
par with the most toxic synthetic insecticides.
Data from systemic poisoning by sabadilla prepa-
rations used as insecticide are rare or nonesixtent 
[36]. This compound is effective against caterpil-
lars, leafhoppers, thrips, sting bugs and squash 
bugs. The major insecticidal components of saba-
dilla are the alkaloids cevadine and veratridine 
which are inside the seeds. The extracted alka-
loids are highly poisonous.
Nicotiana tabacum L
Insecticidal activity
Beside traditional use of botanicals, their commer-
cial use began in the nineteenth century with the 
introduction of pyrethrum from C. cinerariaefolium 
and also nicotine from Nicotiana tabacum. This last 
is another well-established botanical insecticide. 
Nicotine analogues also possess insecticidal prop-
erties. Nicotine is active against piercing-sucking 
insects such as aphids, leafhoppers, whiteflies, thrips, 
and mites. However, because of the high mam-
malian toxicity and detrimental effect on human 
health, its use as an insecticide has decreased con-
siderably [36].
Delphinium staphisagria L
Trypanocidal properties in Chagas disease
Chagas disease or american trypanosomiasis, is a 
devastating disease caused by the kinetoplastid 
protozoan Trypanosoma cruzi commonly transmit-
ted to humans and other mammals by an insect 
vector, the blood-sucking bug of the subfamily 
Triatominae (family Reduviidae) most commonly 
species belonging to the Triatoma infestans (vin-
chuca bug), Rhodnius, and Panstrongylus gen-
era. The disease may also spread through blood 
transfusion and organ transplantation, ingestion 
of food contaminated with parasites, and from a 
mother to her fetus. Chagas disease may lead to 
chronic and systemic stages, which can affect se-
verely heart, esophagus, and colon.
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Chagas disease is endemic throughout Latin 
America and it is the third most widely spread 
tropical disease after malaria and schistosomiasis 
according the World Health Organization (WHO). 
It is estimated that about 100 million people are 
at risk of infection and from 15 to 20 million are 
infected, with some 50 000 persons dying yearly 
from this disease [37].
D. staphisagria is an endemic annual or biennial 
herb from the Mediterranean Basin. Due to its his-
torical medicinal uses, this plant has probably be-
come widespread in the Mediterranean area. Hu-
man-mediated distribution could have promoted 
few migrant genotypes. The limited genetic var-
iability, the high genetic similarity among popu-
lations and the dysploidy of this species, make it 
worthy of conservation [38].
The molecular structure of major alkaloid isolat-
ed from seeds by Lassaigne and Feneulle in 1819, 
delphinine (Figure 5), was determined and syn-
thesized in 1970 [39].
Diterpenoid alkaloids isolated from the aerial 
parts of D. staphisagria has also been studied ex-
tensively [40, 41].
Tissue cell cultures of D. staphisagria L. produced 
dianthramide glucosides. Their formation in cel-
lus tissue of a Delphinium species appears to be 
unprecedented and may be a response to un-
known pathogens. Dianthramides are generally 
considered to be phytoalexins [42].
Finally, the in vitro and in vivo trypanocidal activi-
ties of nine flavonoids (Figure 6) isolated from the 
aerial parts of D. staphisagria, have been studied 
in both the acute and chronic phases of Chagas 
disease [43, 37].
The antiproliferative activity of these substances 
against T. cruzi (epimastigote, amastigote, and try-
pomastigote forms) exhibited in some cases more 
potent antitrypanosomatid activity and lower tox-
icity than the reference drug, benznidazole.
In vitro studies using ultrastructural analysis to-
gether with metabolism-excretion studies were 
also performed in order to identify the possible 
action mechanism of the compounds tested. Al-
terations mainly at mitochondria level may ex-
plain metabolic changes in succinate and acetate 
production, perhaps due to the disturbance of the 
enzymes involved in sugar metabolism within 
the mitochondrion. In vivo studies provided re-
sults consistent with those observed in vitro. No 
signs of toxicity were detected in mice treated 
with the flavonoids tested (Figure 6), and the par-
asitic charge was significantly lower than in the 
control assay with benzimidazole. The effects of 
these compounds were also demonstrated with 
the change in the anti-T. cruzi antibody levels dur-
ing the chronic stage [37].
Leishmanicidal properties in Leishmaniasis
Leishmaniasis is an infection caused by different 
species of the protozoan genus Leishmania, which 
is transmitted by dipterans of the genera Phlebot-
omus in the Old World and Lutzomyia in the New 
World. Leishmaniasis represents one of the most 
significant neglected tropical diseases which ac-
cording to WHO latest report (2013) affects 350 
million people in 88 countries. Approximately 12 
million individuals are currently infected with 
Leishmania spp. with an estimated 2 million new 
cases occurring every year (44). Major endemic 
areas are in the tropics and subtropics; however, 
leishmaniasis exclusively due to Leishmania in-
fantum is also endemic in large parts of southern 
Europe. 
Drug treatment for leishmaniasis has been avail-
able since the beginning of the 20th Century, but 
only a few drugs have been developed for use 
and there are numerous drawbacks to each of the 
treatments: antimonials (meglumine antimoniate 
or glucantime and sodium stibogluconate or pen-
tostan), amphotericin B, paromomycin (aminosi-
dine) and pentamidine isethionate, miltefosine, 
now used in combination with different classes of 
azole oral antifungal agents including ketocona-
zole, juconazole, and itraconazole. In addition to 
the adverse effects of the drugs, resistance to these 
treatments is appearing in the parasites.Figure 5 - Delphinine.
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For all these reasons, further novel drug develop-
ment is necessary to treat these infections. Con-
siderable attention is currently being paid to phy-
totherapy in the search for new drugs.
Leishmanicidal properties may reside in phy-
tochemicals such as javonoids, which are hence 
strong candidates for use in combination therapy 
against these infections.
Flavonoids (Figure 6) from aerial parts of D. sta-
phisagria L. (Ranunculaceae) showed leishman-
icidal activity against promastigote as well as 
amastigote forms of L. infantum and Leishmania 
braziliensis. These compounds were nontoxic to 
mammalian cells and were effective at similar 
concentrations up to or lower than that of the ref-
erence drug (Glucantime) [45].
Anthemis pyrethrum L. 
Anacyclus pyrethrum (L.) Lag
Antiprotozoan activity
Piretro, Anthemis pyrethrum, is Anacyclus pyre-
thrum. Pyretrum does not contain pyrethrins, 
which are presents in several plants of the ge-
nus Chrysanthemum. The ethnomedicinal use 
of Anacyclus pyrethrum as an antimalarial might 
be explained by the activity of lipophilic constit-
uents present in roots. Alkamides were isolated 
and were tested in vitro for antiprotozoal activity 
against Plasmodium falciparum, Trypanosoma brucei 
rhodiense, T. cruzi and Leishmania donovani. Their 
overall antiparasitic activity is low [46].
n CONCLUSIONS
Natural remedies have served as a source of in-
spiration in the development of new drugs. This 
pathway is “experience-driven” and mainly 
based on traditional uses. Thus, ancient studies 
may serve as a valuable starting point to devel-
op plant driven discovery of new drugs. This has 
been proven possible for some important reme-
dies (i.e. Artemisia annua) [47]. Starting from ex-
isting hystorical proofs, one can envisage a stage 
of discovery from herbal ingredients, which in-
cludes the preparation of extracts, structure/
composition elucidation, and in vitro bioactivity 
evaluation.
In the present work, the cross-survey of basic raw 
materials in the preparation of pastile products in 
the past and the most used medical database, has 
led to interesting findings in the fight against pe-
Figure 6 - In vitro and in 
vivo trypanocidal activ-
ity of flavonoids from 
D. staphisagria against 
Chagas Disease [37].
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diculosis (Table 1). To this end, the search had to 
be matched with today’s denomination.
Therefore, the L. palustre, now termed R. tomento-
sum, revealed repellent insect activity, particular-
ly against A. aegypti, responsible for Dengue fever, 
Chikungunya, Zika fever, Mayaro, yellow fever 
and other infectious diseases. A. petrosellinum, to-
day P. crispum, is insecticide for resistant strains of 
A. aegypti. In some cases, lately, interest in the in-
secticide activity of V. sabadilla, today S. officinale, 
and N. tabacum, has dropped dramatically.
In the case of D. staphisagria, the phytochemical 
profile was further investigated with the identifi-
cation of additional molecules in addition to Del-
phinine. The latter have shown interesting activi-
ties against T. cruzi and Leishmania.
Anthemisis pyrethrum, today Anacyclus pyrethrum, 
although not containing pyrethrins present in 
several plants of the genus Chrysanthemum, had 
revealed pediculicidal activity but did not pro-
duce satisfactory results in antiprotozoan activity.
From the past and from the old louse treatment, 
seem to emerge therefore cues to combat some of 
Table 1 - Past and present medical remedies active against lice and other current Infectious Diseases and vectors.
Activity Actual denomination Ongoing studies
Mercurials Lice, scabies, 
bedbugs, crab 
louse
Rosmarino silvestre
Ledum palustre L.
Lice Rhododendron tomentosum 
Harmaja
Insect repellent 
Aedes aegypti
Petrosellino nostrale
Apium petroselinum L. 
Lice Petroselinum crispum (Mill.) 
Fuss
Insecticidal 
against pyrethroid-susceptible and resistant strains 
of Aedes aegypti
Sabadilla
Veratrum sabadilla L.
Lice, bedbugs Schoenocaulon officinale Insecticidal
caterpillars, leafhoppers, thrips, sting bugs and 
squash bugs
Nicotiana tabacum Insecticidal
piercing-sucking insects such as aphids, 
leafhoppers, whiteflies, thrips, and mites
Stafisagria
Delphinium 
staphisagria L.
Active principle:
Delphinine
Lice, crab louse Trypanocidal and leishmanicidal activities
Trypanosoma cruzi 
Leishmania infantum
Leishmania braziliensis
Piretro
Anthemis  
pyrethrum L.
Lice Anacyclus pyrethrum (L.) Lag. Antiprotozoal activity (low)
Plasmodium falciparum
Trypanosoma brucei rhodiense
Trypanosoma cruzi
Leishmania donovani
today’s diseases and vectors that support them, 
such as repellents or insecticides, even in cases of 
resistance.
The use of insecticide-treated nets has become a 
key malaria control strategy, although more effi-
cacious than in the past. All pesticids have been 
shown to be toxic.
We need implementation of strategies to mini-
mize potential risk through careful selection and 
discovery of new products, considering the para-
site resistance to current antimalarian drugs and 
to insecticide by vector mosquitoes [48].
In summary, this context, an approach that takes 
into consideration past experience, such as those 
deriving from tradition, can be plentiful of sug-
gestions and may shorten time to discovery, thus 
reducing overall investment.
Traditional uses still represent the largest clinical 
study ever conducted by human beings.
Principal drawbacks are related to the preparative 
methodologies in use in ancient times, which are 
not easily understandable and do not make clear 
what part of the activity is linked to original mole-
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cules or their by-products that are formed during 
preparation and storage.
This is the most challenging task in the re-inves-
tigation of ancient remedies and ethnobotany 
preparations in the light of the most recent tech-
niques and equipments [49].
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